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1. Introduction 
 
1.1 DNA Methylation 
 
There are three major mechanisms of epigenetic regulation in mammals: DNA methylation, 
histone modification and chromatin remodelling, among which DNA methylation is the most 
stable. It is crucial for X-chromosome inactivation, retrotransposon repression, chromosome 
structure and gene silencing (Dean et al., 2005; Brockdorff, 2011; Probst & Almouzni, 2011). 
Also, it plays a key role in genomic imprinting (Li et al., 1993; Peters, 2014), which is 
a widely-studied function of DNA methylation due to its heritability (Reik & Walter, 2001). 
Methylation of cytosines on C5 in the context of CpG dinucleotides is typically associated 
with transcriptional silencing and chromosome stability. 
Methylated cytosines tend to undergo deamination, which results in their conversion into 
thymines. Thus, CpG dinucleotides are underrepresented in the genome. In contrast, their 
abundance is high in the so-called CpG islands. CpGs in these clusters are mostly 
unmethylated (Deaton & Bird, 2011). Originally, CpG islands were defined by a length of at 
least 200 bp, a CG content exceeding 50 % and a ratio of observed CpGs to expected CpGs 
above 0.6 (Gardiner-Garden & Frommer, 1987). To exclude repetitive sequences, the 
definition was adjusted to at least 500 bp in length, 55 % CG content or greater and the 
observed CpGs to expected CpGs ratio of 0.65 (Takai & Jones, 2002).  
DNA methylation is mostly symmetrical on both DNA strands. Its maintenance and 
establishment relies on DNA methyltransferases, which are conserved in plant and animal 
kingdoms (Bestor, 2000). S-adenosyl-methionine (SAM) serves as a donor of the methyl 
group (Goll & Bestor, 2005). DNMT1 was the first methyltransferase to be identified in 
mammals (Yen et al., 1992). It maintains DNA methylation during replication (Leonhardt et 
al., 1992; Lyko et al., 1999; Goll & Bestor, 2005), since it recognises hemi-methylated DNA 
as its substrate and methylates the newly synthesised DNA strand (Yoder et al., 1997). It is 
essential for the maintenance of DNA methylation at imprinting centres and repetitive 
sequences during embryonic development (Li et al., 1992; Howell et al., 2001; Gaudet et al., 
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2004; Kurihara et al., 2008). A possible de novo methylation activity has been suggested for 
DNMT1, too (Arand et al., 2012; Feltus et al., 2003).  
DNMT3A and DNMT3B are de novo methyltransferases necessary for the establishment of 
DNA methylation. They require the co-factor DNMT3L to function (Bourc'his et al., 2001; 
Hata et al., 2002) and are also indispensable for embryonic development (Okano et al., 1999). 
Maintenance activity during replication has been observed in both DNMT3A and DNMT3B 
(Arand et al., 2012; MacDonald & Mann, 2014).  
 
 
1.1.1 Genomic Imprinting 
 
Presence of both the maternal and the paternal genome copy is mandatory for a normal 
embryonic development. Maternal or paternal uniparental murine embryos exhibited fatal 
developmental failures (Barton et al., 1984; McGrath & Solter, 1984; Surani et al., 1984). 
Maternally diploid embryos contained embryonic structures but no trophoblast. Paternally 
diploid embryos only developed extra-embryonic tissue. Similar phenotypes to those 
described in mice were observed in humans. The absence of the paternal genome resulted in 
the development of ovarian teratoma containing embryonic tissue of all three germ layers but 
without trophoblast. The absence of the maternal genome led to the formation of hydatidiform 
mole consisting of extra-embryonic tissue (Hall, 1990; Williams et al., 2010 Fallahian et al., 
2013). 
The necessity of both parental genomes stems from the asymmetrical DNA methylation 
resulting in parent-of-origin gene expression at specific loci known as genomic imprinting (Li 
et al., 1993). Approximately 100 imprinted genes have been identified in humans including 
protein-coding genes as well as ncRNA (non-coding RNA) genes (Dindot et al., 2009; 
Bartolomei & Ferguson-Smith, 2011; Horsthemke, 2014). Some of them are only expressed 
in certain tissues or at a particular time point during embryonic development, for instance in 
placenta (Prickett & Oakey, 2012). One of the possible hypotheses for the evolution of 
genomic imprinting is the kinship hypothesis, originally formulated as the conflict hypothesis 
(Moore & Haig, 1991; Haig, 1997; Wilkins & Haig, 2003 Trivers & Burt, 1999). According 
to the original hypothesis, paternally expressed genes stimulate growth of the embryo at the 
expense of the mother, whereas the maternally expressed genes restrict the growth of the 
embryo in order to preserve the mother’s resources. The supposed reason for this behaviour is 
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that while males may pass their genes on to offspring through several females, females may 
only do so through consecutive pregnancies. The kinship hypothesis is an expansion of the 
conflict hypothesis operating with the influence of all maternally related kin versus the 
influence of all paternally related kin (Wilkins & Haig, 2003). Among all hypotheses, this is 
the most accepted and empirically supported one. The growth factor IGF2 (insulin-like 
growth factor II) and its receptor IGF2R represent an example supporting the hypothesis. 
IGF2 supporting growth is paternally expressed. The maternally expressed IGF2R binds IGF2 
and mediates its degradation, thereby restricting growth (Chao & D'Amore, 2008). Another 
piece of evidence supporting the hypothesis is that imprinting only occurs in placentals and 
marsupials as well as in some plants, but not in monotremes that lay eggs, so the investment 
of the mother is a priori limited. It is assumed that genomic imprinting co-evolved with the 
placenta of the mammals and the endosperm of the plants (Feil & Berger, 2007; Renfree et 
al., 2013; Horsthemke, 2010). However, the hypothesis does not apply to all imprinted genes. 
Among them, retrotransposed genes seem to be over-represented. It has been hypothesised 
that the host-defence system neutralising potentially deleterious DNA elements erroneously 
silenced other genes, whose inactivity proved to be beneficial (Barlow, 2011). 
Most imprinted genes are organised in clusters of several kb to several Mb in length, 
encompassing a differentially methylated CpG-rich imprinting control region (ICR). The ICR 
regulates the gene expression in cis (Barlow, 2011). Transcriptional interference plays an 
important role in imprinting, especially in the form of long non-coding RNAs (lncRNAs), 
whose presence has been detected at various imprinted loci (Latos et al., 2012; Meng et al., 
2013; Barlow & Bartolomei, 2014). Differential DNA methylation is established already in 
the parental germline. It is maintained after fertilisation during the global wave of 
demethylation (Messerschmidt, 2012; Proudhon et al., 2012; Smallwood et al., 2014; Hanna 
& Kelsey, 2014) and further on throughout development, and preserved in mature tissues 
(Reik & Walter, 2001; Lucifero et al., 2004; Ideraabdullah et al., 2008; Messerschmidt, 2012; 
Kelsey & Feil, 2013).  
In the female germline, the establishment of DNA methylation relies on DNMT3A and its co-
factor DNMT3L. The mechanism targeting DNMT3A and DNMT3L to specific regions has 
yet to be elucidated. However, in the oocyte, transcription overlapping an ICR seems to be 
critical for the specificity of de novo DNA methylation (Chotalia et al., 2009; Horsthemke, 
2010; Lewis et al., 2015). The phenomenon is apparently not restricted to the establishment of 
DNA methylation at imprinted loci (Veselovska et al., 2015). Transcription might indirectly 
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facilitate methylation by inducing histone modifications promoting interactions with 
DNMT3A and DNMT3L (Baubec et al., 2015). Since maternally methylated ICRs localise to 
promoter regions, it is feasible that overlapping transcription does support the establishment 
of the methylation mark. On the other hand, some regions might be protected from being 
methylated. For instance, proteins containing the CXXC domain bind specifically to 
unmethylated CpG dinucleotides in somatic cells. Such a process might also occur in the 
oocyte and prevent methylation of the bound sequences (Kelsey & Feil, 2013; Lewis et al., 
2015). The PWS/AS (Prader-Willi syndrome / Angelman syndrome) locus represents an 
example of a cluster containing a maternally methylated ICR. Methylation on the maternal 
chromosome inhibits the expression of MKRN3, MAGEL2, NDN, NPAP1, SNURF-SNRPN, 
SNORD116, SNORD115 and SNHG14 that are expressed from the unmethylated paternal 
allele. The only gene expressed from the maternal allele is UBE3A (Greally et al., 1999; 
Nicholls & Knepper, 2001). 
 
Figure 1 
Figure 1. Expression at the PWS/AS locus in the brain. Genes expressed from the paternal (pat) allele, 
MKRN3, MAGEL2, NDN, NPAP1, SNURF-SNRPN, SNORD116, SNORD115 and SNHG14 (here UBE3A-ATS), 
are depicted in green. UBE3A is expressed from the maternal allele (mat), displayed in red. The imprinting 
centre regulating the expression of the locus is indicated by a red circle for AS-SRO and a blue oval for PWS-
SRO. Detailed structure of the imprinting centre containing upstream exons is shown in a blow-up. The figure 
was adapted from Lewis et al., 2015. 
 
In the male germline, the processes leading to DNA methylation are even less understood. 
High transcriptional activity was detected at the differentially methylated regions ICR1 and 
IG-DMR in gametes. It mainly occurred on one DNA strand simultaneously with the 
establishment of DNA methylation. Also in these cases, transcription overlapped the ICR. 
However, it is not known if and how transcription contributes to de novo methylation in the 
paternal germline (Henckel et al., 2012; Barlow & Bartolomei, 2014). ICRs methylated on the 
paternal allele are usually intergenic, as in the case of the IGF2/H19 locus (Bartolomei et al., 
1993; Peters, 2014). This locus illustrates the insulator model of imprinted gene expression 
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regulation (Bell & Felsenfeld, 2000; Hark et al., 2000; Nordin et al., 2014). The ICR situated 
between the two genes encompasses a binding site for the zinc-finger CCCTC-binding factor 
(CTCF). The maternal allele is unmethylated, which allows for the binding of CTCF. Its 
presence prevents methylation of the maternal ICR facilitating H19 expression. Moreover, it 
results in the formation of chromatin structures of higher order. Therefore, IGF2 promoters 
lying upstream of the ICR cannot be activated by downstream enhancers and IGF2 
transcription is inhibited on the maternal allele. Methylation on the paternal allele hinders the 
binding of CTCF, thus restricting the insulator function of the ICR, and IGF2 is expressed 
(Bell & Felsenfeld, 2000; Hark et al., 2000). 
Disturbances of imprinted gene expression are caused by various defects including deletions, 
uniparental disomies or discrepancies in methylation of the ICRs. Such conditions result in 
imprinting disorders in humans, since imprinted genes are expressed monoallelically and the 
only active allele is lost. In case of Beckwith-Wiedemann and Silver-Russell syndromes, 
disturbances of the IGF2/H19 locus are involved, although the situation is not 
straightforward. Angelman and Prader-Willi syndromes represent examples of imprinting 
disorders in humans with a single affected locus. 
 
1.1.2 Angelman Syndrome 
 
Angelman syndrome is a rare neurodevelopmental imprinting disorder characterised by 
a happy demeanour, ataxic gait, absence of speech and developmental impairment, and often 
also abnormal EEG readings, microcephaly and seizures (Dagli et al., 2012; Buiting, 2010). It 
was first described by Dr. Harry Angelman in 1965 and occurs with a frequency of 1:12 000 
to 1:20 000. The underlying molecular cause is the lack of a functional E3 ubiquitin protein 
ligase UBE3A in the brain (Kishino et al., 1997; Yu et al., 2007; Rougeulle et al., 1997). 
UBE3A catalyses ubiquitination of lysine residues in proteins targeting such marked proteins 
for degradation by the proteasome. Three different isoforms of UBE3A have been identified 
resulting from alternative splicing of the UBE3A transcript (Scheffner et al., 1993; Yamamoto 
et al., 1997; Martinez-Noel et al., 2012). The UBE3A gene is part of the PWS/AS cluster on 
chromosome 15q11q13. While it is only expressed from the maternal allele in the brain (Dagli 
et al., 2012; Rougeulle et al., 1998; Landers et al., 2004; Meng et al., 2012; Meng et al., 
2013; Meng et al., 2015; Chamberlain & Brannan, 2001; Horsthemke & Wagstaff, 2008; Fink 
et al., 2017), its expression is biallelic in all other tissues (Albrecht et al., 1997; Rougeulle et 
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al., 1997; Vu & Hoffman, 1997; Chamberlain & Lalande, 2010). In the human brain, 
SNHG14 (small nucleolar RNA host gene 14) of 900 kb is transcribed in antisense direction 
to UBE3A and overlaps the whole gene and its promoter (Landers et al., 2004; Numata et al., 
2011; Rougeulle et al., 1997; Runte et al., 2001). Therefore, UBE3A is susceptible to 
mutations occurring on the maternal chromosome because there is no compensation available 
from the paternal allele in the brain. 
The most frequent cause of Angelman syndrome responsible for approximately 70 % of the 
cases is a 5 Mb to 7 Mb large de novo deletion occurring on the maternal chromosome 15 
(Knoll et al., 1989; Buiting, 2010). In about 5-10 % of the cases, it is a mutation in the 
maternal UBE3A gene. Such a mutation led to the identification of this gene as the Angelman 
syndrome gene (Kishino et al., 1997; Loh et al., 2006; Buiting, 2010). An imprinting defect 
causes 2-4 % of the cases. In such cases, the maternal chromosome carries a paternal imprint 
(Buiting et al., 1998; Buiting, 2010). Paternal uniparental disomy was reported to be the cause 
of 1-2 % of the cases (Malcolm et al., 1991; Buiting, 2010; Buiting et al., 2015). In 10 to 
15 % of clinically diagnosed cases of Angelman syndrome, the molecular cause could not be 
determined (Kishino et al., 1997; Matsuura et al., 1997; Buiting, 2010). The different nature 
of the underlying mutation corresponds with the severity of the phenotype. Patients 
harbouring a point mutation in the UBE3A gene present with a less pronounced phenotype 
than those with a large deletion on chromosome 15 (Mertz et al., 2014; Lossie et al., 2001; 
Sahoo et al., 2007; Varela et al., 2004; Gentile et al., 2010; Tan et al., 2011; Margolis et al., 
2015).  
The ICR of the locus encompasses exon 1 of SNURF-SNRPN, its promoter, and a region 
upstream of it. In humans, it is composed of AS-SRO and PWS-SRO (Angelman syndrome / 
Prader-Willi syndrome shortest region of overlap) (Buiting et al., 1999; Ohta et al., 1999a; 
Ohta et al., 1999b; Buiting et al., 2003; Horsthemke & Wagstaff, 2008). An oocyte-specific 
promoter is localised at AS-SRO. Between AS-SRO and PWS-SRO, upstream exons of the 
SNURF-SNRPN gene are localised that are only included in the oocyte-specific transcripts 
and SNHG14 (Fig. 1). Transcription initiated from the oocyte-specific promoter transits PWS-
SRO probably causing its inactivation by inducing DNA methylation. Thus, PWS-SRO 
remains unmethylated and therefore active on the paternal allele only (Dittrich et al., 1996; 
Lewis et al., 2015). Two clusters of small nucleolar RNA (snoRNA) genes, SNORD116 and 
SNORD115, lie downstream of the ICR. They are processed from the intronic regions of 
lncRNA SNHG14. Further downstream, the UBE3A gene is situated in antisense orientation to 
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SNURF-SNRPN, the SNORD clusters and SNHG14 (Runte et al., 2001; Wawrzik et al., 2009; 
Lewis et al., 2015). Expression of SNORD115 and silencing of UBE3A on the paternal allele 
occurs only in neurons, as the lncRNA SNHG14 is significantly longer than in other cell 
types. It has been proposed that a boundary element between the two SNORD clusters 
prevents SNHG14 synthesis beyond this point in non-neural cells (Runte et al., 2001; Runte et 
al., 2004; Martins-Taylor et al., 2014). 
Mouse studies have shown that Snhg14 transcription overlapping the Ube3a gene results in 
monoallelic Ube3a expression (Chamberlain & Brannan, 2001; Landers et al., 2004; Numata 
et al., 2011; Meng et al., 2012). Integration of a stop cassette upstream of the Ube3a gene led 
to a truncation of the Snhg14 transcript and activation of the paternal Ube3a allele. The 
expression pattern of the paternally expressed Ube3a was similar to the maternally expressed 
Ube3a. The paternal Ube3a protein was detected in neocortex, hippocampus and cerebellum 
of the transgenic mice (Meng et al., 2012; Meng et al., 2013). 
Unlike other imprinted genes silenced by antisense transcriptional interference (Sleutels et al., 
2002; Williamson et al., 2011), the paternal Ube3a promoter does not acquire methylation 
(Lossie et al., 2001). Moreover, H3K4me3 can be found in the region, which is a hallmark of 
transcriptionally active promoters (Xie et al., 2012; Meng et al., 2013). Indeed, transcription 
of the paternal Ube3a gene on the 5’-end was shown to occur at a rate comparable to that of 
the maternal Ube3a gene. However, the paternal transcripts undergo premature termination in 
intron 4 excluding the synthesis of mature mRNA and subsequent translation to proteins 
(Numata et al., 2011; Meng et al., 2013). A model was proposed suggesting collision of 
convergent polymerase complexes transcribing Ube3a and Snhg14 in intron 4 of the paternal 
Ube3a. Translocation of the polymerase complex elongating the Ube3a transcript could 
explain the premature termination of Ube3a transcription (Meng et al., 2013). 
 
Since UBE3A silencing on the paternal chromosome is a condition restricted to the brain, 
neurons are essential to study Angelman syndrome and the function of UBE3A at the 
molecular level. The only two means of obtaining them is the generation of induced 
pluripotent stem cells (iPSCs) from an Angelman syndrome patient by reprogramming and 
CRISPR/Cas engineering of human embryonic stem cells, coupled with their consecutive 
neuronal differentiation. Up to date, no therapy has been developed for Angelman syndrome. 
The antibiotic minocycline has been reported to alleviate the symptoms of the syndrome 
(Grieco et al., 2014). Alternatively, topoisomerase I inhibitor topotecan can be applied to 
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activate the paternal UBE3A allele but it can hardly be used in therapy due to its heavy side 
effects (Armstrong, 2004; Markman, 2005; Penson & Seiden, 2005). A very promising 
approach utilising antisense oligonucleotides (ASO) specifically targeting SNHG14 has been 
developed. The method relies on the formation of ASO-RNA heteroduplexes and the 
subsequent cleavage of the RNA strand within them by RNAse H leading to its degradation. 
So far, the technique has successfully been applied in mice, both in vitro and in vivo, resulting 
in the activation of the paternal Ube3a allele (Meng et al., 2015). Concerning clinical therapy, 
delivery of the ASOs into the neurons of Angelman syndrome patients poses a considerable 
problem. Therefore, research on potential novel approaches to treat Angelman syndrome 
is necessary. 
 
 
1.1.3 Epigenetic Reprogramming 
 
Two major waves of epigenetic reprogramming take place during mammalian development 
(Dean et al., 2003). The first one occurs in primordial germ cells. DNA methylation at 
imprinted loci undergoes erasure in order to be reset as germ cells develop (Hajkova et al., 
2002; Lee et al., 2002). Imprint reestablishment is dependent on the activity of DNMT3A 
with its co-factor DNMT3L (Bourc'his et al., 2001; Hata et al., 2002; Kaneda et al., 2004). In 
males, imprints are acquired during late foetal development (Davis et al., 2000; Ueda et al., 
2000). In females, imprint establishment occurs postnatally in the growing oocyte before 
ovulation (Obata & Kono, 2002; Lucifero et al., 2004) (Fig. 2). 
The second wave of reprogramming occurs during embryonic development as genome 
activation is required at the 2-cell stage. The paternal genome exhibits a high level of 
methylation prior to fertilisation (Monk et al., 1987; Kobayashi et al., 2012). It undergoes 
demethylation first, before the maternal genome does. The process is realised actively with 
the contribution of TET (ten-eleven translocation family protein) enzymes. The maternal 
genome displays a lower level of methylation in comparison with the paternal one (Monk et 
al., 1987; Kobayashi et al., 2012). Its demethylation was supposed to be passive, mediated 
merely by the exclusion of DNMT1 from the nucleus during replication. This would explain 
why the process of demethylation is finished later than that of the paternal genome (Santos et 
al., 2002; Dean et al., 2003). However, active demethylation of the maternal genome has been 
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reported as well (Peat et al., 2014; Wang et al., 2004). Once demethylation is completed, de 
novo methylation occurs in the inner cell mass (Santos et al., 2002) (Fig. 2). 
 
 
Figure 2 
Figure 2. Protection of imprinted loci during development. In the growing germ cells, genomic imprints are 
set by de novo methyltransferases DNMT3A and DNMT3L. Major demethylation occurs first in the paternal, 
then also in the maternal genome during early development up to the 2-cell stage. In the blastocyst, the genome 
of the embryo undergoes de novo methylation. ICRs remain protected throughout the latter two phases by 
DPPA3 (here STELLA), TRIM28, ZFP57 and DNMT1. Factors playing important roles in the imprint protection 
are indicated below each stage. The figure was taken from Messerschmidt, 2012. 
 
Imprinted genes are protected throughout the process of DNA demethylation (Messerschmidt, 
2012). There are several proteins known to be involved in imprint maintenance, for instance 
DPPA3 (developmental pluripotency associated 3) encoded by one of the maternal effect 
genes. Maternal effect genes are crucial in the early development. While some are expressed 
only by the oocyte and exert their function during the transition from the oocyte to the 
embryo, others are required later in development and are expressed by the oocyte as well as 
by the embryo (Li et al., 2010). DPPA3 plays a role in distinguishing the parental alleles and 
prevents active demethylation of certain loci (Nakamura et al., 2007). Another maternal effect 
gene essential for imprint maintenance during the preimplantation phase is TRIM28 (tripartite 
motif containing 28). TRIM28 is a key scaffold component of a heterochromatin inducing 
complex. Among other factors, it binds the H3K9me3-catalysing histone methyltransferase 
SETDB1 (SET domain bifurcated 1, SET = Su(var)3-9, Enhancer-of-zeste and Trithorax), 
nucleosome remodelling deacetylase complex (NuRD), and heterochromatin protein 1 (HP1) 
(Schultz, 2002). Binding specificity of the complex to DNA is provided by the interaction of 
TRIM28 with KRAB-ZFPs (Krüppel-associated box-containing zinc-finger proteins), for 
example ZFP57 (Li et al., 2008). ZFP57 is another protein encoded by a maternal effect gene. 
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It recognises DNA methylation at ICRs via a specific hexanucleotide motif (Quenneville et 
al., 2011). Both TRIM28 and ZFP57 are essential for imprint maintenance in embryonic stem 
cells (Messerschmidt, 2012). In human embryonic stem cells, DNMT1, DNMT3A and 
DNMT3B have been reported to be part of the complex as well (Quenneville et al., 2011; Zuo 
et al., 2012). Apart from this observation, it has been proposed that DNMT1, also a product of 
a maternal effect gene, may contribute to the protection of imprints by selectively binding to 
them despite its general exclusion from the nucleus required to allow passive demethylation 
(Borowczyk et al., 2009).  
 
Upon reprogramming, somatic cells need to undergo a number of molecular changes 
including epigenetic reprogramming partly similar to that of early embryonic development to 
reach a state of true pluripotency. The process requires a long time, it is ineffective and often 
yields partly reprogrammed cells or cells carrying epigenetic memory instead of fully 
reprogrammed induced pluripotent stem cells (Chan et al., 2009; Deng et al., 2009; Lister et 
al., 2009; Kim et al., 2010; Kim et al., 2014). This indicates the presence of epigenetic 
barriers difficult to overcome. In addition, disturbances of methylation at imprinted loci occur 
frequently, suggesting their unfaithful protection throughout reprogramming (Johannesson et 
al., 2014; Ma et al., 2014b). Deeper understanding of processes involved in epigenetic 
reprogramming occurring in the early embryo and the protection of DNA methylation at 
imprinted loci during development could contribute to improving the efficiency of 
reprogramming. 
 
 
1.2 Stem Cells 
 
The hallmark of stem cells is their ability of self-renewal and their capacity of differentiation 
into cells with a distinct identity and function (Jaenisch & Young, 2008). Based on their 
differentiation potential, stem cells are divided as follows. Pluripotent stem cells are able to 
differentiate into cells of all three germ layers, ectoderm, mesoderm and endoderm. In vivo, 
they occur exclusively in the inner cell mass of the blastocyst. In vitro, their stable cultivation 
as embryonic stem cells is well-established, while pluripotency is retained. Multipotent and 
oligopotent stem cells are involved in the regeneration of mature tissues. Their differentiation 
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potential is restricted to a few specific cell types within their germ layer (Hochedlinger & 
Plath, 2009). 
 
1.2.1 Pluripotent Stem Cells 
 
Embryonic stem cells are pluripotent giving rise to all embryonic tissues but for placenta. 
They may only be isolated from the inner cell mass of the blastocyst, a stage of embryonic 
development before implantation. Their removal leads to the destruction of the embryo, 
naturally raising ethical issues regarding their use in research. Human embryonic stem cells 
were first established in cell culture in 1998 by James Thomson (Thomson et al., 1998). 
Pluripotent stem cells are characterised by the presence of various features. They exhibit 
enhanced activity of alkaline phosphatase (Wobus et al., 1984; Thomson et al., 1998) and 
express typical markers. Transcription factors OCT4, NANOG and SOX2 represent nuclear 
markers of pluripotency, while SSEA3, SSEA4, TRA-1-60, TRA-1-81 and GCTM-2 
exemplify typical surface pluripotency markers (Thomson et al., 1998; Reubinoff et al., 2000; 
Xu et al., 2001; Henderson et al., 2002; Boyer et al., 2005). Furthermore, stem cells may be 
characterised by their potential to differentiate into derivatives of all three germ layers in vitro 
(Doetschman et al., 1985; Itskovitz-Eldor et al., 2000). In vivo, this ability may be verified by 
teratoma assay. Embryonic stem cells are injected subcutaneously into immunodeficient mice 
and the teratomas they form over time are analysed for the presence of derivatives of all three 
germ layers (Wobus et al., 1984; Thomson et al., 1998).  
The aforementioned transcription factors OCT4, NANOG and SOX2 are crucial for the 
maintenance of pluripotency. They form a regulatory network controlling their own 
expression in a positive feedback loop and the expression of other genes essential for 
retaining pluripotency. Other genes are repressed and maintained in a poised status until their 
expression is required upon differentiation (Boyer et al., 2005; Loh et al., 2006). Apart from 
OCT4, NANOG and SOX2, many more transcription factors have been identified that are part 
of the regulatory network maintaining pluripotency. For instance, KLF4, MYC, LIN28, 
DNMT3B as well as ZFP42 belong to these factors (Li et al., 2005; Wang et al., 2006; Zhou 
et al., 2007). 
As described above, DNA methylation is generally associated with gene repression. 
Therefore, it is not surprising that the overall level of methylation is lower in transcriptionally 
very active embryonic stem cells needing to maintain their pluripotency than in differentiated 
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somatic cells, as shown by a comparison of the respective global methylomes (Collas, 2009). 
Accordingly, chromatin of embryonic stem cells is in a less compact state than that of 
differentiated cells. This finding also corresponds with the observed high chromatin plasticity 
of embryonic stem cells (Strickfaden et al., 2010). Upon differentiation, promoters of genes 
associated with pluripotency such as POU5F1 (encoding OCT4) or NANOG undergo 
extensive methylation, histone modification and alteration of chromatin structure leading to 
their repression (Fisher & Fisher, 2011). 
Signalling involved in retaining pluripotency and promoting self-renewal is a complex, finely 
balanced network of intertwined pathways. PI3K/AKT, MAPK/ERK, TGFβ/SMAD2/3 and 
Wnt pathways play an important role in pluripotency maintenance. This explains the 
dependence of embryonic stem cells on bFGF2 (basic fibroblast growth factor 2) in cell 
culture because bFGF2 activates the PI3K/AKT cascade (Amit et al., 2000; Dalton, 2013). 
The cascade contributes to maintaining pluripotency in several ways. It suppresses 
MAPK/ERK signalling keeping it at a rather low level of activity. High activity of this 
pathway results in destabilisation of c-myc by GSK3 and the induction of differentiation 
(Singh et al., 2012a; Singh et al., 2012b). Furthermore, PI3K/AKT activates mTOR. 
Although the mechanism is not clear, specific mTOR inhibition has a similar effect on 
embryonic stem cells as does the inhibition of PI3K itself, both causing a loss of pluripotency 
and triggering differentiation (McLean et al., 2007; Zhou et al., 2009b). Moreover, 
PI3K/AKT cross-talks with the TGFβ/SMAD2/3 pathway that exhibits dual function in 
embryonic stem cells similar to that of the MAPK/ERK cascade (McLean et al., 2007; Brown 
et al., 2011; Teng et al., 2011; Singh et al., 2012b). High levels of SMAD2/3 induce 
differentiation, whereas at low levels, SMAD2/3 activates transcription of NANOG, for 
instance (Xu et al., 2008; Yu et al., 2011). Even though the exact way of modulating 
SMAD2/3 has not yet been understood, PI3K/AKT maintains pluripotency by restricting the 
activity of SMAD2/3 (Dalton, 2013). In addition, PI3K/AKT indirectly inhibits Wnt 
signalling by suppressing MAPK/ERK, thereby further supporting pluripotency. While a role 
in self-renewal has been suggested for the Wnt pathway by some studies, there is growing 
evidence that its activation leads to differentiation instead (Davidson et al., 2012; Sumi et al., 
2008). Apart from conventional signal transduction, its transcriptional effector β-catenin alters 
the specificity of SMAD2/3 to promote differentiation (Singh et al., 2012b). Therefore, 
suppression of the pathway seems to be significant for pluripotency maintenance. It has been 
reported that also OCT4 functionally represses the Wnt pathway, thereby additionally 
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contributing to self-renewal and pluripotency maintenance, and underlining the opposing 
roles of Wnt signalling and pluripotency-associated networks (Davidson et al., 2012).  
 
1.2.2 Induced Pluripotent Stem Cells 
 
The first experiments on somatic cell nuclear transfer, also known as therapeutic cloning, 
were performed with Xenopus laevis (Gurdon, 1962). The breakthrough in this field was the 
successful cloning of the sheep Dolly (Wilmut et al., 1997). Soon after, cloning of other 
species followed (Wakayama et al., 1998; Polejaeva et al., 2000; Chesne et al., 2002; Byrne 
et al., 2007). Alternatively, pluripotent stem cells may be generated by fusing an embryonic 
and a somatic cell, giving rise to hybrid cells. Pluripotency of murine as well as human hybrid 
cells induced by this method was verified (Tada et al., 2001; Terada et al., 2002; Ying et al., 
2002; Cowan et al., 2005; Yu et al., 2006). A great drawback of cells created this way is their 
tetraploidy excluding therapeutic application. 
To generate iPSCs, transcription factors OCT4, KLF4, SOX2 and MYC, the so-called 
Yamanaka factors, are overexpressed in somatic cells (Takahashi & Yamanaka, 2006; 
Takahashi et al., 2007). MYC was reported to be dispensable (Nakagawa et al., 2008). The 
combination of OCT4, SOX2, NANOG and LIN28 also leads to reprogramming and 
induction of pluripotency in human fibroblasts (Yu et al., 2007). In general, single Yamanaka 
factors may be substituted by other proteins provided that the pluripotency network 
comprising OCT4, NANOG and SOX2 is activated (Buganim et al., 2012). 
Delivery of the factors into the cells usually relies on a self-inactivating retroviral vector, 
although other methods have been developed. Since retroviral delivery invariably results in 
the vector integrating into the host genome, insertion mutations are likely to occur (Woods et 
al., 2003). Furthermore, activation of the vector during differentiation may take place 
preventing successful completion of the process (Okita et al., 2007; Ramos-Mejia et al., 
2012). Therefore, lentiviral vectors have been engineered to allow for virus excision via Flp 
recombinase after reprogramming (Sommer et al., 2010; Voelkel et al., 2010). Systems using 
transposon vectors have also been adjusted to facilitate their removal. Thus, both PiggyBac 
(Kaji et al., 2009; Woltjen et al., 2009; Yusa et al., 2009) and Sleeping Beauty 
(Muenthaisong et al., 2012; Davis et al., 2013; Kues et al., 2013) support the possibility of 
excision as well. Only a very small portion of the exogenic DNA sequence remains in the 
genome after removal. Non-integrating adenoviral or Sendai virus vectors represent a good 
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alternative (Stadtfeld et al., 2008; Zhou & Freed, 2009; Fusaki et al., 2009) and so does 
transient expression of the reprogramming factors from episomal plasmids or non-viral 
minicircles (Gonzalez et al., 2009; Jia et al., 2010; Montserrat et al., 2011). For successful 
reprogramming, it is also sufficient to deliver the required transcription factors in the form of 
their mRNA (Warren et al., 2010) or even as recombinant proteins (Kim et al., 2009; Zhou et 
al., 2009a).  
Reprogramming efficiency ranges from 0.01 % to 0.2 % (Okita et al., 2007; Wernig et al., 
2008) but may be increased by targeted activation of certain transcription factors, chromatin 
remodelling or manipulation of selected signalling pathways (Silva et al., 2008; Mikkelsen et 
al., 2008; Kim et al., 2010; Onder et al., 2012; Huangfu et al., 2008a; Huangfu et al., 2008b; 
Chen et al., 2013). 
 
Derivation of patient-specific induced pluripotent stem cells (iPSCs) was a very important and 
promising step for regenerative medicine. This success partly solved the problem of restricted 
access to human embryonic stem cells due to ethical issues regarding their use and the need of 
cells with the ability to differentiate into cells of tissues inaccessible in patients. Not only may 
iPSCs be cultured over a long period of time facilitating research on the pathogenesis of 
various diseases and drug screening in vitro but they could also be applied in therapy, once 
genetically corrected. As autologous transplants, they would not cause any immune defence 
reaction. It has been shown in a mouse model of sickle-cell anaemia that transplantation of 
corrected iPSCs rescued the phenotype (Hanna et al., 2007). However, concerns regarding 
their utilisation in human therapy due to the risk of oncogenesis are certainly justified and 
need to be resolved first. 
 
 
1.2.3 Epigenetic Stability during Reprogramming 
 
Demethylation of many loci associated with pluripotency is required during reprogramming 
to facilitate the transition from a fully differentiated state to a pluripotent mode. Loosening of 
dense chromatin structure and modification of histone marks are equally important to enable 
their transcription (Cedar & Bergman, 2009). Even after a successful reprogramming process, 
methylomes of human embryonic stem cells (hESCs) and iPSCs are not identical (Deng et al., 
2009; Lister et al., 2009; Tesarova et al., 2016). iPSCs display signs of epigenetic memory 
 Introduction 
 
 26 
influencing their differentiation potential (Kim et al., 2010; Ma et al., 2014b). Interestingly 
though, incomplete deactivation of certain genes may increase reprogramming efficiency (Ohi 
et al., 2011). According to some studies, the methylome profile of iPSCs undergoes changes 
upon prolonged cultivation eventually resembling that of hESCs (Nishino et al., 2011; 
Tesarova et al., 2016). However, aberrant methylation at imprinted loci after reprogramming 
or long-term culture has been observed (Nazor et al., 2012; Johannesson et al., 2014; Ma et 
al., 2014b; Pick et al., 2009). Alteration of imprinting at a certain locus in a clone does not 
predispose other imprinted loci in that clone to a change in methylation, neither to one in the 
same direction, nor in the opposing one. This finding indicates stochastic incidence of such 
abnormalities. Also, specific genes exhibit different frequencies of perturbation, which argues 
in favour of the stochastic occurrence theory as well (Johannesson et al., 2014). Some loci 
such as PWS-SRO have been reported to display exceptional stability but for very rare cases 
(Chamberlain et al., 2010; Ma et al., 2014b). At ICR1 of the IGF2/H19 locus and ICR2 of the 
KCNQ1 cluster, aberrant methylation was detected (Nazor et al., 2012; Johannesson et al., 
2014; Ma et al., 2014b). Similar observations of instability have been described for NESPAS 
of the GNAS cluster (Grybek et al., 2014). CpG85 of the RB1 gene repeatedly showed varying 
methylation between tissues as well (Kanber, unpublished data). Susceptibility of IG-DMR of 
the DLK1/MEG3 cluster to a loss of differential methylation has also been documented 
(Nazor et al., 2012; Stadtfeld et al., 2012; Johannesson et al., 2014; Ma et al., 2014b; Xu et 
al., 2015). Abnormalities may be present in somatic cells to a certain extent and be clonally 
expanded, or they may be introduced during reprogramming. Since methylation at imprinted 
loci is fairly stable in hESCs (International Stem Cell Initiative, 2007; Rugg-Gunn et al., 
2007), it is feasible that the anomalies in reprogrammed cells are a result of their somatic 
origin occurring independently of the method used for reprogramming (Johannesson et al., 
2014). 
In a study comparing hESCs, iPSCs and pluripotent cells generated by somatic nuclear 
transfer (NT-ESCs), significant differences were detected between hESCs clustering together 
with NT-ESCs, and iPSCs clearly forming a separate group in a genome-wide DNA 
methylation microarray analysis (Ma et al., 2014b). An explanation for a more efficient 
reprogramming in NT-ESCs than in iPSCs might be the role of ooplasm. For instance, 
demethylation commences immediately after somatic nuclear transfer (Santos et al., 2002), 
while with factor-induced reprogramming, the process takes days to weeks, likely being 
passive (Mikkelsen et al., 2008). As described earlier, maternal effect genes play an important 
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role in the transition from the oocyte to the embryo as well as in imprint maintenance during 
embryonic development. Obviously, these genes are not present in an active state in adult 
differentiated cells prior to their reprogramming. Taken that into account together with the 
absence of further essential components in somatic cells, it becomes evident that the ooplasm 
contains specific reprogramming factors functioning upstream of pluripotency (Ma et al., 
2014b). Studies focusing on their identification could improve the existing reprogramming 
methods with regard to methylation maintenance as well as removal. 
 
 
1.3 Site-Specific Induction of DNA Methylation 
 
Aberrant expression of imprinted genes resulting from disturbances of methylation at the 
corresponding ICRs is responsible for the development of imprinting disorders in humans, 
such as Angelman and Prader-Willi syndromes or Beckwith-Wiedemann syndrome. Among 
other features, the latter syndrome is characterised by overgrowth and a high predisposition 
for childhood cancer due to the loss of imprinting of IGF2. Particularly Wilms' tumour 
(nephroblastoma), pancreatoblastoma and hepatoblastoma are likely to develop in children 
with Beckwith-Wiedemann syndrome (DeBaun & Tucker, 1998). However, the loss of 
imprinting of IGF2 has also been described in other types of cancer (Ulaner et al., 2003; 
Sakatani et al., 2005). Similarly, the overexpression of other oncogenes often confers growth 
and proliferation advantage and results in cancer. Targeted silencing to suppress transcription 
may represent an effective and useful tool in therapy, at least supporting conventional 
treatment. Since DNA methylation represses transcription efficiently, various methods have 
been established to exploit that property of this epigenetic modification by inducing 
methylation at a selected locus. 
 
1.3.1 Induction of DNA Methylation by Artificial Methylated Oligonucleotides 
 
DNA methylation induction at promoter regions targeted by methylated oligonucleotides has 
been described (Yao et al., 2003; Zhu et al., 2004; Hoffman & Hu, 2006; Ma et al., 2010). 
Oligonucleotides utilised in this method are 21 to 25 nucleotides long. Within their sequence, 
at least two methylated cytosines are present. The oligonucleotides are protected from 
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degradation by cellular nucleases by phosphorothioate backbones. In theory, upon replication 
or transcription initiation when the DNA helix is transiently molten, methylated 
oligonucleotides anneal to the complementary genomic DNA strand forming a hemi-
methylated double-stranded stretch of DNA. DNMT1 recognises the hemi-methylated portion 
of DNA and methylates the endogenous DNA strand. As the endogenous DNA strands 
reanneal, hemi-methylated template is formed again and is targeted by DNMT1 producing 
a fully methylated segment of DNA. 
In an in vitro model of hepatocellular carcinoma, the application of methylated 
oligonucleotides resulted in a rapid significant decrease in RNA expression of the selected 
gene. Methylation induction at the targeted region could already be observed eight hours after 
delivery of the methylated oligonucleotides into the cells (Yao et al., 2003). More 
importantly, the approach employed in vivo led to a markedly prolonged survival of treated 
animals as compared with negative controls. Interestingly, when stability of the effect was 
assayed in vitro, the inhibiting effect was present after one cell passage but lost in the 
following one (Yao et al., 2003). The process leading to demethylation was not examined 
further in detail. In a different study, not only was methylation induced by methylated 
oligonucleotides stable but it also promoted histone modifications associated with chromatin 
silencing (Ma et al., 2010). Also, induced methylation was reported to spread to adjacent sites 
(Zhu et al., 2004). 
 
1.3.2 Induction of DNA Methylation by In Vitro-Methylated Fragments 
 
An alternative to the aforementioned method relies on longer single-stranded DNA fragments 
targeting the selected region (Hsiao et al., 2010; Hsu et al., 2011; Teng et al., 2011). The 
principle of functioning is basically identical to the one described above for methylated 
oligonucleotides, requiring replication or transcription. This approach has the advantage that 
it targets both endogenous DNA strands simultaneously, providing higher efficiency. 
There are two ways to achieve methylation of a fragment in vitro. The first one employs 
methyltransferase SssI and a donor of the methyl group, S-adenosylmethionine. SssI 
methylates cytosines in the context of CpG dinucleotides on both strands, which results in 
methylation of the fragment equivalent to physiological conditions. The other possibility 
utilises direct incorporation of methylated cytosines into the fragment during PCR 
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amplification. As a result, the fragments contain methylated cytosines in the physiological 
context as well as outside of CpG dinucleotides, which occurs rarely in the human genome. 
It has been shown that methylation of the TRIP10 promoter in human mesenchymal stem cells 
mediated by the application of in vitro-methylated fragments accelerates their differentiation. 
Methylation induced by this technique was maintained over several passages but could be 
reversed by methyltransferase inhibitors (Hsiao et al., 2010). Induced methylation of two 
tumour suppressor genes in mesenchymal stem cells was sufficient to cause their 
transformation into malignant cells (Teng et al., 2011). Using in vitro-methylated fragments, 
it is possible to silence even strong viral promoters such as CMV (Hsu et al., 2011). 
 
1.3.3 Induction of DNA Methylation by a Modified CRISPR/Cas System 
 
1.3.3.1 CRISPR/Cas 
 
Bacteria and archaea developed adaptive immune defence systems termed clustered regularly 
interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) as a protection 
against viruses or plasmids (Bhaya et al., 2011; Terns & Terns, 2011; Wiedenheft et al., 
2012). Nearly all archaea and about half of bacteria are equipped with CRISPR/Cas systems 
(Grissa et al., 2007; Rousseau et al., 2009). CRISPR loci contain short repeat sequences of 30 
to 40 nucleotides separating variable sequences of comparable size (Kunin et al., 2007). The 
variable sequences (also named spacers or guides) are derived from invaders (Bolotin et al., 
2005; Lillestol et al., 2006). Transcripts of the CRISPR locus are cleaved into small crRNAs 
(CRISPR RNAs) that target foreign nucleic acids and induce their degradation (Brouns et al., 
2008; Hale et al., 2009). Cas genes are organised in operons situated near CRISPR loci in the 
genome and represent the effector nucleases in the defence systems (Jansen et al., 2002; Terns 
& Terns, 2011; Wiedenheft et al., 2012). Together with crRNAs, Cas proteins form 
ribonucleoprotein complexes (Wang et al., 2011; Gasiunas et al., 2012). tracrRNA 
(transactivating RNA) pairs with a repeat sequence found in crRNA and is essential for 
activating DNA cleavage by Cas. Reaction to invaders occurs in three phases. In the 
acquisition step, foreign fragments are integrated into the host genome at the proximal end of 
a CRISPR locus (Bhaya et al., 2011; Terns & Terns, 2011; Wiedenheft et al., 2012). In the 
expression stage, CRISPR transcripts are generated, processed to produce crRNAs and 
assembled with Cas into ribonucleoprotein complexes (Haurwitz et al., 2010; Deltcheva et al., 
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2011; Wang et al., 2011). In the interference phase, base-pairing of crRNAs mediates target 
recognition and the foreign sequence is eliminated by the nuclease activity of the complex 
(Brouns et al., 2008; Lintner et al., 2011; Hale et al., 2012). 
Out of the three described types of CRISPR/Cas systems (Makarova et al., 2011), especially 
type II relying on Cas9 has been widely adopted as a tool for genetic engineering (Terns & 
Terns, 2014). The only requirement restricting target selection is the presence of a sequence 
motif known as PAM (protospacer adjacent motif) directly neighbouring the target site (Terns 
& Terns, 2014). For Cas9 from Streptococcus pyogenes, this motif is minimal, a 5’-NGG-3’ 
trinucleotide (Fonfara et al., 2014; Jinek et al., 2012; Cong et al., 2013). This system was 
adjusted to a more straightforward variant requiring a single-guide RNA (sgRNA or gRNA) 
molecule instead of the original two, the targeting crRNA and the activating tracrRNA (Jinek 
et al., 2012). Furthermore, diverse variants of Cas9 were developed to better suit research 
purposes (Gasiunas & Siksnys, 2013; Jinek et al., 2013). Wildtype Cas9 utilises different 
nuclease active sites in RuvC and HNH nuclease domains to cut each DNA strand. The 
induced DNA double-strand breaks are repaired by the cellular error-prone non-homologous 
end joining pathway (Terns & Terns, 2014). Inactivation of one of the domains yields 
a nicking enzyme favouring homologous recombination as a repair mechanism with a more 
predictable outcome (Cong et al., 2013; Mali et al., 2013). This system may well be employed 
to introduce insertions or deletions in a reliable manner. Modification of both nuclease 
domains at a time produces a potent, targetable and site-specific DNA-binding complex 
capable of impairing or silencing gene expression by interfering with transcription initiation 
or elongation, respectively (Qi et al., 2013). However, steric hindrance may contribute to gene 
expression activation as well when directed to transcriptional repressor binding sites (Qi et 
al., 2013). Fusion constructs of the Cas9 complex with transcription modulators, for instance 
VP16 for activation, conveys even higher precision in transcription control than mere DNA-
binding complexes (Bikard et al., 2013; Cheng et al., 2013). In general, targeting specificity 
has extensively been studied and the system has undergone substantial engineering to 
minimise off-target effects (Kleinstiver et al., 2016; Slaymaker et al., 2016). It can be tailored 
to facilitate effective genome editing of virtually any kind. 
The CRISPR/Cas9 technology offers several advantages over the established ZFNs (zinc 
finger nucleases) and TALENs (transcription activator-like effector nucleases) gene-editing 
methods. Performance efficiency is comparable or higher relative to both approaches (Jinek et 
al., 2013; Mali et al., 2013). More importantly, targeting a new site only requires designing 
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a gRNA complementary to the selected sequence, which is faster, easier and more cost-
effective than creating a new ZNF or TALEN protein. In addition, more than one site may be 
targeted at a time (Cong et al., 2013; Mali et al., 2013). Also, combining Cas9 proteins with 
different PAM sequence specifications provides further targeting possibilities (Cong et al., 
2013; Esvelt et al., 2013; Fonfara et al., 2014). The flexibility and the straightforward 
implementation of CRISPR/Cas9 outperform both ZFNs and TALENs in more ways than 
one. 
 
1.3.3.2 Induction of DNA Methylation by CRISPR/Cas9 
 
Up to now, most targeted epigenetic tools utilised ZNFs or TALENs. As described above, 
there are certain disadvantages to the systems and CRISPR/Cas9 is gradually replacing them. 
Fusion proteins of the inactivated Cas9 nucleases with histone acetyltransferases or histone 
demethylases targeting regulatory elements represent only some of the possible options the 
technology offers regarding epigenetic modifications (Hilton et al., 2015; Kearns et al., 2015; 
Thakore et al., 2015). Constructs with the C-terminal domain of DNA methyltransferase 
Dnmt3a alone or with Dnmt3L in addition can be utilised to successfully introduce 
methylation at CpG islands free of methylation within gene promoters (Siddique et al., 2013; 
McDonald et al., 2016; Vojta et al., 2016) (Fig. 3). It has been shown that the presence of the 
co-factor Dnmt3L increases the efficiency of methylation induction (Stepper et al., 2017). 
Methylation was most prominent at the sites adjacent to the gRNA binding site, 25 bp 
upstream and 40 bp downstream of it. Spreading of methylation has been observed 
preferentially to regions approximately 200 bp apart from the gRNA binding site, both 
downstream and upstream, suggesting probable blocking by nucleosomes. Such observations 
have also been made previously in studies inducing targeted methylation using ZNFs or 
TALENs. Upon methylation induction, gene repression has been detected (Li et al., 2007; 
Bernstein et al., 2015; Stolzenburg et al., 2015). As described above, modified Cas9 binds to 
DNA and causes impairment of gene expression on its own. Indeed, this effect did contribute 
to the decrease in expression, as shown by a negative control experiment with an inactive 
mutant protein incapable of inducing methylation that also partly reduced expression. 
However, the difference in repression caused by the active and the inactive variant was 
significant (Stepper et al., 2017). Constructs capable of multimerisation due to favourable 
interactions between the interfaces of adjacent proteins facilitate DNA methylation as far as 1 
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kb away from the target site. Fibres formed by the components are likely oligomers but 
methylation of distant regions could be accomplished by DNA looping and subsequent 
assembly of new filaments at these sites (Jurkowska et al., 2008; Rajavelu et al., 2012; 
Emperle et al., 2014). 
 
 
Figure 3 
Figure 3. Schematic depiction of a methylating CRISPR/Cas9 system. A fusion protein of Cas9 from 
Streptococcus pyogenes with catalytic domains of DNMT3A and DNMT3L (blue) is engineered to induce 
methylation (black lollipops) instead of double-strand DNA breaks. Guide RNA (here sgRNA) targeting the 
complex to the selected sequence is indicated. The figure was adapted from www.neb.com. 
 
Implementation of the CRISPR/Cas9 system functionally coupled to methyltransferases has 
a great potential not only in gene expression regulation. Its accuracy and efficiency, yet 
combined with exceptional adaptability, allows for many possible applications with the 
capacity of causing durable effects. Another advantage over the two other methods utilising 
methylated oligonucleotides or in vitro-methylated fragments to induce methylation is the 
independence of the approach from mitosis or transcription. 
 
Up to date, none of the mentioned techniques has been used to target imprinted loci. 
Successful implementation of any of them at an imprinted locus would represent a proof of 
concept in epigenetic therapy and, in the long term, could perhaps contribute to the 
development of a new means of treatment. 
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1.4 Aim 
 
In the first part of this study, the aim was to establish a functional iPSC model of Angelman 
syndrome. The molecular cause of Angelman syndrome is the absence of a functional E3 
ubiquitin protein ligase UBE3A in the brain, whose expression occurs only on the maternal 
allele. The imprinting centre PWS-SRO that indirectly regulates the expression of UBE3A is 
not methylated on the paternal allele. This allows the expression of the long non-coding RNA 
SNHG14 that silences the paternal UBE3A allele by transcriptional interference, thus 
excluding the possibility of allele compensation. Up to now, only a few direct targets of 
UBE3A have been identified. Very limited knowledge is available on the manifestation of 
UBE3A loss on the symptoms characteristic for the disorder. Since brain tissue from patients 
during the course of development cannot be obtained, the first milestone to facilitate the study 
was to successfully reprogram donor skin fibroblasts by a lentiviral vector into patient-
specific and healthy control iPSCs. Their careful characterisation and the confirmation of 
their pluripotency was an essential prerequisite for further work. Standard methods of 
verifying pluripotency were employed, that is, AP staining, immunocytochemistry, FACS and 
qRT-PCR. In addition, EB formation assay, TaqMan array, Epi-Pluri-Score analysis, and 
teratoma formation assay as the most stringent pluripotency test were performed. Quality 
testing included Southern blot, Sanger sequencing, karyotyping and high-resolution HLA 
typing. Second, it was necessary to develop a reliable neuronal differentiation protocol in 
order to obtain mature neurons from the iPSCs. This part of the project was addressed in 
cooperation with Anika Neureiter. Silencing of the paternal UBE3A allele by SNHG14 occurs 
during neuronal maturation. It is the mechanism preventing allele compensation in case the 
maternal allele is lost or damaged. To determine when exactly the silencing takes place, the 
expression dynamics of the respective parental alleles throughout the process of neuronal 
differentiation were investigated. In order to do this, the three-base pair deletion present in the 
maternal UBE3A allele of the patient-derived iPSCs was used as a SNP and single-nucleotide 
primer extension assay of cells at selected stages of neuronal differentiation was performed. 
In addition, I developed a quantitative assay to evaluate the expression levels of both parental 
UBE3A alleles during differentiation separately in more detail. 
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In the second part of the project, I aimed to induce methylation at the paternal PWS-SRO. 
Since the presence of methylation is usually associated with transcriptional silencing, my 
hypothesis was that introducing methylation at this region would lead to the abolishment of 
SNHG14 expression. Successful interference with SNHG14 expression would then activate 
the paternal UBE3A allele and allow compensation for the defective maternal allele. First, it 
was necessary to assess the level of methylation at the locus I planned to methylate and 
evaluate its stability, which was essential for the model to work. Apart from PWS-SRO, I 
analysed the methylation status at five other differentially methylated loci by next-generation 
bisulphite sequencing to investigate their stability during reprogramming. I performed the 
analyses not only in the patient-derived and healthy control iPSCs generated in this study but 
also in hESCs H1 and H9, and the previously published Angelman syndrome iPSC line AGI-
0 and its healthy iPSC counterpart MCH2-10. For comparison, I assessed the methylation 
status in the parental fibroblasts used for reprogramming. To induce methylation at the 
paternal PWS-SRO, I utilised three different methods: 1) artificial methylated 
oligonucleotides, 2) in vitro-methylated fragments, and 3) a modified CRISPR/Cas9 system 
fused with DNMT3A and DNMT3L. I employed the iPSC line AGI-0 for the optimisation 
phase because it harbours a large deletion on chromosome 15 encompassing the whole 
maternal PWS-SRO and therefore exhibits only unmethylated reads in the next-generation 
bisulphite sequencing analysis. Thus, it was easier to evaluate the extent of methylation 
induced by the respective applied methods. 
This study introduced a new iPSC model of Angelman syndrome. In comparison with the 
already existing Angelman syndrome iPSC lines, it has the advantage of both parental UBE3A 
alleles being present. This makes it possible to study their expression dynamics in detail and 
to identify potential interaction partners of UBE3A, thereby also the pathways affected by its 
physical or functional absence. 
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2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Chemicals, Enzymes and Solutions 
 
Chemicals and enzymes were purchased from AppliChem (Darmstadt), BD (Heidelberg), 
Bio-Rad Laboratories (Munich), Biozym Scientific (Hessisch Oldendorf), Carl Roth 
(Karlsruhe), Merck (Darmstadt), New England Biolabs (Ipswich, MA, USA), PeproTech 
(Hamburg), Peqlab (Erlangen), Promega (Mannheim), Qiagen (Hilden), Roche (Mannheim), 
Sellekchem (Munich), Sigma-Aldrich (Hamburg), STEMCELL Technologies (Cologne), 
tebu-bio (Offenbach), Thermo Fisher Scientific (Braunschweig) and VWR International 
(Langenfeld). 
 
2.1.1.1 DNA Markers 
 
FastRulerTM DNA Ladder, Ultra Low Range, Thermo Fisher Scientific 
FastRulerTM DNA Ladder, Low Range, Thermo Fisher Scientific 
FastRulerTM DNA Ladder, Middle Range, Thermo Fisher Scientific 
MassRulerTM DNA Ladder, Low Range, Thermo Fisher Scientific 
 
2.1.1.2 Oligonucleotides 
 
All primers and oligonucleotides including the synthetically methylated ones were created 
with the Geneious and Primer3 software (geneious.com; bioinfo.ut.ee/primer3-
0.4.0/primer3/), and synthesised by Biomers (Ulm), Metabion (Planegg) or Gene Tools 
(Philomath, OR, USA) with the exception of qRT-PCR probes, which were designed with the 
Primer Express software and purchased from Eurogentec (Cologne). 
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2.1.1.3 Enzymes 
 
Restriction and methylation enzymes and their co-factors were purchased from New England 
Biolabs (Ipswich, MA, USA), GoTaq Green 2 Hot Start Polymerase and GoTaq G2 Flexi 
from Promega (Mannheim), Q5 Hot Start High-Fidelity DNA Polymerase from New England 
Biolabs (Ipswich, MA, USA), HotStarTaq from Qiagen (Hilden), DNase I from Promega 
(Mannheim), qRT-PCR master mixes from Qiagen (Hilden) and Roche (Mannheim). 
 
2.1.1.4 Antibodies 
 
Primary antibodies for the determination of pluripotency of iPSCs by immunohistochemical 
staining as well as secondary antibodies were bought from Cell Signaling Technology 
(Leiden, The Netherlands) as part of the StemLightTM Pluripotency Antibody Kit. 
 
Primary antibodies 
 
StemLight™ Pluripotency Antibody Kit #9656 including: 
Oct-4A (C30A3) Rabbit mAb 
Nanog (D73G4) XP® Rabbit mAb 
Sox2 (D6D9) Rabbit mAb 
SSEA4 (MC813) Mouse mAb 
TRA-1-60(S) (TRA-1-60(S)) Mouse mAb 
TRA-1-81 (TRA-1-81) Mouse mAb 
 
Secondary antibodies 
 
Anti-rabbit IgG (H+L), F(ab´)2 Fragment (Alexa Fluor® 555 Conjugate), Cell Signaling 
Technology, #4413S 
Anti-mouse IgG (H+L), F(ab´)2 Fragment (Alexa Fluor® 488 Conjugate), Cell Signaling 
Technology, #4408S 
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Antibodies used for the determination of pluripotency of iPSCs by fluorescence-activated cell 
sorting (FACS) were purchased from BioLegend (Fell). 
 
SSEA4: Alexa Fluor® 647 anti-human #330408 
TRA-1-60: PE anti-human TRA-1-60-R #330610 
TRA-1-81: Alexa Fluor® 488 anti-human #330710 
 
2.1.1.5 Media for Bacterial Culture 
 
All prepared media were sterilised by autoclaving before use. For selection purposes, 
antibiotics were added to the media. 
 
LB liquid medium   10 g/l tryptone 
     5 g/l yeast extract 
     10 g/l natrium chloride 
 
LB agar plates   10 g/l tryptone 
     5 g/l yeast extract 
     10 g/l natrium chloride 
12 g/l agar 
 
Antibiotics    100 g/ml ampicillin 
     30 g/ml kanamycin    
 
2.1.1.6 Media for Culturing Murine and Human Cells 
 
MEFs and HEK293 cell line were cultured in DMEM medium supplemented with 10 % FBS 
and 1 % penicillin/streptomycin. 
 
DMEM medium   10 % (v/v) foetal bovine serum 
     1 % (v/v) penicillin/streptomycin 
     in DMEM, high glucose 
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Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) were 
cultured under feeder-dependent conditions in KSR medium or under feeder-independent 
conditions in the commercially available medium mTeSR™1 purchased from STEMCELL 
Technologies. 
 
KSR medium    10 % knockout serum replacement 
     2 mM glutamine 
     1 % non-essential amino acids 
     50 U/ml penicillin/streptomycin 
     0.1 mM 2-Mercaptoethanol 
     4 ng/ml basic fibroblast growth factor 2 
     in DMEM/F-12 
 
2.1.2 Organisms 
  
2.1.2.1 DH5α Competent E. coli 
 
The bacterial strain DH5α was purchased from Thermo Fisher Scientific (#18265-017). It was 
used for conventional cloning procedures and possesses the following genotype: 
F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 rec A1 end A1 hsdR17(rk-, mk+) phoA supE44 thi-
1 gyrA96 relA1 λ- 
 
2.1.2.2 Murine Embryonic Fibroblasts 
 
In order to prevent differentiation of hESCs and iPSCs, mitotically inactivated MEFs were 
used for their cultivation under feeder-dependent conditions. MEFs were purchased from 
Applied StemCell (Milpitas, CA, USA), expanded in DMEM supplemented with 10 % FBS 
and 1 % penicillin/streptomycin, and mitotically inactivated by ionising irradiation with the 
dose of 40 Gray. 
  
  
 Materials and Methods 
 
 39 
2.1.2.3 Human Embryonic Kidney Cells 293 
 
Cells of the strain HEK293 were transfected with fluorescently labelled compounds or 
plasmids expressing GFP (green fluorescent protein) or YFP (yellow fluorescent protein) to 
test the quality of the fluorescence signal. They were also used for transfection with a plasmid 
carrying wildtype Cas9 together with plasmids carrying gRNAs to verify their efficiency. 
HEK293 cells were kindly provided by Dr. Stefan Heinrichs from the Institute for 
Transfusion Medicine, University Hospital Essen. 
  
2.1.2.4 Human Embryonic Stem Cells 
 
Cell line H1 and, in some cases, also H9 served as positive controls in experiments carried out 
to prove the pluripotency of iPSCs, which were generated in this study in cooperation with the 
group of Dr. Hannes Klump (Institute for Transfusion Medicine). The use of H1 and H9 is in 
compliance with the German Stem Cell Law and covered by permission AZ:3.04.02/0099. 
Both cell lines were purchased from WiCell Research Institute, Inc., Madison, WI, USA and 
their import is covered by permission AZ 1710-79-1-4-49. Human embryonic stem cells were 
first isolated from human blastocysts by James Thomson (Thomson 1998). 
 
2.1.2.5 Induced Pluripotent Stem Cells 
 
Cell lines AGI-0 and MCH2-10 were kindly provided by Prof. Dr. Stormy Chamberlain, 
Farmington, CT, USA (Chamberlain et al., 2010). They represented positive iPSC controls in 
experiments performed with iPSCs generated in this study. AGI-0 is an iPSC line derived 
from a patient with Angelman syndrome carrying a large deletion of approximately 6 Mb on 
the maternal chromosome 15. MCH2-10 is a heathy control iPSC line. 
For the purposes of this study, two cell lines were generated by reprogramming dermal 
fibroblasts with Yamanaka factors. Line AS_Δ3 is a patient-specific cell line, line M55045 is 
a healthy control line. 
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2.1.2.6 Nude mice  
 
Immunodeficient NMRI nude mice Crl:NMRI-Foxn1nu were used for teratoma formation 
assay to confirm the pluripotency of iPSCs studied in this project. The experiment was 
approved by the Committee on the Ethics of Animal Experiments of Landesamt für Natur, 
Umwelt und Verbraucherschutz, LANUV AZ 8.87-50.10.37.09.187 and AZ 84-
04.04.2013.A350 and was performed by Dr. Diana Klein (Institute for Cell Biology, 
University Hospital Essen). 
  
 
2.2 Methods 
 
2.2.1. General Molecular Biology Methods 
 
2.2.1.1 Small-Scale Preparation of Plasmid DNA 
 
A single colony of E. coli transformed with the plasmid of interest was inoculated in 3 ml LB 
medium supplemented with appropriate antibiotics and cultivated at 37 °C at 250 rpm 
overnight (G25 Incubator Shaker, New Brunswick Scientific, Nürtingen). 1.5 ml of the cell 
suspension was centrifuged in a 1.5 ml reaction tube for 20 s at 14 000 rpm and the 
supernatant was discarded. The pellet was resuspended in 300 µl buffer P1 (4 °C, Qiagen). 
300 µl buffer P2 (Qiagen) were added and the reaction tube was inverted several times to mix 
the sample. Incubation at RT followed for 3 min. 300 µl buffer P3 (Qiagen) were added to 
stop the lysis. The sample was mixed by inversion and centrifuged for 10 min at 13 000 rpm. 
The supernatant was transferred to a new reaction tube containing 500 µl 100 % ethanol, 
mixed well by vortexing and centrifuged for 10 min at 13 000 rpm. The precipitated DNA 
pellet was washed with 150 µl 70 % ethanol, centrifuged for 5 min at 13 000 rpm, the 
supernatant was removed and the pellet was left to air-dry for at least 10 min before it was 
resuspended in 30 µl H2O. 
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2.2.1.2 Large-Scale Preparation of Plasmid DNA 
 
Preparations of plasmid DNA in large amounts were performed with the ZymoPURETM 
Plasmid Maxiprep Kit following the manufacturer’s instructions. 250 ml to 500 ml overnight 
culture were used for the preparations. 
 
2.2.1.3 Isolation of Genomic DNA 
 
Cell pellet of maximum 5 x 106 cells was resuspended in 1 ml lysis buffer and, when needed, 
incubated at 56 °C until the solution appeared completely clear. 400 µl saturated 5 M NaCl 
were added, the sample was mixed by inversion several times and centrifuged for 7 min at 
14 000 rpm. The supernatant was transferred to a fresh 1.5 ml reaction tube containing 840 µl 
100 % isopropanol and inverted until DNA precipitate could be seen. The sample was 
centrifuged for 7 min at 14 000 rpm and the supernatant was discarded. The DNA pellet was 
washed with 750 µl 70 % ethanol, centrifuged for 7 min at 14 000 rpm, the supernatant was 
removed and the pellet was left to air-dry for at least 10 min. The DNA was then resuspended 
in 30 µl to 100 µl TE buffer, pH 8, depending on the size of the pellet. 
 
Lysis buffer 
 
TEN buffer    2 ml 
SDS 10 %    1 ml 
Proteinase K    0.5 ml 
H2O     6.5 ml 
 
TEN buffer 10x 
 
Tris-Cl, pH 8    0.1 M 
EDTA pH 8    0.01 M 
NaCl    1 M 
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2.2.1.4 Concentration Measurements of Nucleic Acids in Solution 
 
To determine the concentration of nucleic acids in solution, photometric adsorption of the 
samples was measured at λ = 260 nm, λ = 280 nm and λ = 230 in an ND-1000 
Spectrophotometer (NanoDrop Technologies). OD260 = 1 corresponds to a concentration of 
50 µg/ml DNA or 40 µg/ml RNA. Ratios OD260 / OD280 and OD260 / OD230 indicate the purity 
of the sample. The former ratio equals 1.8 for pure DNA and 2.0 for pure RNA. The latter 
ratio lies between 2.0 and 2.2 for both pure DNA and RNA. Lower values are caused by the 
presence of proteins, phenol or other substances absorbing at λ = 280 nm or λ = 230 nm. 
 
2.2.1.5 Bisulphite Conversion 
 
In order to assess the methylation status of a specific DNA region, bisulphite conversion of 
500 ng DNA was performed using EZ DNA Methylation-Gold™ Kit (Zymo Research). For 
low cell counts, EZ DNA Methylation-Direct™ Kit (Zymo Research) was used, which allows 
for direct conversion from the cells without prior DNA isolation, thereby reducing DNA loss. 
The application was carried out according to the manufacturer’s instructions for the respective 
kits. Bisulphite-converted DNA was subsequently amplified by PCR and sequenced by 
Sanger sequencing or next-generation bisulphite sequencing. 
 
2.2.1.6 PCR 
 
Polymerase chain reaction was performed to amplify regions of interest from plasmid DNA, 
genomic DNA, bisulphite-converted DNA or cDNA. GoTaq G2 Hot Start Green Master Mix 
(Promega), GoTaq G2 Flexi (Promega), HotStarTaq Master Mix Kit (Qiagen), Q5® Hot Start 
High-Fidelity DNA Polymerase (NEB) and Q5® Hot Start High-Fidelity 2x Master Mix 
(NEB) were used. When not using a master mix, the reactions were performed in the buffer 
supplied by the manufacturer of the respective polymerases with MgCl2 added if necessary, 
400 nM to 1000 nM primers, 200 µM to 500 µM dNTP mix, 50 ng to 500 ng DNA template 
and 0.1 U to 0.5 U polymerase in total volumes of 25 µl or 50 µl. 
The initial denaturation phase was followed by 25 to 45 cycles of denaturation, primer 
annealing and elongation, and a final elongation phase. The primer annealing temperatures 
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were given by Geneious, Primer3 or Primer Express software and are generally calculated 
using the formula published by Chester & Marshak, 1993. For applications using products 
from NEB, the annealing temperatures were calculated with the manufacturer’s online tool 
http://tmcalculator.neb.com/#!/. PCR programmes are specified in the Appendix. 
 
2.2.1.7 DNA Sequencing 
 
Sequencing of plasmid DNA, PCR products or bisulphite-converted DNA was performed 
using BigDye® Terminator v1.1 Cycle Sequencing Kit (Thermo Fisher Scientific). 1 µl 
BigDye®, 1 µl reaction buffer, 0.5 µM primer and up to 500 ng template DNA were used in 
a total volume of 10 µl. Sequencing of bisulphite-converted DNA was performed with 4 µl 
BigDye® without the addition of reaction buffer. The sequencing PCR began with 
a denaturation phase at 96 °C for 1 min. 25 cycles of denaturation at 96 °C for 10 s, annealing 
at a temperature determined by the primer for 5 s, and elongation at 60 °C for 4 min ensued. 
The samples were filled up to 20 µl with H2O and purified with sephadex columns. Sephadex 
(GE Healthcare) was filled into a MultiScreen-HV plate (Merck) using the MultiScreen 45 µl 
Loader (Millipore) and 300 µl H2O were added to each well. Columns were incubated at 4 °C 
for at least 3 h. The plate was centrifuged at 900 x g for 5 min before use. The sequencing 
reactions were loaded onto the sephadex columns and centrifuged at 900 x g for 5 min into 
a Thermo-Fast 96 PCR Detection Plate (Thermo Fisher Scientific). 10 µl Hi-Di™ formamide 
(Thermo Fisher Scientific) were added to each well. The samples were analysed with Genetic 
Analyzer 3130xl (Thermo Fisher Scientific) and the results were analysed with the 
programmes Sequencing Analysis v6.0 and Geneious. 
 
2.2.1.8 Next-Generation Bisulphite Sequencing 
 
Samples prepared by bisulphite conversion and subsequent PCR amplification were further 
processed for analysis of DNA methylation on the 454 Roche Genome Sequencer Junior 
System. A Re-PCR was performed with MID primers that bind to tag sequences of primers 
used in the previous PCR. In addition to the tag sequence, the MID primers contain 
a multiplex identifier (hence the name) specific for the sample, an adaptor and a key sequence 
for sequencing on the platform. The Re-PCR reaction contained 2 µl to 6 µl PCR product 
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from the first PCR, and 0.2 µM forward and reverse primer each in HotStarTaq Master Mix 
(Qiagen) in a total volume of 50 µl. After initial denaturation at 95 °C for 15 min, 35 cycles of 
denaturation at 95 °C for 30 s and annealing/extension at 72 °C for 1 min ensued, followed by 
a final elongation phase at 72 °C for 5 min. In rare cases, three-step Re-PCR was performed 
with the usual annealing step in addition. The Re-PCR products were analysed by gel 
electrophoresis. In case it was necessary to purify the fragments of interest, gel excision and 
isolation with Wizard® SV Gel and PCR Clean-Up System (Promega) were performed. The 
volume of the samples was filled up to 45 µl with H2O. The subsequent steps were executed 
by laboratory technicians Sabine Kaya, Melanie Heitmann or Claudia Mertel (Institute of 
Human Genetics, University Hospital Essen). The Re-PCR products were purified with 
Agencourt® AMPure® XP system (Beckman Coulter) following the instructions of Roche 
Diagnostics (Amplicon Library Preparation Method Manual). Then the samples were diluted, 
pooled and clonally amplified in single droplets in emulsion PCR (emPCR Amplification 
Method Manual – Lib-A). The droplets contain a single amplicon bound to one DNA capture 
bead and primers that bind to the adaptor sequence of the MID primers used in the Re-PCR. 
After amplification, the beads were washed, recovered, enriched and transferred to 
a microtiter plate (GS Junior Titanium PicoTiterPlate Kit, Roche), whose wells accommodate 
exactly one bead to ensure purity of the amplicons. The plate was then loaded onto the 
sequencing platform (GS Junior Titanium Sequencing Kit, Roche) and analysed. Evaluation 
of the results ensued using the Amplikyzer software (Rahmann et al., 2013) with default 
settings but for rare cases. 
 
2.2.1.9 DNA Precipitation 
 
DNA solution was filled up to 100 µl with H2O, 10 µl 3 M sodium acetate, 250 µl 100 % 
ethanol and optionally 1 µl glycogen were added and the sample was incubated at -20 °C for 
at least 2 h. Then it was centrifuged for 30 min at 14 000 rpm at 4 °C and the supernatant was 
discarded. The DNA precipitate was washed with 500 µl 70 % ethanol and centrifuged again 
for 30 min at 14 000 rpm at 4 °C. The pellet was left to air-dry for at least 10 min and then 
resuspended in H2O. 
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2.2.1.10 DNA Purification  
 
Purification of PCR products was performed using the DNA Clean & Concentrator Kit (Zymo 
Research) or Agencourt® AMPure® XP system (Beckman Coulter) according to the 
manufacturers’ instructions. 
 
2.2.1.11 Agarose Gel Electrophoresis 
 
PCR products or DNA fragments generated by restriction digests were separated by size on 
1 % to 2 % (w/v) agarose gels. Agarose was boiled in 1 x TAE buffer and cooled. 0.4 µg/ml 
ethidium bromide (EtBr) was added. Samples were mixed with loading dye prior to loading to 
the wells. DNA markers were used to determine the size of the fragments. Gels were run in 
1 x TAE buffer containing 0.4 µg/ml EtBr at 60 V for Southern blots and at 120 V for all 
other applications. Fragments were visualised on a UV-transilluminator with λ = 312 nm. 
 
Buffer for Gel Electrophoresis 
 
1 x TAE Buffer   40 mM Tris 
     40 mM acetic acid 
     1 mM EDTA pH 8.0 
 
2.2.1.12 Gel Extraction of DNA 
 
DNA fragments of interest were excised from agarose gels after electrophoresis using the gel 
extraction tool X-Tracta II (Biozym) on a UV-transilluminator with λ = 312 nm. Wizard® SV 
Gel and PCR Clean-Up System (Promega) was used to purify the DNA according to the 
manufacturer’s instructions. 
 
2.2.1.13 Insertion of DNA Fragments into TOPO Vector 
 
Fragments bearing 3’-overhangs added by the polymerase during PCR were inserted into 
pCRTM2.1 using TA Cloning® Kit (Thermo Fisher Scientific) in a one-step ligation reaction. 
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2 µl PCR product and 2 µl pCRTM2.1 were incubated with 4 U T4-ligase in 1 x ligation buffer 
in a final volume of 10 µl at 14 °C overnight. 
 
2.2.1.14 Transformation of Competent Bacteria 
 
Transformation was performed using Subcloning Efficiency™ DH5α™ (Thermo Fisher 
Scientific) following the manufacturer’s instructions. Bacteria were plated onto agar plates 
supplemented with antibiotics and incubated at 37 °C overnight. 
 
2.2.1.15 Restriction Digests 
 
Genomic or plasmid DNA was digested by restriction enzymes suitable for the respective 
applications. Under optimal conditions, 1 U enzyme digests 1 µg DNA in 1 h. The restriction 
reactions were performed under conditions recommended by the manufacturer. The 
incubation times were 15 min to 20 h depending on the application. 
 
2.2.1.16 Southern Blot 
 
10 µg to 15 µg genomic DNA were digested with EcoRV and BamHI at 37 °C for at least 
16 h. The whole reaction was loaded onto a 1.0 % agarose gel and run at 60 V for 5 h to 6 h. 
A picture of the gel was taken with a fluorescent ruler on a UV-transilluminator with 
λ = 312 nm. The gel was denatured twice in denaturing solution (438 g NaCl and 100 g 
NaOH in 5 l) for 30 min. Southern blot assembly ensued. Three layers of Whatman paper 
(35 cm x 15 cm) were soaked in denaturing solution and placed over a block the size of an 
agarose gel set in a container half-filled with denaturing solution. Air bubbles were removed 
with a glass rod. The agarose gel was laid on the layer of Whatman papers and bubbles were 
removed again. Strips of Parafilm® M (Pechiney Plastic Packaging) were placed around the 
gel. Amersham Hybond™-XL membrane (GE Healthcare) soaked in denaturing solution was 
laid on the gel and bubbles were removed. Three additional Whatman paper were soaked in 
denaturing solution and layered over the blotting membrane. Bubbles were removed. A stack 
of paper towels was positioned at the top of the blot sandwich and weighted down with 
a metal block. The transfer of the DNA to the membrane ensued for at least 16 hours. The blot 
 Materials and Methods 
 
 47 
was then disassembled, gel slots were marked on the membrane with a pencil and the 
membrane was soaked in 20 mM Na2HPO4. With the help of a glass rod, the membrane was 
transferred into a 50 ml Falcon tube and a hole was pierced in the lid of the tube. Pre-
hybridisation in 4 ml pre-warmed Church buffer (7 % SDS, 1 mM EDTA, 0.5 M 
Na2HPO4/NaH2PO4 pH 7.2) ensued at 65 °C for 30 min. The probe was labelled with -32P-
dCTP using the Megaprime DNA Labeling System, dNTP (GE) and purified with the 
QIAquick Nucleotide Removal Kit (Qiagen) by Dr. Laura Steenpass (Institute of Human 
Genetics). Hybridisation followed at 65 °C overnight in 4 ml fresh Church buffer with 15 µl 
probe added. The membrane was briefly rinsed with pre-warmed Church buffer, washed twice 
with Church buffer for 30 min, sealed and exposed to film. 
 
2.2.1.17 Isolation of Total RNA 
 
Total RNA was isolated from cells using TRIzol® (Thermo Fisher Scientific) according to 
the manufacturer’s instructions or RNeasy® Mini Kit (Qiagen) also following the protocol 
supplied with the kit.  
 
2.2.1.18 Reverse Transcription of RNA 
 
In order to prevent false-positive results due to contamination with DNA, samples were 
treated with DNase using the RQ1 RNase-free DNase Kit (Promega) according to the 
manufacturer’s instructions prior to performing reverse transcription reaction. 1 U DNase was 
used to treat 1 µg RNA. The reverse transcription reaction ensued with 500 ng RNA, 
5 mM MgCl2, 1 mM dNTP each, 2.5 µM random hexamers, 1 U/µl RNase inhibitor and 
2.5 U/µl MuLV reverse transcriptase in PCR Buffer II in a total volume of 50 µl. A control 
reaction without the MuLV reverse transcriptase was performed. All substances were 
purchased from Thermo Fisher Scientific. 
 
2.2.1.19 Reverse-Transcription PCR 
 
To verify the specificity of selected primer pairs used in this project, PCR was performed on 
cDNA and the result was analysed by gel electrophoresis. 
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2.2.1.20 Quantitative Real-Time PCR 
 
qRT-PCR was used to assess the expression of a number of genes relative to a stably 
expressed housekeeper gene most suitable for the respective assays, GAPDH, RPL13A or 
ACTB. The normalisation of the studied gene to a housekeeper gene also serves the purpose of 
correcting variations, which may occur during the process of preparing cDNA, and allows for 
the results of different qRT-PCRs to be compared between each other in a reliable manner. 
The ΔΔCT method was used for calculation and the expression levels of the respective genes 
were set to 1 in the chosen reference sample. The result of a qRT-PCR is given as fold-
difference in the expression of the studied gene. SYBR Green binds to the newly synthesised 
DNA strands, thus the fluorescence detected at the end of each cycle is proportionate to the 
amount of PCR products. The cycle in which the fluorescence crosses a set threshold is 
determined as the CT (threshold cycle). This value is used to calculate the fold-change in the 
gene expression. Apart from not having to employ a labelled probe for each specific target, 
another advantage of performing qRT-PCR with SYBR Green is the possibility of verifying 
the specificity by subsequent melting curve analysis. The reactions contained 10 µl SYBR 
Green master mix, 0.5 µM forward and reverse primer each, and 10 ng cDNA in a total 
volume of 20 µl. The initial denaturation at 95 °C for 1 min was followed by 40 cycles of 
denaturation at 95 °C for 15 s and annealing/elongation at 60 °C for 30 s. The melting curve 
analysis ensued starting by denaturation at 95 °C for 1 min and annealing at 55 °C for 30 s, 
followed by a rise in temperature to 95 °C by 0.5 °C per step held for 30 s, after which the 
fluorescence was read. Plates were run on a CFX96™ Real-Time System C1000™ Thermal 
Cycler (Bio-Rad) and the generated data was analysed with the Bio-Rad CFX Manager 3.1 
software. 
 
2.2.1.21 Single-Nucleotide Primer Extension Assay 
 
The three-base pair deletion in Angelman syndrome iPSCs was used as a SNP to determine 
the allelic ratios of UBE3A. Analysis of cDNA prepared from mRNA isolated from 
pluripotent cells, neural progenitors and terminally differentiated neurons was performed 
using the ABI PRISM® SNaPshot™ Multiplex Kit (Thermo Fisher Scientific). Genomic 
DNA served as reference. The samples were prepared and sequenced by Michaela Hiber 
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(Institute of Human Genetics) and the data were evaluated using the Gene Mapper 4.0 
software (Applied Biosystems) by Dr. Laura Steenpass. 
 
2.2.1.22 Quantitative Allele Distinction of UBE3A 
 
To distinguish and quantify the expression from the wildtype paternal UBE3A allele and the 
maternal UBE3A allele harbouring a three-base pair deletion in Angelman syndrome iPSCs, 
qRT-PCR was employed utilising fluorescently labelled minor groove binding probes. The 
probes were designed with the Primer Express software to detect specifically the sequence 
with and without the triplet, respectively, and to match the Tm of 60 °C, while being as 
similar in length as possible. Artificial wildtype and mutant templates were developed by 
cloning a 280 bp cDNA fragment from Angelman syndrome iPSCs with the site of the 
deletion positioned in the middle into a vector. The presence or absence of the triplet was 
verified by Sanger sequencing. The respective plasmids were mixed in defined ratios from 
0:100 to 100:0 to create a standard curve for both targets at a time detected by probes labelled 
with different fluorophores. When using probes labelled with the same fluorophore, two 
separate standard curves were calculated for the paternal and the maternal UBE3A allele, 
respectively. 
  
2.2.2 Cell Culture 
 
2.2.2.1 Reprogramming of Fibroblasts into iPSCs 
 
Skin fibroblasts from a healthy control person were cultivated, expanded and subjected to 
reprogramming by a lentiviral vector expressing POU5F1, SOX2, KLF4 and MYC, and 
a reporter fluorescent protein (Voelkel et al., 2010). 5 x 105 cells were seeded on a 10-cm dish 
and transduced with an MOI (multiplicity of infection) of 5, that is, in a ratio of five virus 
particles per cell. Seven days later, cells expressing the reporter protein were isolated by 
fluorescence-activated cell sorting and 1000 cells/cm2 were plated on 10-cm dishes or 6-well 
plates in KSR medium supplemented with Rho-associated protein kinase (ROCK) inhibitor 
Y-27632 (Sellekchem), which enhances the recovery of freshly thawed cells or cells passaged 
as single cells. Colonies were isolated approximately four weeks later. Skin fibroblasts from 
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an Angelman syndrome patient were reprogrammed by Kristin Stolp in the laboratory of Dr. 
Hannes Klump at the Institute of Transfusion Medicine.  
 
2.2.2.2 Thawing Cryopreserved Cells 
 
Cells were stored at -80 °C for short-term storage and at -195 °C for long-term storage in 
liquid nitrogen. Frozen aliquots were thawed quickly in a water bath heated to 37 °C and 
diluted in 9 ml pre-warmed culture medium. Cells were centrifuged at 1000 rpm for 4 min, 
the pellet was resuspended in 1 ml culture medium and transferred to appropriate culture 
vessels. Stem cells were plated on a well of a 6-well plate (Nunc™ Cell Culture Treated 
Multidishes, Thermo Fisher Scientific) coated either with 0.2 % gelatine and a layer of feeder 
cells, or with Vitronectin XF™ (STEMCELL Technologies) containing 1 ml culture medium. 
The culture medium was supplemented with ROCK inhibitor. MEFs were transferred into 
a 75 cm2 culture flask after thawing (Greiner). 
 
2.2.2.3 Maintenance 
 
Cells were cultured in KSR medium or in mTeSR™1 at 37 °C and 5 % CO2 in a humidified 
incubator. When they reached confluency, they were passaged using Collagenase Type IV 
(STEMCELL Technologies), if grown under feeder-dependent conditions, Gentle Cell 
Dissociation Reagent (STEMCELL Technologies), if grown under feeder-free conditions, or 
StemPro® Accutase® Dissociation Reagent (Thermo Fisher Scientific), if single cells were 
needed.  
 
KSR medium    10 % knockout serum replacement 
     2 mM glutamine 
     1 % non-essential amino acids 
     50 U/ml penicillin/streptomycin 
     0.1 mM 2-Mercaptoethanol 
     4 ng/ml FGF2 
     in DMEM/F-12 
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2.2.2.4 Cryopreservation of Cells 
 
Cells were dissociated in the same manner as for passaging, centrifuged at 1000 rpm for 
4 min and the pellet was resuspended in freezing medium. 1 ml cell suspension was 
transferred to each cryo tube (Nunc™ CryoTubes™, Thermo Fisher Scientific) and incubated 
on ice for 20 min. The cells were kept in a polystyrene box at -80 °C for at least a week 
before being transferred to a liquid nitrogen tank. 
 
Freezing Medium   90 % foetal bovine serum 
     10 % DMSO 
 
 
2.2.2.5 Neuronal differentiation 
 
2.2.2.5.1 Dual SMAD Inhibition by Koch et al. 
 
Cell clumps were transferred to a 10-cm low-attachment dish and kept in basic medium. The 
medium was changed on day 2. On day 4, neuronal differentiation was initiated by dual 
SMAD inhibition; neural differentiation medium (NDM) was changed every other day. On 
day 12, embryoid bodies (EBs) were plated on a matrigel-coated 10-cm dish in NDM; 
medium change ensued every other day. On day 18, rosettes and neuroectodermal islands 
were isolated, treated with trypsin or TrypLE Express (Thermo Fisher Scientific) to obtain 
a single-cell suspension and seeded on a matrigel-coated well of a 6-well plate at high density. 
Neural progenitors were then differentiated further in NDM to terminally differentiated 
neurons (day 48). Alternatively, the cells were cultured in lt-NES medium to maintain them in 
the neural progenitor stage (Koch et al., 2009). 
 
NDM     50 % DMEM/F12 (120.5 ml) 
     50 % Neurobasal (120.5 ml) 
    2 mM glutamine 
    0.4 g glucose 
    100 U/ml penicillin/streptomycin 
 Materials and Methods 
 
 52 
     0.5 % N2 supplement 
     0.5 % B27 supplement 
     0.75 µg cAMP 
    0.25 µM LDN-193189 
    10 µM SB-431542 
 
Lt-NES    2 mM glutamine 
    0.4 g glucose 
    100 U/ml penicillin/streptomycin 
     1 % N2 supplement 
     0.1 % B27 supplement 
     10 ng/ml EGF 
     10 ng/ml FGF2 
     238.5 ml DMEM/F12 (filled up to 250 ml) 
 
2.2.2.5.2 Dual SMAD Inhibition by Chambers et al. 
 
Single cells were subjected to neuronal differentiation when confluency reached 90 % by 
changing the culture medium to SRM. On day 4, the medium was changed to SRM:N2 mixed 
in a ratio of 3:1, on day 6 to SRM:N2 mixed in a ratio of 1:1 and on day 8 to SRM:N2 mixed 
in a ratio of 1:3. On day 10, three wells of a 6-well plate were transferred to one well of a 6-
well plate in BASF medium and cultured for six days. The medium was replaced with 
BAGTC on day 17 and the cells were cultured for seven more days. BASF and BAGTC 
media were changed every other day (Chambers et al., 2009). Samples for the extraction of 
RNA were harvested on day 0, day 5, day 10, day 17 and day 24. 
 
SRM     15 % knockout serum replacement 
    2 mM glutamine 
  1 % non-essential amino acids 
     0.5 mM 2-Mercaptoethanol 
     100 nM LDN-193189 
     10 µM SB-431542 
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     in Knockout DMEM 
 
N2     1 % N2 supplement 
     2 mM glutamine 
     100 nM LDN-193189 
     10 µM SB-431542 
     in Neurobasal 
 
BASF     2 % B27 supplement without retinoic acid 
     1 % N2 supplement 
2 mM glutamine 
     20 ng/ml BNDF 
     200 µM ascorbic acid 
     50 ng/ml SHH 
     100 ng/ml FGF8 
     in Neurobasal 
 
BAGTC    2 % B27 supplement without retinoic acid 
     1 % N2 supplement 
2 mM glutamine 
     20 ng/ml BNDF 
     200 µM ascorbic acid 
     20 ng/ml GDNF 
     1 ng/ml TGFβ-III 
     500 µM dbcAMP 
     in Neurobasal 
 
2.2.2.5.3 Neuronal Differentiation by STEMdiff™ Neural Induction Medium 
 
Single cells were plated on a matrigel-coated well of a 6-well plate in STEMdiff™ Neural 
Induction Medium (STEMCELL Technologies) and cultured for 11 days. Medium was 
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changed every day. The cells were split and seeded on a new matrigel-coated well of a 6-well 
plate at the density of 2 x 105 cells/cm2 when they reached confluency, that is, on day 7 to 9. 
 
2.2.2.5.4 Dual SMAD Inhibition by Boissart et al. 
 
Neuronal induction was initiated by plating cell clumps on a matrigel-coated well of a 6-well 
plate in induction medium supplemented with ROCK inhibitor. Medium was changed every 
other day. On day 10, the monolayer was replated on a new matrigel-coated well of a 6-well 
plate in expansion medium, cultured for four more days and harvested on day 14 (Boissart et 
al., 2013). 
 
Induction medium   50 % DMEM/F12 
     50 % Neurobasal 
     0.5 % N2 supplement 
     0.5 % B27 supplement 
     100 nM LDN-193189 
     20 µM SB-431542 
     4 ng/ml FGF2 
 
Expansion medium   50 % DMEM/F12 
     50 % Neurobasal 
     0.5 % N2 supplement 
     0.5 % B27 supplement 
     10 ng/ml EGF 
     10 ng/ml FGF2 
 
2.2.2.6 Transfection of HEK Cells and iPSCs 
 
Cells were transfected using Lipofectamine® RNAiMAX Transfection Reagent (Thermo 
Fisher Scientific) following the manufacturer’s protocol. Methylated oligonucleotides, single-
stranded in vitro-methylated DNA or plasmid DNA, and lipofectamine were diluted in Opti-
MEM medium separately, then combined and incubated at RT for 5 min to allow for 
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complexes to form. The mixture was added dropwise to the cells. Medium was changed 24 
hours later. The efficiency of the transfection was analysed the following day by microscopy. 
 
2.2.2.7 Nucleofection of iPSCs 
 
Cells were nucleofected using the Amaxa™ Nucleofector™ Technology (Lonza) and the 
Human Stem Cell Nucleofector® Kit 2 according to the manufacturer’s instructions. The 
appropriate volume of the supplement and the Nucleofector® Solution were combined just 
prior to performing nucleofection. Cells were dissociated by StemPro® Accutase® 
Dissociation Reagent (Thermo Fisher Scientific) and the cell count was determined. The 
required number of cells was centrifuged at 1000 rpm for 4 min and the pellet was 
resuspended in the prepared Nucleofector® Solution in a ratio of 100 µl per 800 000 cells. 
DNA to be delivered into the cells was added to the cell suspension and the sample was 
mixed gently. 100 µl were transferred to a cuvette supplied with the kit without bubbles, the 
cuvette was closed and inserted into the Nucleofector™ 2b (Lonza), and the programme B016 
was applied. 500 µl culture medium were added to the cuvette and the cell suspension was 
gently transferred into a prepared 24-well plate with the supplied plastic pipettes. The 
efficiency of the nucleofection was analysed the following day by microscopy. 
 
2.2.2.8 Electroporation of iPSCs 
 
Cells were electroporated using the Neon® Transfection System (Thermo Fisher Scientific) 
following the protocol recommended by the manufacturer. Cells were dissociated by 
StemPro® Accutase® Dissociation Reagent (Thermo Fisher Scientific) and the cell count was 
determined. The required number of cells was centrifuged at 1000 rpm for 4 min and the 
pellet was resuspended in Opti-MEM to reach the density of 5 x 105 cells per 10 µl. DNA to 
be electroporated into the cells was added to the cell suspension and the sample was mixed 
gently. 10 µl cell suspension were taken into the Neon® Pipette tip, set into the pipette holder 
and the electric pulse of 1100 V was applied for 30 ms. Electroporation was performed by 
Sebastian Vogt (Department of Medical Oncology, University Hospital Essen). Cells were 
then seeded into prepared wells of 6-well or 24-well plates. The efficiency of the 
electroporation was analysed the following day by microscopy and on the third day by FACS. 
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2.2.2.9 Pluripotency Tests 
 
2.2.2.9.1 Alkaline Phosphatase Staining 
 
Colonies of hESCs and iPSCs were tested for the activity of alkaline phosphatase, whose high 
activity is a general marker of pluripotency, using the Alkaline Phosphatase Detection Kit 
(EMD Millipore) according to the manufacturer´s instructions. 
  
2.2.2.9.2 Immunocytochemistry 
 
Immunofluorescent antibody staining was performed using StemLight™ Pluripotency 
Antibody Kit (Cell Signaling Technology). Primary and secondary antibodies are listed in the 
section Materials. Cells were washed with PBS and fixed with 4 % paraformaldehyde for 
15 min. Washing thrice with PBS followed. Cells to be stained with nuclear markers were 
treated with 0.3 % Triton X-100 for 5 min and washed thrice with PBS. Blocking was 
performed for 30 min to 60 min with blocking buffer (48.5 ml PBS with 1.5 ml goat serum). 
Primary antibodies were diluted in antibody dilution buffer (49.5 ml PBS with 0.5 ml goat 
serum) as follows: Oct-4A, Sox2 and SSEA4 1:200, Nanog, TRA-1-60(S) and TRA-1-81 
1:100. Incubation ensued at 4 °C overnight. Cells were washed thrice with PBS and 
secondary antibodies diluted 1:1000 were added. After incubation at RT for 2 h in the dark, 
cells were washed thrice with PBS and incubated with DAPI diluted 1:200 at RT for 30 min 
in the dark. Finally, the cells were washed thrice with PBS and stored in 500 µl PBS at 4 °C 
in the dark until pictures were taken. 
 
2.2.2.9.3 Fluorescence-Activated Cell Sorting (FACS) 
 
Cells were dissociated with StemPro® Accutase® Cell Dissociation Reagent (Thermo Fisher 
Scientific) and feeder removal was performed with Feeder Removal MicroBeads (Miltenyi) 
according to the manufacturer’s instructions. 1 x 105 cells in 100 µl FACS buffer (90 % PBS, 
10 % FBS) were used per staining with antibodies or isotype controls. The volume of the 
respective antibodies and isotype controls added to the cells was either given by the 
manufacturer, or calculated using the general rule of 1 µg antibody per 1 x 106 cells. 
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Incubation at 4 °C for 20 min in the dark ensued. 1 ml FACS buffer was added and the 
samples were centrifuged at 700 x g for 5 min. The pellet was resuspended in 200 µl FACS 
buffer and transferred to FACS tubes for analysis on ARIA III (BD). BD FACSDiva™ 
software V8.0.1 and FlowJo® V10 (FlowJo LLC) software were used for evaluation of the 
results. Anika Neureiter performed the analysis and evaluation of the pluripotency assays. 
  
2.2.2.9.4 Quantitative Real-Time PCR 
 
cDNA prepared by reverse transcription of RNA was used for comparing expression levels of 
pluripotency marker genes POU5F1, SOX2, KLF4, MYC, NANOG, LIN28, DNMT3B and 
REX1 in hESCs and iPSCs. RPL13A and GAPDH were used for normalisation by the ΔΔCT 
method. Expression levels in hESCs were set to 1. QuantiFast SYBR Green PCR Kit was 
purchased from Qiagen and samples were analysed using BIORAD software. Detailed 
description of the method can be found in section 2.2.1.20. 
 
2.2.2.9.5 EB Formation Assay 
 
8 000 cells to 15 000 cells per well were seeded into V-bottom or U-bottom 96-well plates 
(Nunc™ 96-well Polystyrene V-bottom or U-bottom MicroWell™ Plates, Thermo Fisher 
Scientific), in 100 µl AggreWell™ EB Formation Medium (STEMCELL Technologies). On 
day 6, the formed embryoid bodies were transferred to 6-well plates with or without coating 
with 0.2 % gelatine and cultured until day 14 when they were harvested. Culture medium was 
changed every other day. EBs were analysed by qRT-PCR. 
 
2.2.2.9.6 Teratoma Assay 
 
For teratoma formation assay, cells were dissociated with StemPro® Accutase® Cell 
Dissociation Reagent (Thermo Fisher Scientific), centrifuged at 1000 rpm for 4 min, 
resuspended in DMEM/F-12 medium in a ratio of 50 µl medium per 1 x 106 cells and kept on 
ice. 50 µl growth factor reduced Matrigel (BD) were added per 50 µl medium and 100 µl 
(equals 1 x 106 cells) were injected into both hind limbs of two immunodeficient NMRI nude 
mice Crl:NMRI-Foxn1nu. Teratomas were explanted when skin lesions appeared or after the 
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maximum of 67 days. They were fixed, embedded in paraffin and cut into microsections. The 
assay was performed by Dr. Diana Klein. Staining with haematoxylin and eosin ensued at the 
Institute of Pathology, University Hospital Essen. Microscopic analysis for the presence of all 
three germ layers was performed by Prof. Dr. Agnes Bankfalvi (Institute of Pathology). 
 
2.2.2.10 Integrity Tests 
 
2.2.2.10.1 Karyotyping 
 
Cells were treated with 100 ng/ml colcemid (Roche) for at least four hours, then dissociated 
with StemPro® Accutase® Cell Dissociation Reagent (Thermo Fisher Scientific), centrifuged 
at 1000 rpm for 10 min, resuspended in 8 ml pre-warmed KCl solution (0.3 g KCl, 0.02 g 
EGTA, 0.48 g HEPES in 96 ml H2O) and incubated at 37 °C for 20 min. 1.5 ml freshly 
prepared fixative (methanol : acetic acid = 1:3) was added, the sample was mixed by 
inversion and centrifuged at 1000 rpm for 10 min. The supernatant was discarded and the 
pellet was washed thrice with 8 ml fixative. Finally, the pellet was resuspended in 250 µl to 
500 µl fixative and stored at -20 °C. Metaphase spreads were prepared by dropping the cell 
suspension onto glass slides, which were stored in 100 % ethanol at -20 °C and rinsed well 
with water prior to use. The slides were dried briefly on a plate heated to 60 °C, then baked 
overnight at 60 °C, treated with 2.5 % trypsin for 4 min, washed thrice in 0.9 % NaCl 
solution, stained with 10 % Giemsa solution for 3 min to 5 min, rinsed with water, air-dried 
and sealed with coverslips. Most metaphases were prepared and analysed by Elke Jürgens 
(Institute of Human Genetics) with an  Axioskop microscope (Zeiss) and Ikaros software v5.8 
(MetaSystems). 
 
2.2.3. Methylation Induction 
 
2.2.3.1 Methylated Oligonucleotides 
 
Artificial methylated oligonucleotides are protected from degradation by cellular nucleases by 
a phosphorothioate backbone. One non-bridging oxygen atom on the phosphate backbone is 
replaced by a sulphur atom, thus forming a phosphorothioate bond. The delivery of the 
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oligonucleotides into the cells was performed by transfection with Lipofectamine® 
RNAiMAX (Thermo Fisher Scientific) at the following concentrations: 0.5 µM, 2.0 µM, 
5.0 µM and 10.0 µM. The cells were harvested 24 h, 48 h and 72 h post transfection and 
analysed for the induction of DNA methylation at the targeted locus by Sanger sequencing of 
bisulphite-converted DNA. The concentration of 2.0 µM proved to be optimal for cell 
survival after treatment and was used in subsequent experiments. Three to six consecutive 
transfections were used to deliver the oligonucleotides into the cells every other day, or every 
three days. The cells were analysed microscopically for the presence of a fluorescence signal 
from one of the oligonucleotides 24 h post transfection and harvested after the third or the 
sixth round of treatment, respectively. Analysis of the targeted locus ensued by Sanger 
sequencing of bisulphite-converted DNA. As an alternative, nucleofection using the Amaxa™ 
Nucleofector™ Technology (Lonza) was employed for delivery in otherwise identical 
experimental settings. 
 
2.2.3.2 In Vitro-Methylated DNA Fragments 
 
DNA fragments were methylated in vitro using the M.SssI CpG methyltransferase (NEB) or 
during PCR with methylated dCTPs. For the former application, up to 4 µg DNA were 
incubated with 1 U/µl M.SssI methyltransferase and 320 µM SAM as the donor of the methyl 
group in NEB Buffer 2 in a total volume of 20 µl at 37 °C for 4 h. Then, fresh SAM was 
added to the reaction and the incubation continued overnight. For the latter application, 
plasmid DNA containing the required fragment was used as template and methylated dCTPs 
(Zymo Research) were added to the reaction. The ratio of methylated dCTPs to unmethylated 
dCTPs was 60:40. GoTaq G2 Flexi polymerase (Promega) was used for amplification. The 
success of the methylation was validated by restriction digest of 200 ng DNA with the 
methylation-sensitive enzyme HpaII. DNA fragments that had been methylated in vitro either 
by M.SssI CpG methyltransferase, or by PCR with methylated dCTPs were denatured at 95 
°C for 5 min and incubated on ice for at least 2 min prior to transfection. They were delivered 
into the cells by three to six consecutive rounds of transfection with Lipofectamine® 
RNAiMAX (Thermo Fisher Scientific) and harvested for analysis after the third, fourth, fifth 
and sixth round of transfection. DNA was subjected to bisulphite conversion and analysed by 
Sanger sequencing or next-generation bisulphite sequencing. 
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2.2.3.3 Modified CRISPR/Cas9 System 
 
The wildtype variant of the Cas9 protein was engineered to induce methylation of the targeted 
sequence instead of double-strand breaks. It was fused with the active domains of DNMT3A 
and DNMT3L. Four different gRNAs were designed to target the sequence covered by the 
amplicon used for next-generation bisulphite sequencing. All constructs were kindly provided 
by Dr. Pavel Bashtrykov from the laboratory of Prof. Dr. Albert Jeltsch, Stuttgart. Plasmids 
carrying the modified Cas9 construct were delivered into the cells by nucleofection using the 
Amaxa™ Nucleofector™ Technology (Lonza) together with one or two plasmids containing 
the gRNAs. Alternatively, the plasmid DNA was delivered into the cells by electroporation 
using the Neon® Transfection System (Thermo Fisher Scientific). Altogether, 5 g plasmid 
DNA were used for a single delivery. Cells were harvested three days post treatment, sorted 
by fluorescence-activated cell sorting by the expression of YFP by Hannah de Oliveira 
Kessler (Institute for Transfusion Medicine) and either analysed directly for the presence of 
DNA methylation, or seeded and harvested seven and fourteen days later for analysis. 
 
2.2.3.3.1 T7 assay 
 
HEK cells were transfected with 2 µl Lipofectamine® 2000 (Thermo Fisher Scientific) 
diluted in 25 µl Opti-MEM medium combined with 500 ng plasmid carrying wildtype Cas9 
and 120 ng plasmid containing gRNA also diluted in 25 µl Opti-MEM medium. Cells were 
lysed 48 h later. PCR was performed using Q5® Hot Start High-Fidelity 2x Master Mix 
(NEB), 0.5 µM forward and reverse primer each, and 100 ng DNA as template. PCR products 
were purified using DNA Clean & Concentrator Kit (Zymo Research) and the concentration 
of the samples was adjusted to 20 ng/µl. The subsequent annealing reaction contained 2 µl 
NEB Buffer 2 and 18 µl purified PCR product. Initial denaturation at 95 °C for 10 min was 
followed by five steps of lowering the temperature from 95 °C to 85 °C by 2 °C/s, then by 
600 steps of lowering the temperature from 85 °C to 25 °C by 0.1 °C/s. Restriction digest by 
T7 Endonuclease I ensued. 1 µl enzyme was added to each of the annealed samples and the 
reaction was incubated at 37 °C for 15 min. The result was analysed by agarose gel 
electrophoresis.  
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3. Results 
 
Some results presented in this thesis are included in the paper Stanurova et al. 2016 published 
in cooperation with Anika Neureiter. After reprogramming fibroblasts from an Angelman 
syndrome patient into induced pluripotent stem cells by Kristin Stolp (Institute for 
Transfusion Medicine), characterisation of eight patient-derived clones ensued. Clones D, F 
and H were assayed at the Institute of Human Genetics as part of my PhD project; clones B1, 
W, Y, Q and P, and the human embryonic stem cell line H1 representing the gold standard for 
pluripotency were analysed by Anika Neureiter within her PhD project at the Institute for 
Transfusion Medicine. Alkaline phosphatase staining, immunohistochemistry, qRT-PCR, EB 
formation assay and teratoma assay were executed separately. FACS of all eight clones was 
done jointly at the Institute for Transfusion Medicine and evaluated by Anika Neureiter. 
Sequencing, Southern blot and karyotyping of all eight clones were performed at the Institute 
of Human Genetics. Based on the result of the Southern blot, clones D, H, B1 and P with 
a single virus integration site were selected for further experiments. Ten healthy control 
clones isolated after reprogramming were first subjected to Southern blot analysis to choose 
those with a single virus integration site. Only then did their characterisation follow. Both 
selected control clones 42 and 645 were characterised at the Institute of Human Genetics, but 
for FACS analysis and evaluation done by Anika Neureiter. Neuronal differentiation 
according to the protocol from Koch et al. was carried out with patient-derived clones D and 
H, and previously published cell lines AGI-0 and MCH2-10 (Chamberlain et al., 2010) at the 
Institute of Human Genetics. Experiments on neuronal differentiation employing the protocol 
from Chambers et al. were performed separately; patient-derived clones D and H, and healthy 
control clones 42 and 645 were assayed at the Institute of Human Genetics. Experiments 
relying on the STEMdiff™ protocol and the protocol from Boissart et al. were conducted 
both at the Institute of Human Genetics and the Institute for Transfusion Medicine with the 
four patient-derived clones, the two control clones and human embryonic stem cell lines H1 
and H9. Further work on neuronal differentiation optimisation was done by Anika Neureiter. 
Samples obtained with her protocol were processed for single-nucleotide primer extension 
assay at the Institute of Human Genetics. Quantitative allele distinction assay, methylation 
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analyses of imprinted and pluripotent loci, and methylation induction experiments were 
performed at the Institute of Human Genetics. Results displayed here are generally restricted 
to patient-derived clone D, healthy control clone 645 and human embryonic stem cell line H1 
for comparison. Patient-derived clone D, along with patient-derived clone H, exhibited the 
best results regarding methylation stability at imprinted loci among patient-derived clones. 
The healthy control clone 645 showed a higher potential for differentiation than clone 42. 
Thus, patient-derived clone D and healthy control clone 645 were chosen as representative 
examples. 
 
 
3.1 Reprogramming of Skin Fibroblasts 
 
Fibroblasts from a skin biopsy of a healthy control person were reprogrammed with 
a lentiviral vector as described in 2.2.2.1 and 48 iPSC colonies were isolated manually 
approximately four weeks post selection by FACS. Of these clones, six were selected for 
further analysis; the rest was cryopreserved. Fibroblasts from a skin biopsy of an Angelman 
syndrome patient carrying a three-base pair deletion in the UBE3A maternal allele 
(Horsthemke et al., 2011) were reprogrammed by Kristin Stolp and eight iPSC clones were 
selected. The reprogramming efficiencies were comparable (Stanurova et al., 2016). 
 
 
3.2 iPSC Characterisation 
 
The isolated iPSC clones were characterised by various tests in order to validate their 
pluripotency. Pluripotency was verified by AP staining, immunocytochemistry, fluorescence-
activated cell sorting, qRT-PCR, EB formation assay and teratoma assay.  
 
3.2.1 Pluripotency Verification 
 
3.2.1.1 Alkaline Phosphatase Staining 
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Alkaline phosphatase is a hydrolase enzyme, which catalyses dephosphorylation of substrates 
such as nucleotides under alkaline conditions. It is highly expressed in pluripotent stem cells 
and the activity of the enzyme is a general marker of pluripotency. If alkaline phosphatase 
converts the colourless substrate, the colonies exhibit a pink/red colour. iPSC colonies were 
tested using the Alkaline Phosphatase Detection Kit and all clones stained positive for the 
activity of alkaline phosphatase. Results are shown in Fig. 4A. 
 
3.2.1.2 Immunocytochemistry 
 
Immunofluorescent staining was used to verify the presence of nuclear pluripotency markers 
OCT4, NANOG and SOX2, and surface pluripotency markers SSEA4, TRA-1-60 and TRA-
1-81. All clones stained positive for all markers. Results are shown in Fig. 4B. 
 
3.2.1.3 Fluorescence-Activated Cell Sorting 
 
The presence of surface pluripotency markers SSEA4, TRA-1-60 and TRA-1-81 was proved 
by FACS, as seen in Fig. 4C. Results were analysed by Anika Neureiter. All clones exhibited 
pluripotency in these experiments. 
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Figure 4 
Figure 4. Characterisation of patient-derived and control iPSCs in comparison with hESCs H1. A) Patient-
derived line D and control line 645 exhibit high activity of alkaline phosphatase. hESCs H1 are shown for 
comparison. B) Immunofluorescent staining of nuclear markers OCT4, NANOG and SOX2 (red), and surface 
markers SSEA4, TRA-1-60 and TRA-1-81 (green) confirm expression of pluripotency markers in patient-
derived line D and control line 645 in comparison to hESCs H1. C) FACS analysis of surface markers SSEA4, 
TRA-1-60 and TRA-1-81 shows the comparison of isotype controls in white with the staining with a specific 
antibody in grey. A positive result is indicated by a shift of the assayed population to the right. hESCs H1 are 
depicted for comparison. hESCs H1 analyses, and FACS analysis and evaluation were performed by Anika 
Neureiter. The figure was adapted from Stanurova et al., 2016. 
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3.2.1.4 Quantitative Real-Time PCR 
 
qRT-PCR was employed to assess the expression of eight pluripotency markers: POU5F1 
coding for the pluripotency marker OCT4, SOX2, KLF4, MYC, NANOG, LIN28, DNMT3B 
and REX1 coding for the pluripotency marker ZFP42. Housekeeper genes RPL13A and 
GAPDH were used for normalisation. Results are shown in Fig. 5. All genes showed 
expression levels comparable to those in hESCs H1 in all clones. 
 
Figure 5 
Figure 5. Pluripotency confirmation of patient-derived and control iPSCs by qRT-PCR. Expression of 
eight selected markers associated with pluripotency was analysed by qRT-PCR. Results for the assayed lines are 
shown relative to hESCs H1. Both A) the patient-derived line D and B) the control line 645 are similar to hESCs 
H1 in expression levels of all evaluated markers (iPSCs in light blue, hESCs H1 in dark blue). Standard 
deviation of three technical replicates is indicated. 
 
3.2.1.5 EB Formation Assay 
 
iPSCs were assayed for their ability to differentiate into all three germ layers. Upon initial 
cultivation in suspension, iPSCs form three-dimensional aggregates and start to differentiate. 
Further cultivation in suspension gives rise to different types of tissue than adherent 
 Results 
 
 66 
cultivation on gelatine. The samples were analysed by qRT-PCR for the expression of 
a pluripotency marker POU5F1, an ectodermal marker PAX6, a mesodermal marker 
BRACHYURY, and an endodermal marker SOX17. Their expression was normalised to ACTB. 
Results are shown in Fig. 6. All clones showed a loss of pluripotency manifested by the 
decrease of POU5F1 expression and the increase in expression of the markers representing 
the respective germ layers. 
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Figure 6 
Figure 6. Differentiation potential of patient-derived and control iPSCs. Expression of the pluripotency 
marker POU5F1 and markers representative of the three germ layers was assessed by qRT-PCR. A) Decreasing 
levels of POU5F1 indicate the loss of pluripotency within 14 days of differentiation in patient-derived line D. 
Expression of the three differentiation markers rises confirming the pluripotency of patient-derived iPSCs. B) 
Pluripotency is lost during 14 days of differentiation, as shown by the reduction in POU5F1 expression in 
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control line 645. The ectodermal and endodermal markers are upregulated. The expression level of the 
mesodermal marker rises temporarily. Susp – cultivation in suspension, gel – cultivation on gelatine. 
 
3.2.1.6 Teratoma Assay 
 
Teratoma formation assay was performed as the most stringent test of pluripotency. Cells 
were injected into immunodeficient NMRI nude mice Crl:NMRI-Foxn1nu and tumours were 
explanted when skin lesions appeared or after a maximum of 67 days. All clones formed 
tumours with 100 % efficiency. Tumours were explanted, fixed, embedded in paraffin, cut 
into microsections, stained with haematoxylin and eosin (H&E), and analysed 
microscopically for the presence of derivatives of the respective germ layers. All tested clones 
proved to be pluripotent. Pictures with examples representative of each germ layer are shown 
in Fig. 7. 
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Figure 7 
Figure 7. Teratoma assay of patient-derived and control iPSCs. H&E staining of teratomas formed by hESCs 
H1, patient-derived line D and control line 645. Derivatives of all three germ layers are present. Structures 
typical for the indicated germ layer are marked by black arrows, such as neuroectodermal rosettes for ectoderm, 
fat cells for mesoderm, and clear cells for endoderm. Other structures found in the image but not characteristic 
for the given germ layer are marked by blue arrows. 
 
All analysed clones passed all applied pluripotency tests. In addition, their Epi-Pluri-Score 
was assessed in the laboratory of Prof. Dr. Wolfgang Wagner (Helmholtz Institute for 
Biomedical Engineering, RWTH Aachen), and a TaqMan array was performed (Stanurova et 
al., 2016). Also in these experiments, the pluripotency of the studied iPSCs was verified 
successfully.  
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3.2.2 Quality and Identity Tests 
 
Identity and quality of the iPSCs derived in this study were tested by sequencing for the 
presence of the three-base pair deletion in case of the Angelman syndrome iPSCs, Southern 
blot and karyotyping. Furthermore, high-resolution HLA typing was conducted to verify the 
genetic identity between iPSCs and the primary fibroblasts they had been derived from 
(Stanurova et al., 2016). 
 
3.2.2.1 Sequencing 
 
Eight patient-derived iPSC clones were sequenced to verify the presence of the three-base 
pair deletion causing Angelman syndrome in the patient. All eight clones (Stanurova et al., 
2016) proved to bear the mutation as is shown in Fig. 8A. 
 
3.2.2.2 Southern Blot 
 
The number of virus integration sites was determined by Southern blot. Eight patient-derived 
clones were analysed along with ten healthy control clones. Clones with a single integration 
site were selected for further experiments. These clones are indicated in Fig. 8B. 
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Figure 8 
Figure 8. Sanger sequencing and Southern blot. A) Patient-derived clones display presence of the three-base 
pair deletion, as shown by Sanger sequencing. Forward and reverse sequencing of clone D is depicted in 
comparison with a normal healthy control at the top. A GGA triplet marked by the red rectangle is deleted, 
which is indicated by the ambiguity of the sequence starting at the site of the deletion. B) Southern blot of 
patient-derived and control iPSCs determined the number of integration sites of the lentiviral vector used for 
reprogramming. The results are given beneath the image. DNA isolated from patient-derived clones was digested 
with BamHI, while DNA extracted from control clones was subjected to restriction by EcoRV. The figure was 
adapted from Stanurova et al., 2016. 
 
3.2.2.3 Karyotyping 
 
To evaluate whether the studied clones possess a normal karyotype, at least eleven metaphase 
spreads were analysed per sample. Both healthy control clones and three out of four patient-
derived clones displayed a normal female karyotype 46, XX as shown in Fig. 9A. The 
exception was the patient-derived clone H exhibiting a marker chromosome, whose nature 
was determined by whole-chromosome painting as isochromosome 12p (Stanurova et al., 
2016) (Fig. 9B). Due to this abnormality, this clone was excluded from further analyses. 
 Results 
 
 72 
 
Figure 9 
Figure 9. Karyotyping. A) Normal female karyotype 46, XX of patient-derived clone D (left) and control clone 
645 (right). B) Patient-derived clone H exhibits a marker chromosome identified by whole-chromosome painting 
as i12p (right). Chromosome 12 is depicted in red, chromosome 17 in green. The figure was taken from 
Stanurova et al., 2016. 
 
 
3.3 Neuronal Differentiation 
 
Direct differentiation of iPSCs or hESCs into terminally differentiated neurons via embryoid 
bodies using the protocol published by Koch et al. was successful and yielded neural 
networks intertwined with axons. The progress of the development is shown in Fig. 10. Cell 
clumps were kept in suspension forming embryoid bodies upon induction of neuronal 
differentiation by dual SMAD inhibition in NDM containing N2, B27, the BMP signalling 
inhibitor LDN-193189 and TGFβ signalling inhibitor SB-431542. On day 12, embryoid 
bodies were plated on a matrigel-coated dish. Rosettes and neuroectodermal islands were 
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isolated and plated as single cells at high density on a matrigel-coated well of a 6-well plate 
on day 18. Further cultivation in NDM generated terminally differentiated neurons. 
 
  
Figure 10 
Figure 10. Neuronal differentiation according to the protocol by Koch et al.. iPSCs form embryoid bodies in 
differentiation medium on D8. Neural precursors visible on D14 organise into rosettes occurring on D18. Neural 
progenitors observed on D20 develop outgrowths that establish complex intertwined networks upon further 
culture in differentiation medium, as seen on D40. 
 
Since it takes rather long to obtain mature neurons (four weeks for terminal differentiation of 
neural progenitors), I aimed to establish a neural progenitor culture with this protocol, which I 
could expand and subject to terminal differentiation any time. The attempts to culture neural 
progenitors in lt-NES medium containing N2, B27, EGF and FGF2 instead of NDM starting 
from day 18 failed repeatedly. They only yielded non-neuronal cells, whose identity I did not 
specify more closely. Most likely, these cells were neural crest cells, as this lineage tends to 
proliferate more quickly than neurons. Not even a gradual transition by plating the progenitors 
on day 18 in NDM and then replacing a quarter, a half and three quarters of NDM by lt-NES 
on consecutive days led to a stable neural progenitor culture. 
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Since the first approach resulted in successful differentiation of iPSCs into mature neurons 
but not the development of a long-term culture of neural progenitors, we tried to reproduce 
neuronal differentiation with the protocol described by Chambers et al. used to derive neurons 
from the iPSC lines AGI-0 and MCH2-10. Neural induction of single cells was induced by 
SRM containing LDN-193189 and SB-431542, and its gradual replacement by N2 medium 
containing N2 and both inhibitors. On day 10, three wells were combined into one and 
cultured further in BASF medium containing BDNF, ascorbic acid, SHH (sonic hedgehog) 
and FGF2. On day 17, the medium was changed to BAGTC containing BDNF, ascorbic acid, 
GDNF, TGFβ-III and dbcAMP. Samples for analysis were collected on the days when one 
medium replaced the other completely, that is, on day 0, day 5, day 10, day 17 and day 24 at 
the end of the experiment. The results between clones analysed by qRT-PCR differed 
substantially. For instance, the patient-derived clone D displayed considerable upregulation of 
neuronal markers NURR1, TH and TUJ3 (Fig. 11A) and an obvious increased expression of 
neural markers NESTIN, PAX6 and SOX1. On the contrary, the control clone 645 manifested 
hardly any significant change in the expression of the assayed genes (Fig. 11B, note the 
scale). 
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Figure 11 
Figure 11. Neuronal differentiation according to the protocol by Chambers et al.. A) qRT-PCR analysis of 
patient-derived clone D shows a very strong upregulation of neuronal markers NURR1, TH and TUJ3, and an 
increase in expression of neural markers NESTIN, PAX6 and SOX1. Dark blue = D0, light blue = D24. B) qRT-
PCR analysis of control clone 645 exhibits virtually no neural induction. Dark blue = D0, light blue = D24. 
 
Therefore, we performed neural induction of single cells with the commercially available 
STEMdiff™ Neural Induction Medium. The composition of the medium is defined and relies 
on a mechanism of neural induction other than dual SMAD inhibition. Cells were harvested 
for analysis on day 11 (Fig. 12). With this method, we did not obtain a stable neural 
progenitor culture and decided to return to neural induction by dual SMAD inhibition.  
Neural induction by dual SMAD inhibition using the protocol by Boissart et al. was initiated 
by plating cell clumps on a matrigel-coated well of a 6-well plate in induction medium 
containing N2, B27, both inhibitors and FGF2. On day 10, the cells were replated on a new 
matrigel-coated well and cultured in expansion medium containing N2, B27, EGF and FGF2. 
The cells were harvested for analysis on day 14. qRT-PCR analysis of the samples obtained 
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by neural induction with STEMdiff™ Neural Induction Medium and by utilising the protocol 
by Boissart et al. showed virtually no consistency among the assayed clones and the outcome 
for single clones was not reproducible between biological replicates (Fig. 12). For example, in 
the first replicate, the patient-derived clone D exhibited no presence of the neural marker 
PAX6 neither with the STEMdiff™ medium, nor with the expansion medium according to 
Boissart et al. (Fig. 12A). In the second replicate, the upregulation of PAX6 was massive with 
both media (Fig. 12B, note the scale). Similarly, the neural marker PLZF showed a decrease 
with STEMdiff™ medium and a slight increase with the expansion medium according to 
Boissart et al. in the first replicate (Fig. 12A). An increase in the expression level of PLZF 
even more prominent than that of PAX6 could be observed in the second replicate (Fig. 12B).  
 
Figure 12 
Figure 12. Neuronal differentiation using STEMdiff™ and the protocol by Boissart et al.. A) As 
determined by qRT-PCR, neural marker PAX6 is absent in the first biological replicate of differentiation of 
patient-derived clone D with both STEMdiff™ and the expansion medium according to Boissart et al.. Neural 
marker PLZF shows a decrease in expression with STEMdiff™ and a mild increase in the expansion medium 
according to Boissart et al.. B) In the second biological replicate of neuronal differentiation, PAX6 exhibits 
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considerable upregulation with both protocols and the increase in expression levels of PLZF is even more 
pronounced. Blue = D0, orange = STEMdiff™ protocol, D11, red = protocol from Boissart et al., D14. 
 
Employing the protocol from Boissart et al. without optimisation led neither to reproducible 
results, nor to the establishment of a stable neural progenitor culture. Only after applying 
positive selection using magnetic anti-PSA-NCAM MicroBeads on day 13 did we obtain 
a rather stable culture of neural progenitors. Their further differentiation for another three 
weeks on poly-D/L-ornithine and laminin yielded terminally differentiated neurons on day 35 
(Stanurova et al., 2016). The positive selection and terminal differentiation were performed 
by Anika Neureiter. 
 
 
3.4 Single-Nucleotide Primer Extension Assay 
 
Expression of UBE3A and SNHG14 was determined by RT-PCR in a commercially available 
cDNA from adult human lung tissue and human foetal brain tissue, cDNA generated from 
lymphoblastoid cell lines (LCLs) from a Prader-Willi patient and an Angelman syndrome 
patient, both carrying a large deletion on their paternal and maternal chromosome 15, 
respectively, and neurons obtained by neuronal differentiation of patient-derived clone D for 
35 days. UBE3A transcripts should be present in all samples. In lung, both the maternal and 
the paternal allele are expressed. In foetal brain, the analysis detected maternally expressed 
UBE3A. The same holds true for PWS LCLs. AS LCLs display paternally expressed UBE3A. 
Neurons obtained by differentiation express UBE3A from the maternal allele. Indeed, I 
observed UBE3A transcripts in all samples (Fig. 13). Since the expression of SNHG14 is 
restricted to the brain, it should only be detected in foetal brain and in generated neurons, if 
the neuronal differentiation had been successful. Presence of SNHG14 transcripts in foetal 
brain but not in lung and the LCL lines demonstrates the specificity of the primers I utilised 
for the analysis (Fig. 13). By proving SNHG14 expression in neurons harvested on day 35 of 
our experiment, I was able to verify successful derivation of mature neurons (Fig. 13). 
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Figure 13 
Figure 13. Expression of UBE3A and SNHG14 in different tissues. UBE3A is expressed in lung, foetal brain, 
PWS LCL, AS LCL and neurons obtained by differentiation for 35 days (top). Expression of SNHG14 is only 
detectable in foetal brain and generated neurons indicating primer specificity, successful neuronal differentiation 
and upregulation of SNHG14 expression in the neurons (middle). Housekeeper gene GAPDH was included to 
confirm cDNA integrity (bottom). –RT samples are the negative controls for the respective cDNA preparatory 
reactions. 
 
Samples obtained on day 0, day 14, day 21, day 28 and day 35 of neuronal differentiation of 
Angelman syndrome iPSCs were subjected to qRT-PCR analysis in order to assess the 
expression of UBE3A and SNHG14 during the course of the experiment. As shown in Fig. 14, 
expression levels of UBE3A are slightly elevated already at the neural progenitor stage on day 
14. In more mature neurons on day 28 and day 35, the upregulation of UBE3A is even 
stronger. Expression levels of SNHG14 rise gradually throughout neuronal differentiation 
(Fig. 14). Increased expression was detected early into differentiation at the neural progenitor 
stage on day 14. The more differentiated the neurons were, the more enhanced the expression 
levels of SNHG14 became. From one week to the next, upregulation of SNHG14 increased by 
an order of magnitude throughout the whole experiment. 
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Figure 14 
Figure 14. UBE3A and SNHG14 expression levels during neuronal differentiation. Mild upregulation of 
UBE3A is observed already at the neural progenitor (NPC) stage of differentiation on D14 and the expression 
level further increases in more mature neurons on D28 and D35, as shown by qRT-PCR. Levels of SNHG14 rise 
gradually throughout neuronal differentiation from mild upregulation at the neural progenitor stage to a very 
strong increase in expression on D35. The figure was adapted from Stanurova et al., 2016. 
 
Single-nucleotide primer extension assay (SNaPshot) was employed to determine when 
silencing of the paternal UBE3A allele occurs during the process of neuronal differentiation. 
The three-base pair deletion in the maternal allele of the Angelman syndrome iPSC clone D 
served as a SNP by that the expression from the parental alleles was distinguished. In the 
reaction, the primer is extended either by a G, if it annealed to the wildtype paternal allele, or 
by an A, if it annealed to the maternal allele carrying the deletion. The G/A ratio is calculated 
and normalised to the G/A ratio of genomic DNA, which stays constant. In pluripotent cells 
on day 0, the ratio should equal approximately 1, since the expression of UBE3A is expected 
to be biallelic. As shown in Fig. 15, this is indeed the case. On day 14 at the stage of neural 
progenitors, as well as on day 21 at the stage of early neurons, the G/A ratio remained 
unaltered. On day 28, the G/A ratio decreased to 0.82 indicating a weaker expression from the 
paternal allele. On day 35, the reduction in the G/A ratio became more pronounced declining 
to 0.66. Based on these results, I conclude that silencing of the paternal UBE3A allele by 
SNHG14 only begins in rather mature neurons at around day 28. 
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Figure 15 
Figure 15. SNaPshot analysis. Ratio of the paternal (G) to the maternal (A) allele suggests biallelic expression 
of UBE3A in iPSCs, neural progenitors (NPC) and early neurons up to D21 of neuronal differentiation. On D28, 
the ratio decreases to 0.82 indicating a weaker expression from the paternal allele. The effect of silencing by 
SNHG14 becomes even more prominent on D35 of differentiation when the ratio further drops to 0.66. The 
figure was taken from Stanurova et al., 2016. 
 
 
3.5 Quantitative Allele Distinction of UBE3A 
 
Results from the single-nucleotide primer extension assay indicated skewing of UBE3A 
expression towards the maternal allele starting on day 28 of neuronal differentiation due to the 
silencing of the paternal UBE3A allele by SNHG14 (see Fig. 15). Nonetheless, I showed by 
qRT-PCR that the overall expression of UBE3A rises during the course of differentiation in 
spite of the silencing taking place (Fig. 14) and by Western blot that the protein level does not 
change throughout the experiment (Stanurova et al., 2016). To demonstrate that the silencing 
does occur and the expression from the maternal allele rises to compensate for the loss of the 
expression from the paternal allele in order to maintain a stable protein level, I designed an 
assay to quantify the contributions of the respective parental alleles to the pool of UBE3A 
mRNA molecules in the cells. Minor groove binding (MGB) probes were designed to bind to 
the site of the mutation on the maternal allele and to its corresponding healthy paternal 
counterpart, respectively. 280 bp cDNA fragments from Angelman syndrome iPSCs 
containing the target sequences of the probes in the middle were cloned into a vector. 
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Plasmids verified by Sanger sequencing for the absence (mat) or presence (pat) of the triplet, 
respectively, were mixed in the following ratios to create a standard curve for both probes: 
0:100, 10:90, 25:75, 50:50, 75:25, 90:10, 0:100. The first calibration multiplex qRT-PCR with 
a FAM-labelled paternal probe and a TET-labelled maternal probe showed substantial 
differences in the probes’ fluorescence capacities. While the FAM-labelled probe’s capacity 
was satisfactory, the TET-labelled probe hardly showed any (Fig. 16A). A test with the TET-
labelled probe treated with DNase I prior to qRT-PCR to release the full fluorescence 
potential did not yield a better result. To rule out the possibility of target or probe 
interference, a singleplex qRT-PCR experiment was performed. The fluorescence signal of 
the TET-labelled probe did not display any improvement in comparison with the multiplex 
qRT-PCR, so interference of any kind could not have been the issue. The TET-labelled probe 
was replaced by an MGB probe labelled with Yakima Yellow (YY) to obtain a stronger 
fluorescence signal. However, the substitution of the fluorescent dye did not lead to 
a satisfactory result either (Fig. 16B). 
 
Figure 16 
Figure 16. Quantitative allele distinction optimisation. A) Multiplex qRT-PCR plot of all standard mixes 
using a FAM-labelled paternal probe (blue) and a TET-labelled maternal probe (red) shows a great difference 
between the fluorescence capacities of the probes. B) Multiplex qRT-PCR plot of standard mixes pat:mat = 
75:25, 50:50 and 25:75 using a FAM-labelled paternal probe (blue) and a YY-labelled maternal probe (red) 
displays a better, yet still insufficient performance of the new maternal probe in comparison with the original 
one. RFU = relative fluorescence unit. 
 
I turned to the analysis of the assay design itself because the probability that two probes 
synthesised at different times would contain a mismatch in the sequence was rather low. I first 
examined the specificity and the efficiency of the primers. qRT-PCR with SYBR Green and 
the same set of templates and primers as in the multiplex qRT-PCR confirmed the presence of 
a single product and no variation between template mixes (Fig. 17A), which was expected, 
since the amount of the target sequence is equal in all of them. A different set of primers 
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originally used for cloning the 280 bp cDNA fragment yielded similarly convincing results 
(not shown). Next, I utilised a 10-fold serial dilution of cDNA from Angelman syndrome 
iPSCs as template. The amount of cDNA input corresponded to 10 ng, 1 ng, 0.1 ng and 0.01 
ng reverse-transcribed RNA. Perfect doubling each cycle yields curves separated by 3.32 
cycles and an efficiency of 100 %. In the primer test, the curves were separated by 3.36 cycles 
and the efficiency reached 98 %. The efficiency of the reaction was stable over three orders of 
magnitude and the sensitivity only reached its limits with the last dilution (Fig. 17A and 17B).  
 
Figure 17 
Figure 17. Quantitative allele distinction optimisation. A) qRT-PCR analysis of the standard mixes with 
SYBR Green confirms the reliability of the standard mixes in terms of overall DNA concentration (top). A 10-
fold serial dilution of cDNA prepared from patient-derived clone D assayed with SYBR Green displays a very 
good efficiency over at least three orders of magnitude validating the primers (bottom). B) Multiplex qRT-PCR 
with a 10-fold serial dilution of cDNA prepared from patient-derived clone D indicates a moderately satisfactory 
detection by the YY-labelled maternal probe (top). Multiplex view (bottom) illustrates the disparity between the 
probes, as the signal from the FAM-labelled paternal probe (blue) is much stronger than the one from the YY-
labelled maternal probe (red). Note the different scales. RFU = relative fluorescence unit. 
 
However, the test with cDNA dilutions drew my attention to the plasmid templates again. As 
the test with SYBR Green showed, the curves coming from the reactions containing plasmid 
mixes entered the logarithmic phase about 15 cycles earlier than those coming from the 
cDNA dilution samples (Fig. 17A). I obtained similar results with the respective templates 
and the fluorescent probes. However, in this case, the curves of the plasmid mixes flattened 
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with decreasing target concentration (Fig. 16) indicating that the efficiency of the reaction 
drops, unlike with the cDNA samples (Fig. 17B). It would mathematically be possible to 
derive the respective target concentrations from a standard curve calculated from mixes 
containing much more target than the samples subjected to evaluation. In other words, a big 
difference in CT values between the standards and the analysed samples is, of course, not 
preferable but it is acceptable provided that the efficiencies of the reactions are equal or close 
to 100 %. Since the plasmid mixes did not fulfil this essential condition in combination with 
the fluorescent probes, I speculated that perhaps the vectors are in a supercoiled state, which 
might interfere with the binding of the probes. Therefore, I performed enzymatic restriction 
with a single cutter and I used the linearised plasmids in the qRT-PCR. There was no 
difference between the untreated and the treated templates (not shown), so steric hindrance 
did not explain the problem with the efficiency.  
Lastly, I replaced the probe detecting the maternal allele with a FAM-labelled MGB probe in 
order to determine, whether the fluorescence signal would finally match the one of the 
paternal probe. I utilised both the plasmid mixes and the cDNA serial dilutions for this 
analysis as templates.  
 
Figure 18 
Figure 18. Quantitative allele distinction optimisation. A) Multiplex qRT-PCR plot of standard mixes using 
a FAM-labelled paternal probe (blue) and a FAM-labelled maternal probe (red) exhibits a perfect overlay of the 
signals. B) Multiplex qRT-PCR with a 10-fold serial dilution of cDNA prepared from patient-derived clone D 
indicates satisfactory reliability of the reactions with both the paternal and the maternal probe and their sufficient 
similarity in terms of detection and fluorescence potential. RFU = relative fluorescence unit. 
 
If the sequence of the maternal probe is correct, the signals from both probes should overlay, 
since there is no difference between the strength of the fluorophores and the amounts of the 
respective target sequences should be equal as well. In case of the plasmid mixes, the amounts 
of targets are inversely correlated, so the expectation still holds true. Indeed, I observed 
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a perfect overlay of the curves originating from the reactions containing the respective 
parental probes. This applied to both template variants (Fig. 18). Since now the analysis of the 
respective parental alleles had to be performed separately due to the labelling of the probes 
with the same fluorophore, the idea of a single standard curve for both probes at a time 
became irrelevant. Therefore, to construct a standard curve for each parental probe, 10-fold 
serial dilutions of the plasmids carrying the paternal and the maternal target, respectively, 
were prepared and analysed by qRT-PCR. The curves of the maternal standard samples were 
separated by 3.32 cycles, the efficiency reached 99 % and was stable over seven orders of 
magnitude. Similarly, 3.45 cycles spacing was observed between the curves of the paternal 
standard samples, the efficiency equalled 94 % and was also stable over seven orders of 
magnitude. The precise overlay of the curves generated by the respective parental standard 
samples is shown in Fig. 19. 
 
 
Figure 19 
Figure 19. Quantitative allele distinction optimisation. qRT-PCR plot of 10-fold serial dilutions of the 
plasmids carrying the respective parental targets using a FAM-labelled paternal probe (blue) and a FAM-labelled 
maternal probe (red) exhibits a perfect overlay of the signals. The efficiencies of the respective reactions were 
stable over seven orders of magnitude. RFU = relative fluorescence unit. 
 
The standard curves can be used to calculate the exact contributions of the respective parental 
alleles to the pool of UBE3A mRNA molecules in analysed samples, since the size of the 
plasmids is known and so is the number of copies present in each reaction. In comparison 
with single-nucleotide primer extension assay, the output of quantitative allele distinction 
analysis provides much more precise and therefore more valuable information. While the 
result obtained by single-nucleotide primer extension assays theoretically allows for 
ambiguous interpretation, the developed method facilitates accurate quantification of the 
expression dynamics of both parental alleles in an exact manner. 
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3.6 Methylation Analyses 
 
Stability of DNA methylation at the gametic ICRs of six imprinted loci was examined in two 
healthy control clones, four patient-derived clones, the parental fibroblasts, two hESC lines, 
and iPSC lines AGI-0 and MCH2-10 (Chamberlain et al., 2010) by next-generation bisulphite 
sequencing. The results are depicted in Fig. 20 and 21. The status was determined at PWS-
SRO, whose methylation regulates the expression of UBE3A; ICR1 and ICR2, which regulate 
the expression of IGF2/H19 and the KCNQ1OT1 locus, respectively; NESPAS of the GNAS 
locus; CpG85 of RB1; and IG-DMR of DLK1/MEG3 locus. Since one allele is methylated and 
the other one is not, a level of approximately 50 % methylation is expected at imprinted loci. 
Such levels were observed at PWS-SRO in all samples but for AGI-0, which correctly 
showed no methylation, since it harbours a large deletion on the maternal chromosome 15 
including the PWS-SRO (Fig. 21). At ICR1, 50 % methylation levels were detected with the 
exception of patient-derived clone B, which exhibited a loss of methylation, and hESC line 
H9, which displayed a gain of methylation at a higher passage (Fig. 21). ICR2 showed only 
one deviation from the otherwise stable methylation level of 50 % in patient-derived clone P, 
whose methylation was lost at this region (Fig. 20). A loss of methylation at NESPAS was 
detected in both healthy control clones, patient-derived clones B1 and P, and MCH2-10; all 
other samples showed 50 % methylation levels (Fig. 20 and Fig. 21). CpG85 exhibited 
a consistent gain of methylation in almost all lines; the sole exception was a 50 % methylation 
level in the healthy control fibroblasts (Fig. 20). A gain of methylation was observed at IG-
DMR in both H1 and H9 hESC lines, both healthy control clones and both iPSC lines 
published by Chamberlain et al., whereas all four patient-derived clones displayed 50 % 
methylation levels. Patient fibroblasts, which had been immortalised due to poor growth in 
culture (Stanurova et al., 2016), showed a complete loss of methylation at IG-DMR (Fig. 20). 
Differential methylation was detected at both CpG85 and IG-DMR in an additional analysis 
of the patient’s blood sample and healthy control fibroblasts from two other independent 
healthy donors, although the methylation levels were moderately elevated at both loci in one 
of the fibroblast samples (Fig. 21). 
Both hESC lines H1 and H9 showed a gain of methylation at CpG85 and IG-DMR, and an 
expected level of methylation of approximately 50 % at all other loci. Control fibroblasts 
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exhibited a 50 % methylation level at all loci. Both iPSC clones derived from these fibroblasts 
displayed a loss of methylation at NESPAS and a gain of methylation at CpG85 and at IG-
DMR. Patient-specific immortalised fibroblasts showed a gain of methylation at CpG85 and 
a loss of methylation at IG-DMR, whereas expected levels of methylation were detected at all 
other loci. Patient-derived clones D and H exhibited 50 % methylation at all loci but CpG85, 
which was hypermethylated. Patient-derived clones B1 and P displayed a loss of methylation 
at ICR1 and ICR2, respectively. Both clones also showed a gain of methylation at CpG85, 
and a loss of methylation at NESPAS (Fig. 20). In lines AGI-0 and MCH2-10, moderately 
elevated levels of methylation were observed at ICR1; CpG85 and IG-DMR were 
hypermethylated. In MCH2-10, also a loss of methylation at NESPAS was detected (Fig. 21). 
In addition, I determined methylation status at two pluripotency loci, POU5F1 and NANOG, 
in the cell lines. Products of both genes, OCT4 and NANOG, are key players in pluripotency 
maintenance. Upon differentiation when downregulation of their expression is required, their 
promoters acquire methylation. Therefore, higher levels of methylation are expected at these 
loci in differentiated cells than in pluripotent cells. Indeed, I observed low levels of 
methylation in all pluripotent samples, whereas in fibroblasts, methylation levels were high 
(Fig. 20 and Fig. 21).  
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Figure 20 
Figure 20. Methylation status of six imprinted ICRs and two pluripotent loci. A level of 50 % methylation 
is expected at imprinted loci. This is true for PWS-SRO without exception. ICR1 and ICR2 show one loss of 
methylation each. NESPAS exhibits a loss of methylation in four samples. CpG85 displays a consistent gain of 
methylation in all samples but one. Methylation levels are elevated at IG-DMR in four samples; one sample 
manifests a loss of methylation. Pluripotent loci POU5F1 and NANOG acquire methylation upon differentiation. 
Accordingly, the levels of methylation in fibroblasts are higher than in hESCs and iPSCs. The figure was taken 
from Stanurova et al., 2016. 
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Figure 21 
Figure 21. Additional methylation analyses of six imprinted ICRs and two pluripotent loci. PWS-SRO 
shows hypomethylation in AGI-0 due to the loss of the maternal allele. ICR1 exhibits a gain of methylation in 
hESCs H9 at a higher passage. Methylation at ICR2 is preserved. NESPAS displays one loss of methylation. 
CpG85 and IG-DMR manifest a gain of methylation in pluripotent cells. In two additional fibroblast samples and 
the patient’s blood sample, differential methylation at CpG85 and IG-DMR is maintained. Levels of methylation 
at pluripotent loci POU5F1 and NANOG in pluripotent samples are lower than in fibroblasts; compare with the 
previous figure. The figure was adapted from Stanurova et al., 2016. 
 
 
3.7 Methylation Induction 
 
To establish the induction of methylation, I used the iPSC line AGI-0 for all experiments. As 
described above, the methylation level at PWS-SRO in this cell line is zero or close to zero 
due to the large deletion on the maternal chromosome 15 including the PWS-SRO. Presence 
of only the unmethylated paternal allele makes the cell line especially suitable for studying 
induction of methylation at PWS-SRO. The analysis is straightforward and the results clearly 
show whether the induction of methylation had been successful or not. 
 
3.7.1 Methylation Induction by Artificial Methylated Oligonucleotides 
 
Methylated oligonucleotides have successfully been used to induce methylation at targeted 
loci. They are protected from degradation by cellular nucleases by phosphorothioate 
backbones. Replication or transcription are required to facilitate annealing of the 
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oligonucleotides to their target sequence, since only then do the DNA strands transiently 
separate. Upon annealing, a hemi-methylated stretch of DNA is formed that is targeted by 
DNMT1, which methylates the endogenous DNA strand. As the endogenous DNA strands 
reanneal, the hemi-methylated portion of DNA is methylated by DNMT1 fully. Delivery of 
the oligonucleotides into the cells was performed by transfection with Lipofectamine® 
RNAiMAX or by nucleofection using the Amaxa™ Nucleofector™ Technology. The position 
of the nucleotides in the genome is indicated in Fig. 22A. Success of the delivery was verified 
by microscopy one day post transfection, since one of the oligonucleotides was fluorescently 
labelled (Fig. 22B). The transfection efficiency reached approximately 50 %. DNA isolated 
from cells harvested at different time points was subjected to bisulphite conversion and 
sequenced. Single deliveries of the oligonucleotides at various concentrations did not lead to 
an induction of methylation at the targeted region. The results were independent from the time 
of harvest. Therefore, the concentration of 2 M that proved to be optimal for cell survival 
after the treatment was used for multiple rounds of transfection every two or three days. 
However, neither three, nor six rounds of transfection yielded methylation of the target 
sequence. These results were also independent from the time point, at which the cells were 
harvested for analysis. The frequency of transfection did not influence the output, since there 
was no difference in the samples transfected every two or three days. An example of a fully 
converted sample is shown in Fig. 22C. 
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Figure 22 
Figure 22. Artificial methylated oligonucleotide treatment. A) The designed methylated oligonucleotides all 
lie within the amplicon analysed by next-generation bisulphite sequencing indicated by the upper black bar. B) 
Methylated oligonucleotides are absorbed by the cells. C) 24 h or 72 h after treatment, cells exhibit no induced 
methylation at the targeted region. CpG dinucleotides in the sequence are indicated by black bars. 
 
3.7.2 Methylation Induction by In Vitro-Methylated DNA Fragments 
 
3.7.2.1 M.SssI-Methylated Fragments 
 
Fragments methylated in vitro by M.SssI methyltransferase have been shown to efficiently 
induce methylation leading to downregulation of transcription at the targeted loci. Similarly to 
the previous method, this approach also relies on separation of the endogenous DNA strands 
during replication or transcription, and methylation by DNMT1. A 1413-bp DNA fragment 
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encompassing the whole CpG77 at the SNURF-SNRPN promoter (Fig. 23) was amplified by 
PCR from a plasmid, purified and 4 g DNA were methylated in vitro by M.SssI 
methyltransferase. The success of the methylation was validated by restriction digest with 
HpaII as shown in Fig. 24A. Methylated DNA is resistant to digestion with HpaII, as the 
enzyme’s restriction sites CˇCGG are blocked by methylation present on the second cytosine. 
Hence, a fully methylated fragment should not be cut by HpaII. Apart from the intact full-
length fragment, smaller restriction products can be observed indicating incomplete 
methylation. Approximately 80 % methylation of the fragment was achieved. Denatured 
DNA was delivered into the cells by three rounds of transfection with Lipofectamine® 
RNAiMAX. Genomic DNA was isolated from harvested cells, subjected to bisulphite 
conversion and sequenced. The result displayed a partial methylation of the targeted region 
(not shown). To determine the extent of the methylation precisely, analysis by next-generation 
bisulphite sequencing ensued. The level of methylation induced by this method reached 
38.6 % as shown in Fig. 25. In order to verify that the observed induction was not a false-
positive result originating from the transfected DNA fragment, reads were separated by a SNP 
that had been introduced into the sequence beforehand by site-directed mutagenesis by Nadja 
Utz (Institute of Human Genetics). Since there were no reads present for the sequence 
containing the substitute nucleotide, the detected methylation came exclusively from the 
endogenous DNA. 
 
 
Figure 23 
Figure 23. Position of the selected fragment in the genome. The DNA fragment chosen for induction of 
methylation encompasses the whole CpG77. Methylated oligonucleotides and the region analysed by next-
generation bisulphite sequencing are included for comparison. 
 
In a follow-up experiment, cells that had already been transfected thrice were either treated 
with three more rounds of transfection and harvested for analysis after each of them, or left 
untreated and harvested at the same time points as the treated cells. Methylation analysis by 
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next-generation bisulphite sequencing followed. As shown in Fig. 25, treated cells maintained 
approximately the same level of methylation, whereas the previously induced level was not 
retained in untreated controls, decreasing to 11.7 % within a week.  
 
 
Figure 24 
Figure 24. Methylation validation of M.SssI-methylated and PCR-methylated fragments by methylation-
sensitive HpaII restriction. A) Fragments do not become completely methylated by M.SssI, as shown by the 
presence of restriction products smaller than the full-length fragment marked by an arrow. B) PCR-methylated 
fragments exhibit methylation to a higher extent than M.SssI-methylated fragments. 
 
Since a pool of cells was analysed, I tested whether the decline of induced methylation was 
caused by a general loss in the whole population, or because the subpopulation of cells 
carrying methylation got overgrown by unmethylated cells. These cells might proliferate more 
quickly because they had not been transfected, which confers a selection advantage per se, or 
because they lose or remove the methylation, which might lead to faster growth in 
comparison to methylated cells. After three rounds of treatment, single cells were seeded at 
a low density to allow for the isolation of single subclones. 24 subclones that formed large 
colonies and 24 subclones that formed small colonies were isolated manually, expanded and 
assayed for the presence of methylation. If a subpopulation overgrowth was the reason for the 
overall decline of methylation, clones with large colonies would expectedly display no 
methylation, whereas clones forming small colonies would show methylation to at least some 
extent. Since all analysed clones exhibited a complete loss of methylation (not shown), I 
conclude that the induced methylation only remains stable upon additional treatment and is 
gradually lost upon its withdrawal. 
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Figure 25 
Figure 25. Induction and stability of methylation by M.SssI-methylated fragments. Top: experimental 
workflow. Green = days of transfection, orange = days of harvest, black = days without treatment. Bottom: after 
three rounds of transfection, the level of methylation increases to 38.6 % on D7. Methylation status of 2.0 % 
assessed prior to treatment on D0 is displayed for comparison. Level of methylation induced by three rounds of 
transfection is maintained upon additional treatment (green line). Untreated cells lose methylation gradually 
(black line). 
 
3.7.2.2 PCR-Methylated Fragments 
 
A 1413-bp DNA fragment was amplified from a plasmid by PCR with methylated dCTPs. 
The ratio of methylated to unmethylated dCTPs was 60:40. The methylated fragment was 
purified and the rate of methylation was determined by restriction digest with HpaII as shown 
in Fig. 24B. Denatured DNA was then delivered into the cells by three rounds of transfection 
with Lipofectamine® RNAiMAX. Genomic DNA was isolated from harvested cells, 
subjected to bisulphite conversion and sequenced. A follow-up experiment was conducted in 
the same settings as with the M.SssI-methylated fragments. The delivery of the PCR-
methylated fragments did not lead to any induction of methylation in the treated cells (not 
shown). 
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3.7.3 Methylation Induction by a Modified CRISPR/Cas9 System 
 
Four different gRNAs were designed by Dr. Pavel Bashtrykov, Institute of Biochemistry, 
University of Stuttgart, to target the region analysed by next-generation bisulphite sequencing 
(Fig. 26). The efficiency of single gRNAs was evaluated in HEK293 cells by their co-
transfection with a plasmid encoding wildtype Cas9 and subsequent T7 assay. gRNA forms 
a ribonucleoprotein complex with Cas9 and guides it to its target sequence. Cas9 induces 
double-strand breaks in the DNA that are repaired by the cell rendering the DNA non-
perfectly matched. After amplification of the targeted region and subsequent annealing of the 
fragments, restriction by T7 endonuclease ensues. The enzyme recognises and cleaves 
segments containing mismatches. As shown by the presence of restriction products, all four 
gRNAs proved to target the desired sequence efficiently (Fig. 27). 
Plasmids encoding Cas9 protein fused with the active domains of DNMT3A and DNMT3L 
were delivered into the cells together with one or two plasmids each containing one gRNA. 
Cells were inspected microscopically for the expression of YFP from the plasmid carrying the 
modified Cas9 one day post treatment. Delivery by transfection with Lipofectamine® 
RNAiMAX was successful in HEK293 cells with an efficiency of approximately 60 %. 
However, the method did not work for iPSCs, as no cells expressing YFP were found (not 
shown). The delivery by Amaxa™ Nucleofector™ Technology was evaluated by FACS but 
yielded hardly any cells positive for the YFP signal (25 cells out of 10 000 input cells; not 
shown).  
 
 
Figure 26 
Figure 26. gRNA design for methylation induction by a modified CRISPR/Cas9 system. Four gRNAs target 
the region analysed by next-generation bisulphite sequencing, which is shown for comparison. 
 
Electroporation using the Neon® Transfection System proved to be the most successful 
approach, although still with significant limitations. The viability of iPSCs after 
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electroporation (defined as the ratio of live cells as determined by FACS to the number of 
input cells on the day of electroporation) did not reach 10 %. No more than a fifth of the 
sorted live cells was positive for the expression of YFP. These cells were either directly 
subjected to analysis by next-generation bisulphite sequencing to quantify the induction of 
DNA methylation, or cultured further and harvested for analysis seven or fourteen days later, 
respectively (Fig. 28). The viability of the cells after sorting posed another problem, since 
only about 1 % of the seeded cells survived.  
 
 
Figure 27 
Figure 27. T7 assay with gRNAs targeting CpG77. gRNAs target the desired region effectively, as confirmed 
by the presence of restriction products in the respective reactions containing T7 endonuclease (lanes marked by 
+). Unrestricted fragments (lanes marked by -) are shown for comparison. 
 
A follow-up assay was planned in the same settings as with the M.SssI-methylated or PCR-
methylated fragments but scaling up the experiment failed to deliver the required number of 
cells. Therefore, the sampling of cells to investigate the stability of induced DNA methylation 
over the period of two weeks had to be reduced to two time points, 7 and 14 days after 
seeding of sorted cells on day 0. As expected, no methylation was induced by electroporation 
of the plasmid carrying the fusion protein alone at any analysed time point (Fig. 28). 
Combining gRNA1 and gRNA3 with the Cas9-DNMT3A-DNMT3L construct resulted in an 
increase in methylation to 15.7 % on day 7 and an additional rise to 30.0 % on day 14. By 
applying gRNA2 and gRNA4 instead, methylation level was induced to 5.6 % on day 7 and 
further to 11.8 % on day 14.  
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Figure 28 
Figure 28. Induction of methylation by a modified CRISPR/Cas9 system and its stability. Control samples 
with only the vector used for electroporation remain unmethylated at all three time points analysed. Combination 
of gRNA1 and gRNA3 with the plasmid induces methylation to 15.7 % on D7 that further rises to 30.0 % on 
D14. Application of gRNA2 and gRNA4 together with the construct yields less notable results with an increase 
in methylation to 5.6 % on D7 and 11.8 % on D14. 
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4. Discussion 
 
4.1 Characterisation of iPSCs 
 
Reprogramming of patient and control fibroblasts in order to obtain iPSCs occurred with 
a similar efficiency. Hence, we conclude that the UBE3A mutation has no effect on 
reprogramming. Based on the result of the Southern blot analysis, four patient-specific and 
two control lines were selected for further work that harboured only a single integration site 
of the lentiviral vector used for reprogramming. The six lines were subjected to a number of 
pluripotency tests to verify their pluripotency and to choose the most suitable ones for the 
final experiments. Pluripotency of the analysed lines was confirmed by alkaline phosphatase 
staining, immunohistochemical staining, FACS, qRT-PCR, EB formation assay, TaqMan 
array, Epi-Pluri-Score analysis and teratoma formation assay. High-resolution HLA typing 
and sequencing for the presence of the three-base pair deletion in the patient-specific iPSC 
lines proved the identity of the cells. Karyotyping revealed a normal 46, XX karyotype in 
three patient-derived lines and both control lines, and an aberrant karyotype in patient iPSC 
line H. The additional marker chromosome was identified by whole-chromosome painting as 
isochromosome 12p. The gain of chromosome 12 or isochromosome 12p has been described 
as a frequent anomaly in hESCs and iPSCs (Buzzard et al., 2004; Draper et al., 2004; Pera, 
2004; Mitalipova et al., 2005; Mayshar et al., 2010). Genes located on 12p are associated with 
pluripotency and proliferation. Their increased expression supposedly confers a selection 
advantage to single cells, which corresponds to the recurrent presence of isochromosome 12p 
in tumours and clonally isolated cell lines. Isochromosome 12p in a mosaic state leads to 
Pallister-Killian syndrome, a severe developmental disorder characterised by distinct 
craniofacial features, pigmentation anomalies, epilepsy, congenital heart defects and 
intellectual disability (Mauceri et al., 2000). The severity of this disorder depends on the level 
of mosaicism and is thought to be lethal in non-mosaic state. Because of the abnormality in its 
karyotype, patient iPSC line H was excluded from subsequent analyses performed with other 
unaffected lines.  
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The existing Angelman syndrome cell line AGI-0 harbours a large deletion on the maternal 
chromosome 15 encompassing many genes (Chamberlain et al., 2010), which makes it 
difficult to attribute certain phenotypes to the loss of UBE3A. The newly published cell lines 
derived from a patient with a paternal uniparental disomy of chromosome 15 (Takahashi et 
al., 2017) add a further tool for studying AS in vitro. In these cells, both alleles exhibit the 
paternal pattern of expression. Accordingly, SNURF-SNRPN, SNORD116, SNORD115 and 
SNHG14 are expressed biallelically. Hence, UBE3A is silenced by SNHG14 on both alleles. 
Therefore, phenotype attribution is not less complicated than in AGI-0. Similarly, cell lines 
carrying an imprinting defect are not more informative in this respect. Both alleles carry the 
paternal imprint, so the expression pattern at the locus resembles that of paternal uniparental 
disomy. The most promising cell lines in this regard are the newly published cell lines 
obtained by genetic engineering via CRISPR/Cas (Fink et al., 2017). The engineering resulted 
in a one-base pair insertion in both UBE3A alleles preventing successful splicing and 
translation of the UBE3A protein. Therefore, in these cells, the expression pattern at the locus 
is similar to the physiological state but for the expression of UBE3A. This does allow for 
phenotype attribution but the expression dynamics cannot be studied in these cells. 
Identification of interaction partners of UBE3A is not possible either. 
The cell lines we established have both parental UBE3A alleles present. Moreover, the 
molecular defect they harbour is an in-frame deletion in the maternal UBE3A gene 
(Horsthemke et al., 2011) giving rise to a UBE3A protein only missing a single amino acid in 
comparison with its healthy counterpart. Therefore, our cell lines feature two significant 
advantages in comparison with the cell lines described above. First, the expression pattern at 
the locus is completely true to the physiological state including UBE3A expression. This 
facilitates faithful analysis of the expression dynamics of both parental UBE3A alleles during 
neuronal differentiation. Second, the UBE3A protein is present in the cells, which allows for 
the identification of interaction partners of UBE3A and the attribution of all observed 
phenotypic manifestations directly to the loss of the protein function. Our cells represent 
a very valuable tool to study Angelman syndrome and to develop potential therapy.  
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4.2 Allelic Expression of UBE3A during Neuronal Differentiation 
 
Development of a reliable protocol for neuronal differentiation was the aim of the doctoral 
thesis of Anika Neureiter and will be described there in detail. Utilising the protocol outlined 
in Stanurova et al., 2016, we were able to generate terminally differentiated neurons, as 
confirmed by immunofluorescent staining for MAP2 and β-III-TUBULIN, both markers of 
post-mitotic neurons. In particular, I was interested in the development of UBE3A expression 
during neuronal differentiation because the silencing of the paternal allele takes place during 
this process (Chamberlain et al., 2010; Sato & Stryker, 2010; Judson et al., 2014; Fink et al., 
2017). Since my goal was to interfere with the silencing of the paternal UBE3A allele by 
SNHG14, I first needed to determine when exactly during neuronal differentiation the process 
occurs. I assessed expression levels of UBE3A and SNHG14 in embryoid bodies after 14 days 
of differentiation by qRT-PCR. This period of time proved to be insufficient to observe 
significant changes in expression. During neuronal differentiation over 35 days, I observed 
a gradual increase in expression of both UBE3A and SNHG14. The latter corresponds with the 
onset of silencing of the paternal UBE3A allele. The former can be explained by enhancing 
UBE3A expression from the maternal allele to compensate for the loss of expression from the 
paternal allele due to its silencing. This is in accordance with no decrease in overall mRNA 
expression and unaltered level of UBE3A protein in iPSCs and neurons (Chamberlain et al., 
2010; Stanurova et al., 2016). To address the phenomenon in more detail, single-nucleotide 
primer extension assay was employed. The three-base pair deletion in the maternal UBE3A 
allele was utilised as a SNP to assess the expression dynamics of both parental UBE3A alleles 
during neuronal differentiation. In iPSCs, neural progenitors and early neurons, a ratio of 
about 1 was detected indicating biallelic expression of UBE3A. Only on day 28 of 
differentiation did we observe a decrease in the ratio to 0.82 that became more pronounced on 
day 35, dropping to 0.66. This correlates with the onset of silencing of the paternal UBE3A 
allele by SNHG14 (Fig. 15). The evidence implies that silencing of the paternal UBE3A allele 
might be tightly coupled to neuron maturation, which is in line with the results based on the 
mouse model of Angelman syndrome (Sato & Stryker, 2010; Judson et al., 2014). 
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4.3 Quantitative Allele Distinction 
 
Single-nucleotide primer extension assay is a useful method and the output is a valuable piece 
of information in itself. However, the result may potentially be misinterpreted, since no 
absolute figures are available. If a ratio rises or drops, it might be due to a change in the 
numerator, or the denominator, or both at a time. In case of the UBE3A gene, I observe 
a decrease in the ratio of the paternal to the maternal allele. The outcome may occur due to 
a decrease in the paternal allele expression (numerator) brought upon by silencing, or because 
of an increase in the maternal allele expression (denominator) caused by compensation, or as 
a combination of both effects. The results indicate that the latter variant is true. Silencing of 
the paternal UBE3A allele has been described (Chamberlain et al., 2010; Stanurova et al., 
2016) and I observed an overall gradual rise of UBE3A expression throughout the course of 
neuronal differentiation by qRT-PCR and a stable protein level by Western blot (Stanurova et 
al., 2016). Theoretically though, a ratio decrease determined by single-nucleotide primer 
extension assay might not be caused by silencing of the paternal allele, but merely by an 
increase of the maternal allele expression instead, while the paternal allele expression remains 
stable. Given all the indications, this is a rather unlikely scenario but I wanted to establish an 
analysis to follow the development at the locus as accurately as possible. I designed the 
quantitative allele distinction assay to study the behaviour of both parental UBE3A alleles 
separately and to precisely quantify their contributions to the pool of UBE3A mRNA 
molecules in the cells during neuronal differentiation when the silencing of the paternal allele 
takes place. 
The generation of a standard curve is an essential prerequisite for any method utilised for 
absolute quantification. I designed two MGB probes to specifically detect the site of the 
mutation on the maternal UBE3A allele and its healthy counterpart on the paternal UBE3A 
allele by quantitative real-time PCR. 280 bp cDNA fragments from Angelman syndrome 
iPSC clone D containing the respective target sites were cloned into a vector. The plasmids 
were screened for accuracy of the inserted sequence and the two selected ones carrying the 
respective target sequences were mixed in defined ratios as templates for the standard curve. 
At first, I encountered a problem with the detection capacity of the TET-labelled probe 
detecting the maternal allele. The fluorescence signal was so weak that it was hardly possible 
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to evaluate the samples with the highest concentration of the target. A DNase I digestion test 
to release the full fluorescence potential of the probe did not lead to any improvement in the 
readout. qRT-PCR in multiplex and in singleplex settings excluded interference between the 
probes that would hinder the binding of one or the other probe to its target, as there was no 
difference between the outputs. Furthermore, the addition of salmon sperm DNA to the 
reactions verified that the probes only bind to their designated targets and not somewhere else 
on the vectors. The results with a requested replacement probe labelled with a stronger 
fluorophore, Yakima Yellow, were still unsatisfactory. Since it is very improbable that two 
different probes would contain a mismatch, I re-examined the assay design thoroughly. There 
was no way to alter the design of the probes because they had to fulfil a number of criteria 
that gave no room for adjustment. I first confirmed the primer specificity by using SYBR 
Green and the same set of templates as before. The expected output was an overlay of all 
curves because the amount of the target sequences should be equal in all reactions. Indeed, I 
observed an overlay without exception and the melting curve analysis proved the presence of 
a single PCR product. A 10-fold serial dilution of cDNA from Angelman syndrome iPSCs 
demonstrated primer efficiency of 98 % over four orders of magnitude. My experiment with 
SYBR Green not only showed that the primers were well designed but also that the plasmid 
mixes serve as appropriate templates, since the curves exhibited an overlay and a perfect 
sigmoid shape. However, when the respective probes were used with the standard samples, 
the curves flattened progressively with the decreasing amount of target. This indicates 
impaired efficiency of the reactions. My speculation that the phenomenon might be caused by 
a supercoiled structure of the plasmids restricting the access of the probes to their respective 
targets proved incorrect. Vectors linearised by enzymatic digestion with a single cutter did not 
differ from the untreated samples, so possible steric hindrance does not influence the 
accessibility of the targets.  
Lastly, I replaced the YY-labelled maternal probe with a FAM-labelled one to assay, whether 
its fluorescence signal would match that of the paternal probe. I tested the probe on both sets 
of templates. Signals of equal strength were anticipated from the probes because the 
fluorophores were the same, the target concentrations in the standard mixes are inversely 
correlated, and the amounts of targets in the cDNA serial dilution samples should be at least 
comparable, if not identical. Indeed, the result of the analysis displayed a perfect overlay of 
the signals generated by the respective probes with both sets of templates. Since the idea of 
a single standard curve for both probes at a time became irrelevant due to the labelling of both 
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probes with the same fluorophore, two separate standard curves were constructed instead.   
10-fold serial dilutions of the plasmids carrying the respective target sequences displayed the 
same sigmoid shape at all dilutions without any signs of flattening. Efficiencies of almost 
100 % were stable over seven orders of magnitude. The decreasing efficiency of the standard 
samples in mixed ratios was most likely only apparent. A feasible explanation of the 
phenomenon is that the PCR reaction occurs on both templates in the mix simultaneously at 
a joint efficiency reaching or nearing 100 %. Since only a defined portion of the reactions is 
detected by the respective probe, it appears as a decrease in efficiency when a lower amount 
of the target is available because the rest is omitted. Under such conditions, a standard curve 
cannot be created. 
The successful construction of a reliable standard curve for each probe allows for an exact 
calculation of the respective target amounts in analysed samples over a wide range of 
concentrations. The output obtained by the technique is much more informative than that of 
single-nucleotide primer extension assay. It facilitates the monitoring of expression dynamics 
of both parental UBE3A alleles in a very precise and unambiguous manner. If a fluorophore is 
developed that would match FAM in its fluorescence potential, multiplex qRT-PCR could be 
used for target detection to simplify the method. 
 
 
4.4 Methylation Analyses of Imprinted ICRs 
 
Since our aim was to establish a reliable model of Angelman syndrome and also to 
manipulate the methylation level at PWS-SRO, its stability and thus retained functionality 
with regard to UBE3A expression dynamics was an essential prerequisite for my work. 
Imprinted loci are expected to have a methylation level of 50 %. However, defects in 
maintenance during reprogramming or upon prolonged culture may occur (Pick et al., 2009; 
Nazor et al., 2012; Johannesson et al., 2014; Ma et al., 2014b). I analysed the methylation 
level at six imprinted loci. PWS-SRO proved to be the sole ICR with stable differential 
methylation in fibroblasts, iPSCs derived from them, hESC lines and the control iPSC line 
MCH2-10. Line AGI-0 harbours a large deletion on the maternal chromosome 15 including 
the imprinting centre, which is in concert with only unmethylated reads detected in the 
analysis (Fig. 25). My findings on the stability of the methylation level at PWS-SRO during 
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reprogramming are in line with previously published results (Chamberlain et al., 2010; Ma et 
al., 2014b). At ICR1, I observed a loss of methylation in patient iPSC line B1 and a gain of 
methylation in hESC line H9. Aberrant methylation towards both a loss and a gain of 
methylation have been reported (Nazor et al., 2012; Johannesson et al., 2014; Ma et al., 
2014b). ICR2 showed expected levels of methylation but for one exception in patient iPSC 
line P, in which the methylation was lost. A loss of methylation at NESPAS was detected in 
five out of 13 samples analysed. This result corresponds with previously published evidence 
on variable methylation at NESPAS in hESCs and iPSCs (Grybek et al., 2014). CpG85 only 
exhibited differential methylation in four out of 16 assayed samples. Methylation was 
consistently elevated in all other samples. Variation at this locus between tissues has been 
observed with an obvious trend towards hypermethylation (Kanber, Institute of Human 
Genetics, unpublished data). IG-DMR showed a gain of methylation in seven out of 16 
samples. This observation is in agreement with its reported susceptibility to acquiring 
methylation (Stadtfeld et al., 2012; Johannesson et al., 2014; Ma et al., 2014b). I detected 
a loss of methylation at IG-DMR in immortalised fibroblasts of the patient but not in three 
other fibroblast samples. Therefore, this result is most likely the consequence of 
immortalisation. Alterations in methylation at imprinted loci and in the expression of 
imprinted genes have been described in immortalised lymphoblastoid cell lines and 
fibroblasts (Saferali et al., 2010; Okamura et al., 2011). 
My results indicate a tendency towards either a loss of methylation, or its gain at a certain 
locus. I detected only a loss of methylation at ICR2 and at NESPAS, while solely a gain of 
methylation at CpG85 and at IG-DMR was observed. ICR1 was an exception to this trend 
showing both an increase and a decrease of methylation in different samples. Mechanisms 
favouring a loss or a gain of methylation at an ICR in hESCs or in iPSCs have not been 
understood so far. Imprint stability is expected in hESCs because imprints are already set in 
the parental germline, protected during the global wave of reprogramming in early embryonic 
development and passed on to daughter cells upon division. iPSCs are generated by 
reprogramming differentiated cells, whose imprints should be stable as well. Anomalies in 
methylation at imprinted loci therefore probably occur due to a defective maintenance during 
the cultivation of hESCs, fibroblasts and iPSCs, or as a result of reprogramming (Rugg-Gunn 
et al., 2007; Johannesson et al., 2014; Ma et al., 2014b). In general, my observations on the 
stability of the analysed ICRs in hESCs and in iPSCs are in line with previous reports. Most 
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importantly, I confirmed the stability of the methylation at PWS-SRO in the cells and thereby 
their adequacy for the purposes of the study. 
 
 
4.5 Methylation Induction 
 
Successful targeting of selected regions by artificial methylated oligonucleotides (MONs) in 
order to interfere with the expression of a certain gene or RNA has previously been described 
(Yao et al., 2003; Zhu et al., 2004; Hoffman & Hu, 2006; Ma et al., 2010). In theory, the 
method relies on the annealing of the MONs to their target during mitosis or transcription. 
The hemi-methylated stretch of DNA is recognised by the maintenance methyltransferase 
DNMT1 and the newly synthesised strand is methylated. Once the MONs dissociate and the 
DNA double helix is formed, DNMT1 completes the methylation. Several groups 
demonstrated efficient induction of methylation and a subsequent silencing of gene 
expression. For instance, in a model of hepatocellular carcinoma, expression levels of the 
targeted gene decreased rapidly upon methylation induction. Moreover, the survival of rats 
treated with MONs was significantly prolonged in comparison with negative controls (Yao et 
al., 2003). Successful results were obtained using various cell lines but neither hESCs nor 
iPSCs were among them. I employed transfection and nucleofection to deliver the MONs into 
the cells and tested a range of MONs concentrations to determine the most suitable one. 
Although the delivery was rather efficient, the method did not induce methylation at the 
targeted PWS-SRO (Fig. 22). Prolonging the time of the treatment before harvest did not lead 
to any improvement in the outcome. I performed repeated delivery every two or three days 
involving six rounds of transfection at most. The region remained unmethylated when 
targeted by a single MON as well as by a combination of MONs.  
The efficiency of the MONs delivery into the cells was probably not the limiting factor of the 
technique, though it is often an issue. In case of nucleofection, the viability of the cells was 
strongly impaired after the treatment but the surviving cells did absorb additional MONs 
during subsequent rounds of transfection. It is feasible that a combination of other aspects 
prevented the successful application of the approach. Even at a high concentration, it is 
unlikely for the MONs to find their target. Experiments on the plasticity of nuclear 
organisation in embryonic stem cells and fibroblasts demonstrated high stability of the 
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chromatin structure in differentiated cells, while the positions of the chromatin domains 
fluctuated substantially within 40 minutes in embryonic stem cells (Strickfaden et al., 2010; 
Cremer, personal communication). The increased plasticity does not favour the binding of the 
MONs. Furthermore, mitosis of hESCs and iPSCs is a fast process (Becker et al., 2006), 
which does not contribute to the MONs annealing either. There is only a very short time 
frame for the pairing to occur. In addition, methylation by DNMT1 is a process much slower 
than replication, so the probability that DNMT1 acts at the correct moment is low. All the 
described circumstances make the approach ineffective. If methylation is induced to a small 
extent, it is most likely not maintained or even actively removed by TET enzymes, whose 
activity is rather high in hESCs and iPSCs because it is required for maintaining pluripotency 
(Tahiliani et al., 2009; Pastor et al., 2011; Gao et al., 2013). It would be worthwhile to try 
applying the method in neural progenitors. 
 
Induction of methylation at a targeted locus using in vitro-methylated fragments has been 
published (Hsiao et al., 2010; Hsu et al., 2011; Teng et al., 2011). Adjustments to the method 
described in the article were required, since methylation by M.SssI was not working 
efficiently. Gel elution proved to be an unsuitable means of purifying the desired fragment 
after PCR. Probably, impurities present in the eluate inhibited the M.SssI activity. Purification 
by the Agencourt® AMPure® XP system produced an eluate of sufficient purity. 
Optimisation of the methylation reaction yielded fragments methylated to approximately 80 
%. After the initial problems I encountered with MONs, I resorted to multiple transfections 
from the beginning, as indicated in the publication (Hsiao et al., 2010). By employing this 
approach, I accomplished an increase of 38.6 % methylation at the targeted region after three 
rounds of transfection. I pursued the development of the methylation after three rounds of 
transfection with and without additional delivery. When transfection ensued, the methylation 
level remained stable (Fig. 25). When no further substrate was provided, I observed a rapid 
decrease of the methylation level by roughly 5 % per day. The loss could have been general in 
the whole population, or due to clonal expansion of cells that had not been transfected and 
thereby possessed a selection advantage. The analysis of single clones confirmed the former 
hypothesis, since all analysed clones exhibited a complete loss of methylation. It is possible 
that the gradual loss of methylation is caused simply by the lack of its maintenance and it 
passively gets diluted out. Alternatively, it can be removed by the activity of TET enzymes. 
Since the approach did not induce stable methylation, I decided not to work with it further. 
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Therefore, I did not determine the exact mechanism of the methylation loss. It would have 
been possible to employ TET inhibitors to identify whether it is an active or a passive process. 
However, considering that my aim was to develop a means of therapy, an additional treatment 
in the form of TET inhibitors would be highly undesirable. 
The experiment with the PCR-methylated fragments surprisingly led to no induction of 
methylation at the targeted locus. Based on the HpaII validation result, it seemed to be more 
promising than the M.SssI approach, even though the fragments were not methylated to full 
extent by this method either (Fig. 24). Considerable optimisation was required to obtain 
a PCR product at all because methylated cytosine is not a substrate polymerases recognise 
readily. Since the methylated cytosines are incorporated by the polymerase on a random basis 
during PCR, they occur in the sequence not only in the context of CpG dinucleotides. The 
presence of methylated cytosines outside of this context is not physiological. Such a piece of 
DNA might therefore be interpreted as potentially deleterious and eliminated. 
 
Especially type II CRISPR/Cas system relying on Cas9 has been widely adopted as a tool for 
genetic and epigenetic engineering. Fusion proteins of the inactivated nucleases with histone 
deacetylases, transcription repressors or enhancers represent only some of the possible options 
the technology offers (Hilton et al., 2015; Kearns et al., 2015; Thakore et al., 2015). The 
CRISPR/Cas9 fusion construct with DNMT3A and DNMT3L active domains was shown to 
be an efficient tool to induce methylation at targeted loci (Jurkowska et al., 2008; Rajavelu et 
al., 2012; Siddique et al., 2013; Emperle et al., 2014; McDonald et al., 2016; Vojta et al., 
2016; Stepper et al., 2017). The published experiments were performed in differentiated cells 
and not in iPSCs. Transfection of HEK293 cells was successful and I proved the specificity 
and efficiency of the designed gRNAs by T7 assay (Fig. 27). However, the delivery of the 
constructs into iPSCs proved to be an issue difficult to deal with. Delivery by transfection 
yielded no cells positive for YFP, although HEK293 cells are not larger in size than hESCs or 
iPSCs. hESCs as well as iPSCs are cells generally difficult to transfect by any means of 
delivery (Eiges et al., 2001; Gerrard et al., 2005; Liu et al., 2005; Braam et al., 2008; 
Hohenstein et al., 2008; Siemen et al., 2008). Moreover, the plasmids carrying the constructs 
are larger than 12 kb, which itself is a hindrance. Nucleofection that proved to be more 
efficient for the delivery of MONs into the iPSCs than conventional transfection yielded 
virtually no YFP-positive cells. Also in this case, the size of the construct was presumably the 
critical factor because I observed a delivery efficiency of up to 60 % with a smaller GFP-
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expressing plasmid provided with the kit as positive control. Electroporation was the sole 
method by that I obtained YFP-positive cells, although also this approach was rather 
inefficient. Approximately 10 % of the input cells survived the treatment. Out of the 
remaining cells, no more than 9.6 % were positive for YFP, as determined by FACS. Merely 
1 % of the cells was viable after sorting when seeded for expansion. The limited efficiency 
and the poor viability of the cells after electroporation and especially after sorting cannot be 
improved with current methods. Scaling up as the only means of retrieving a number of cells 
sufficient for the planned analyses was extremely inefficient, the output after sorting being 
0.03 % at best. This was most probably due to technical reasons, as the experiment took 
a considerable amount of time and the viability of the cells decreases rapidly, if they do not 
adhere to the surface of the culture vessel as soon as possible. When it is compromised by 
electroporation in addition, the likelihood of survival is low. Alternatively, lentiviral 
transduction, though a laborious and time-consuming method, represents another possibility 
of delivery into cells difficult to transfect. However, the overall size of the vector is restricted 
to around 10 kb and the insert should not exceed 6 kb, which is a condition that the constructs 
I employ do not fulfil, even if the minimal necessary portion were used. Moreover, the 
method would lead to the integration of the vector into the genome. 
Methylation levels detected in electroporated cells immediately after sorting, that is, three 
days after treatment, were unexpectedly low. Since the cells were positive for YFP, the fusion 
protein was also present in the cells. The surprising outcome could have been caused by 
diverse reasons or, more likely, their combination. First, technical issues associated with 
sorting may have been a problem. Doublet exclusion is essential because doublets with only 
one cell positive for YFP are interpreted as a positive event. If these doublets are not 
excluded, unmethylated cells are carried over and bias the results. Even with proper gating 
and careful analysis, doublets may escape the negative selection. Second, the efficiency of 
gRNAs is dose-dependent. When the gRNA-protein complexes are formed, probing of DNA 
sequence neighbouring the PAM triplet begins. If the complex does not find its target, it 
disintegrates and loses its methylation potential. As 5’-NGG-3’ PAM sites are very abundant 
in the genome, a lot of the fusion protein is needed to target the correct sequence. Even when 
large amounts of the protein are available in the cells, the methylation capacity might be 
dissipated before the gRNA-protein complex reaches the target sequence. Third, it is 
generally rather difficult to methylate promoters of actively transcribed genes, which is likely 
also the case of SNURF-SNRPN. The region is probably occupied by transcription factors and 
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RNA polymerase complexes. This creates steric hindrance, which inhibits the access of the 
gRNA-protein complexes to the target. Moreover, TET enzymes are active at such promoters, 
which further decreases the probability that the region would acquire methylation and retain it 
(Pastor et al., 2011; Wu et al., 2011).  
The best result I obtained by electroporation was 30.0 % methylation at the targeted locus 
after two weeks of cultivation post sorting. The level of methylation nearly doubled within 
a week from 15.7 % on day 7. It is difficult to estimate the development of the methylation 
between day 0, which shows 22.8 % methylation, and day 7. Since only very few cells were 
available for DNA isolation on day 0, the results are affected by a strong bias. An obvious 
clonal expansion and a patchy pattern of methylation indicate the inaccuracy of the outcome 
on day 0. Most likely, the cells exhibit significantly lower levels of methylation than 
suggested by the analysis. I probably would have been able to see an increase in methylation 
from day 0 to day 7, had it been possible to analyse more material. On day 7 and day 14, the 
pattern of the induced methylation was not patchy, which would imply its active removal by 
TET enzymes. On the contrary, it was evenly distributed indicating that methylation is not 
restricted to regions directly neighbouring the binding sites of the gRNAs but gets spread 
beyond the targeted segments of DNA. This is a very promising result because I observe reads 
with all CpGs methylated despite occasional template switching. Also, the stability of the 
methylation is exceptional especially considering the rapid decrease of methylation induced 
with M.SssI-methylated fragments.  
It is possible that the gain of methylation to 30.0 % occurred due to the lasting presence of the 
vectors in the cells. Nevertheless, methylation spreading and self-propagation is plausible and 
even quite feasible, since the plasmids do get diluted out over time. Another explanation of 
the gain in methylation may be the clonal expansion of cells, whose SNURF-SNRPN 
expression had been abolished due to the introduced repressive methylation. This might 
confer a selection advantage to the cells that would then overgrow the population of 
unmethylated cells. Further long-term time-course assays and qRT-PCR analyses of SNURF-
SNRPN expression to test the biological effects of the induced methylation are required to 
determine the true mechanism.  
Although an increase of 30 % in methylation is a very good result, it would be desirable to 
achieve a higher level of methylation for experimental purposes. Positive selection by 
applying kanamycin represents one of the ways to accomplish this. The process would yield 
only cells carrying the plasmid; however, there are certain drawbacks to the method. When 
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selection conditions suitable for healthy cells are applied to cells with impaired viability due 
to electroporation, they may as well not survive the stringent pressure. Another possibility 
would be to indirectly induce DNA methylation by histone modifications, for instance by 
employing complexes containing the SET domain catalysing H3K9 trimethylation (Xiao et 
al., 2003). Transcriptional regulation is a sophisticated mechanism involving an interplay of 
diverse factors including chromatin remodelling, so this process would most likely also 
contribute. Alternatively, artificial reporter constructs could be implemented to induce DNA 
methylation. Such systems may contain SssI methyltransferase, Krüppel-associated 
suppression box (KRAB) that functions as a strong transcriptional repressor (Witzgall et al., 
1994), and a reporter to monitor the effects (Ma et al., 2014a). Both described options rely on 
large complexes that would pose a problem with delivery into the cells similar to the one 
I encountered with the CRISPR/Cas9 system. Probably the most reliable method of inducing 
stable methylation would be the generation of stable cell lines with any of the fusion proteins 
integrated into the genome and constantly expressed. The most important reason why I did 
not resort to creating stable cell lines was that my goal was to develop a means of therapy. 
However, establishing stable cell lines to prove my hypothesis might contribute to a better 
understanding of the methylation dynamics and support optimisation of the non-integrative 
approaches. 
I chose to induce methylation in iPSCs rather than in neurons for various reasons. At the time 
the study was initiated, the published methods of accomplishing methylation induction all 
required mitosis to function and iPSCs certainly are mitotically active. On the contrary, the 
more mature neurons become, the more they cease to proliferate, so it would have hardly been 
possible to use them for my experiments. Moreover, neurons exhibit very high levels of TET 
enzymes (Kriaucionis & Heintz, 2009; Globisch et al., 2010; Szwagierczak et al., 2010), 
which would also have been counterproductive for my purposes. Lastly, neurons are fragile, 
challenging to obtain and generally demanding to work with. As I experienced difficulties 
delivering constructs into the iPSCs, I considered employing neural progenitors instead. The 
reason was that all of the described approaches relied on differentiated cells and neural 
progenitors would probably be more suitable in this regard than iPSCs. Also, unlike neurons, 
they are still mitotically active. On the other hand, the activity of TET enzymes is high in 
neural progenitors as well (Hahn et al., 2013; Lister et al., 2013; Zhang et al., 2013). I did not 
perform the methylation induction in neural progenitors because a stable culture had not yet 
been established. It would definitely be worthwhile to proceed with research on inducing 
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methylation in neural progenitors. The modified CRISPR/Cas9 system was only developed 
recently. Although there are particular disadvantages to the approach, its indisputable 
advantage in comparison with the other methods is its independence from mitosis. Thus, its 
application in neural progenitors or even terminally differentiated neurons is well practicable. 
Optimisation of delivery would surely be necessary but the combination could yield very 
interesting results and is unquestionably worth further investigation. 
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5. Conclusion 
 
In this study, an iPSC model of Angelman syndrome was developed. iPSCs were generated 
from an Angelman syndrome patient harbouring a three-base pair deletion in the maternal 
UBE3A allele and from a healthy control person. The maternal UBE3A allele is expressed but 
the protein UBE3A is not functional. Therefore, the cells exhibit normal expression of all 
genes at the PWS/AS locus. In comparison with all iPSC lines generated as a model of 
Angelman syndrome so far, this is a significant advantage because all observed effects may 
be attributed directly and solely to the inactive UBE3A protein. 
Using lentiviral transduction, we reprogrammed fibroblasts from the patient and from the 
healthy control person, and isolated several clones. Their thorough characterisation followed 
confirming their pluripotency, identity and integrity by various methods. Based on the results, 
clones most suitable for further analyses were selected. The stability of the imprint at the 
PWS/AS locus is a critical prerequisite for the faithful analysis of imprinted expression and 
for the induction of DNA methylation on the paternal allele. Therefore, the methylation status 
at six imprinted loci and two pluripotent loci was determined in the iPSCs generated at the 
beginning of this project, their parental fibroblasts, in hESCs H1 and H9, and in published cell 
lines AGI-0 and MCH2-10 that represented iPSC controls. Most importantly, I observed an 
exceptional stability of the methylation imprint at PWS-SRO. Three imprinted loci showed 
a tendency towards a loss of methylation and two exhibited susceptibility to acquiring 
methylation. Both pluripotent loci displayed a higher level of methylation in differentiated 
cells than in pluripotent cells. My results on the stability of the assayed loci upon 
reprogramming are in agreement with previously reported observations.  
In cooperation with Anika Neureiter from the Institute for Transfusion Medicine, iPSCs were 
differentiated into neurons. We determined by single-nucleotide primer extension assay that 
silencing of the paternal UBE3A allele by SNHG14 occurs late during the process of neuronal 
differentiation. These findings are also in line with previously published results. I developed 
a quantitative qRT-PCR analysis to follow the expression dynamics of the maternal and the 
paternal UBE3A allele separately in the generated iPSCs during differentiation. The method 
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allows for a much more precise evaluation of the respective alleles’ expression than single-
nucleotide primer extension assay.  
In the second part of the study, I aimed to induce methylation at the paternal PWS-SRO in the 
cell line AGI-0, which only harbours the unmethylated paternal allele. I observed a transient 
increase of methylation at the paternal PWS-SRO to 38.6 % upon transfecting the cells with 
methylated DNA fragments. By employing the modified CRISPR/Cas9 system fused with 
DNMT3A and DNMT3L, I was able to induce methylation at the paternal PWS-SRO in AGI-
0 to 30.0 %. Not only was the methylation stable at the locus over the course of two weeks 
but its level also increased during the time. The result is especially valuable because the 
approach does not require mitosis for its functioning and could therefore potentially be used 
even in non-dividing cells such as neurons. 
It would certainly be worthwhile to pursue the stability of the induced methylation in a longer 
time-course experiment. Also, the investigation of a direct biological impact in the form of 
a qRT-PCR assay of SNURF-SNRPN expression would be of importance. The effect of the 
methylation on the expression of SNHG14 in neurons is even more relevant for my purposes 
and so is the subsequent impact on the expression of UBE3A. Should the methylation lead to 
abolishment of SNHG14 expression and thereby prevent silencing of the paternal UBE3A 
allele in neurons, it would be a significant step towards possible compensation for the loss of 
maternal UBE3A by the intact paternal allele. Therefore, further optimisation of the method 
and its application in iPSCs generated in this study ought to be performed. 
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6. Zusammenfassung 
 
In dieser Arbeit wurde ein iPS-Zellmodell für das Angelman-Syndrom etabliert. Wir 
generierten iPS-Zellen von einem Angelman-Syndrom Patienten mit einer Deletion von 3 bp 
im mütterlichen UBE3A Allel, sowie von einer gesunden Kontrollperson. Durch diese 
definierte Mutation im mütterlichen UBE3A Allel exprimieren die Zellen UBE3A, aber das 
daraus hergestellte Protein ist nicht funktionell. Die Zellen zeigen somit eine normale 
Expression aller Gene im PWS/AS Genlokus. Im Vergleich mit allem bisher als Modell für 
das Angelman-Syndrom generierten iPS-Zelllinien ist das ein bedeutsamer Vorteil, denn so 
können beobachtete Effekte direkt und ausschließlich auf das inaktive UBE3A-Protein 
zurückgeführt werden. 
Mithilfe lentiviraler Transduktion wurden sowohl patienten-spezifische Fibroblasten, als auch 
Kontrollfibroblasten in iPS-Zellen reprogrammiert und anschließend einige Klone isoliert. 
Ihre Charakterisierung mittels verschiedener Methoden bestätigte die Pluripotenz, Identität 
und Integrität der Zellen. Die meistgeeigneten Klone wurden für weitere Analysen 
ausgewählt. Eine kritische Voraussetzung für die Analyse der geimprinteten Expression und 
der Induktion von DNA-Methylierung auf dem väterlichen Allel ist die Stabilität des 
Methylierungsimprints des PWS/AS-Genlokus. Daher wurde der Methylierungsstatus an 
sechs geimprinteten Lozi und zwei mit Pluripotenz assoziierten Lozi in den in dieser Studie 
generierten Zelllinien, in deren elterlichen Fibroblasten, in den humanen embryonalen 
Stammzelllinien H1 und H9, sowie in den publizierten iPS-Zelllinien AGI-0 und MCH2-10, 
welche iPS-Kontrollen darstellten, bestimmt. Der Imprint des PWS-SROs erwies sich als 
außergewöhnlich stabil. Drei der geimprinteten Lozi wiesen eine Tendenz zur 
Hypomethylierung auf, während die zwei anderen Lozi eine Neigung zur Hypermethylierung 
zeigten. Die Methylierung an den beiden mit Pluripotenz assoziierten Lozi war in 
differenzierten Zellen höher als in pluripotenten Zellen. Die Ergebnisse bezüglich Stabilität 
geimprinteter Lozi unter Reprogrammierung entsprechen zuvor publizierten Erkenntnissen. 
Die Differenzierung von iPS-Zellen in Neurone erfolgte in Kooperation mit Anika Neureiter 
aus dem Institut für Transfusionsmedizin. Mithilfe der single-nucleotide primer extension 
Methode wurde festgestellt, dass die Stilllegung des väterlichen UBE3A Allels durch 
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SNHG14 erst spät während der neuronalen Differenzierung auftritt. Auch diese Ergebnisse 
stehen im Einklang mit früheren Beobachtungen. Es wurde eine quantitative qRT-PCR-
Analyse entwickelt, die die Untersuchung der Expressionsdynamik beider elterlichen Allele 
getrennt in den generierten iPS-Zellen während neuronaler Differenzierung zulässt. Diese 
Methode ermöglicht eine Evaluierung der Expression der jeweiligen UBE3A-Allele, die viel 
präziser ist als die der single-nucleotide primer extension Analyse. 
Im zweiten Teil des Projektes wurden Experimente zur Einführung von Methylierung am 
väterlichen PWS-SRO der Zelllinie AGI-0, die nur das unmethylierte väterliche Allel enthält, 
durchgeführt. Transiente Methylierung von 38.6 % wurde mittels Transfektion der Zellen mit 
methylierten DNA-Fragmenten erzielt. Durch den Einsatz eines modifizierten CRISPR/Cas9-
Systems, in dem Cas9 fusioniert mit DNMT3A und DNMT3L vorliegt, wurde Methylierung 
von 30.0 % am väterlichen PWS-SRO induziert. Die Methylierung war über zwei Wochen 
stabil und das Ausmaß nahm in dieser Zeitspanne zu. Dieses Ergebnis ist von Bedeutung vor 
allem wegen der Unabhängigkeit des Verfahrens von Mitose, durch die die Verwendung der 
Methode in sich nicht teilenden Zellen wie Neuronen sehr vielversprechend ist. 
Es wäre interessant die Stabilität der induzierten Methylierung über einen längeren Zeitraum 
zu verfolgen. Weiterhin wäre die Erforschung direkter biologischer Auswirkung der 
Methylierung auf die Expression von SNURF-SNRPN von Bedeutung. Die Auswirkung auf 
die Expression von SNHG14 in Neuronen wäre noch wichtiger und gleichermaßen der 
nachfolgende indirekte Einfluss auf die Expression von UBE3A. Sollte die Methylierung die 
Expression von SNHG14 unterdrücken und dadurch die Stilllegung des väterlichen UBE3A 
Allels verhindern, wäre das ein wichtiger Schritt zur potentiellen Kompensierung des 
Verlustes des mütterlichen UBE3A Allels durch das intakte väterliche Allel. Deshalb sollte 
eine weitere Optimierung der Methode und deren Einsatz in den in dieser Studie generierten 
iPS-Zellen unbedingt verfolgt werden. 
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8. Appendix 
 
8.1 PCR Programmes 
 
 
Table 1. qRT-PCR programme for all qRT-PCR applications including quantitative 
allele distinction. 
 
95 °C 1 min 
 95 °C 15 s 
 40x 
60 °C 30 s 
95 °C 1 min 
 55 °C 30 s 
 95 °C by 0.5 °C 
 4 °C ∞ 
 Table 1 
Table 2. PCR programme for Sanger sequencing. 
 
96 °C 1 min 
 96 °C 10 s 
 25x 50-56 °C 5 s 
60 °C 4 min 
4 °C ∞ 
 Table 2 
Table 3. PCR programme for cloning the 280 bp UBE3A fragment from patient-specific 
cDNA. 
95 °C 15 min 
 95 °C 30 sec 
 35x 50-60 °C 30 sec 
72 °C 30 sec 
72 °C 7 min 
 4 °C ∞ 
 Table 3 
Table 4. PCR programme for amplifying bisulphite-converted DNA. 
 
95 °C 15 min 
 95 °C 30 sec 
 35x 
50-60 °C 30 sec 
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72 °C 30 sec 
72 °C 7 min 
 4 °C ∞ 
 Table 4 
Table 5. Primer annealing temperatures for amplifying bisulphite-converted DNA. 
 
PWS-SRO  56 °C 
ICR1 59 °C 
ICR2  56 °C 
NESPAS  54 °C 
CpG85  54 °C 
IG-DMR  55 °C 
Table 5 
Table 6. PCR programme for Re-PCR with MID primers preceding next-generation 
bisulphite sequencing. 
 
95 °C 15 min 
 95 °C 30 sec 
 35x 
72 °C 1 min 
72 °C 5 min 
 4 °C ∞ 
 Table 6 
Table 7. PCR programme for amplifying the 1413 bp fragment encompassing CpG77. 
 
98 °C 30 sec 
 98 °C 10 sec 
 35x 52 °C 30 sec 
72 °C 70 sec 
72 °C 7 min 
 4 °C ∞ 
 Table 7 
Table 8. PCR programme for amplifying DNA for T7 assay. 
 
98 °C 30 sec 
 98 °C 10 sec 
 35x 60 °C 30 sec 
72 °C 30 sec 
72 °C 7 min 
 4 °C ∞ 
 Table 8 
  
 Appendix 
 
 139 
Table 9. Annealing programme for T7 assay. 
 
95 °C 10 min 
95 °C => 85 °C by 2 °C/s 
85 °C => 25 °C by 0.1 °C/s 
4 °C ∞ 
Table 9 
 
8.2 Oligonucleotides 
 
 
Table 10. Primer sequences, probes, methylated oligonucleotides and gRNAs. 
 
Name Sequence 5’ => 3’ Product 
size (bp)     
Sequencing UBE3A      
UBE3A_100bp_fw CCTGCAGACTTGAAGAAGCA 
100 
UBE3A_100bp_r CCTCCACAACCAGCTGAAA 
      
Pluripotency     
RPL13A_F CCATCGTGGCTAAACAGGAGT 
112 
RPL13A_R AGGAAAGCCAGGTACTTCAACTT 
GAPDH_F TGCACCACCAACTGCTTAGC 
87 
GAPDH_R GGCATGGAGTGTGGTCATGAG 
OCT4_F GAAGGTGAAGTTCAATGATGCTG 
139 
OCT4_R ATTCCCATCCCTACCTCAGTAAC 
SOX2_F AGTATCAGGAGTTGTCAAGGCAG 
79 
SOX2_R TCCTAGTCTTAAAGAGGCAGCAA 
KLF4_F CTAAATGATGGTGCTTGGTGAGT 
124 
KLF4_R GGTCATAAATGTTGATCGGAAGAC 
MYC_F TCCTGAGCAATCACCTATGAACT 
110 
MYC_R TTGAGGCAGTTTACATTATGGC 
NANOG_F ACCTCAGCTACAAACAGGTGAAG 
156 
NANOG_R ATCCCTGGTGGTAGGAAGAGTAA 
LIN28A_F TTGAGGAGCAGGCAGAGTGG 
162 
LIN28A_R TGCATTTGGACAGAGCATGG 
DNMT3B_F GGATGTTTGAGAATGTTGTAGCC 
72 
DNMT3B_R GATTACACTCCAGGAACCGTGA 
ZFP42_F AGCTGAAACAAATGTACTGAGGCT 
127 
ZFP42_R CTCCAGGCAGTAGTGATCTGAGTA 
      
EB differentiation     
b_ACTIN_F CTGGAACGGTGAAGGTGACA 139 
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b_ACTIN_R AAGGGACTTCCTGTAACAATGCA 
OCT4_F TGGGCTCGAGAAGGATGTG 
78 
OCT4_R GCATAGTCGCTGCTTGATCG 
PAX6_F AACAGACACAGCCCTCACAAACA 
275 
PAX6_R CGGGAACTTGAACTGGAACTGAC 
BRACHYURY_F TGCTTCCCTGAGACCCAGTT 
121 
BRACHYURY_R GATCACTTCTTTCCTTTGCATCAAG 
SOX17_F GAACGCTTTCATGGTGTGGG 
151 
SOX17_R CTCTGCCTCCTCCACGAAGG 
      
Neuronal differentiation     
OCT4_F GAAGGTGAAGTTCAATGATGCTG 
139 
OCT4_R ATTCCCATCCCTACCTCAGTAAC 
NESTIN_F GGAAGAGAACCTGGGAAAGG 
122 
NESTIN_R CTTGGTCCTTCTCCACCGTA 
PAX6_F AATAACCTGCCTATGCAACCC 
275 
PAX6_R AACTTGAACTGGAACTGACACAC 
SOX1_F CAATGCGGGGAGGAGAAGTC 
95 
SOX1_R CTCGAAACATTTTGGGTGGGG 
PLZF_F CCTGGATAGTTTGCGGCTGA 
144 
PLZF_R GCCATGTCAGTGCCAGTATG 
NR2F1_F ACAGGAACTGTCCCATCGAC 
194 
NR2F1_R GATGTAGCCGGACAGGTAGC 
FOXG1_F TGCCAAGTTTTACGACGGGA 
79 
FOXG1_R GGGTTGGAAGAAGACCCCTG 
NURR1_F TTCTCCTTTAAGCAATCGCCC 
332 
NURR1_R AAGCCTTTGCAGCCCTCACAG 
TH_F GAGTACACCGCCGAGGAGATTG 
279 
TH_R GCGGATATACTGGGTGCACTGG 
PAX2_F CAGGCATCAGAGCACATC 
165 
PAX2_R GTCACGACCAGTCACAAC 
β-III TUBULIN_F CTCAGGGGCCTTTGGACATC 
160 
β-III TUBULIN_R CAGGCAGTCGCAGTTTTCAC 
UBE3A_F CTCTTCTTGCAGTTTACAACGG 
152 
UBE3A_R CTTGAGTATTCCGGAAGTAAAAGC 
SNHG14__RT17_F GGCACTGAAAATGTGGCATCCAGTC  
120 
SNHG14__RT17_R GGTGTGTCAGCTGTGCTGGTGTCAA 
      
Bisulphite sequencing     
SNRPN_Ftag CTTGCTTCCTGGCACGAGGGAGGGAGTTGGGATTTTTGTATTG 
275 
SNRPN_RM13 CAGGAAACAGCTATGACCCCCAAACTATCTCTTAAAAAAAACCACC 
H19-in-Ftag CTTGCTTCCTGGCACGAGGGTAYGGAATTGGTTGTAGTTGTGG 
204 
CTCF-RM13_R_CTCF6 CAGGAAACAGCTATGACATATCCTATTCCCAAATAACCCC 
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LIT1-Not1-F-tag CTTGCTTCCTGGCACGAGTTTATAGGTTTTTATATYGAGGGTTTATAGTAG 
156 
LIT1-Not1-R-M13 CAGGAAACAGCTATGACAAATAAACYRAAAACACRAACCAATTCTCTAC 
NESPAS_F_neu_Bis CTTGCTTCCTGGCACGAGGTAGTAGTTTTTGGATGGAGATTTT 
272 
NESPAS_R_neu_Bis CAGGAAACAGCTATGACAAAAAAATACTTTTCCTCCCTCC 
RB1_CpG85_Ftag_1 CTTGCTTCCTGGCACGAGTTTGGATGGTTTTTTTAG 
221 
RB1_CpG85_RM13_1 CAGGAAACAGCTATGACAACAAAAAAACAAAAACAACC 
IG-DMR-Ftag CTTGCTTCCTGGCACGAGGTTTATTGGGTTGGGTTTTGTTAG 
302 
IG-DMR-RM13 CAGGAAACAGCTATGACACCAATTACAATACCACAAAATTAC 
Bis_hOCT4_R2a_Ftag CTTGCTTCCTGGCACGAGGGGGTTAGAGGTTAAGGTTAGTG 
267 
Bis_hOCT4_R2a_RM13 CAGGAAACAGCTATGACATTCCTAACCCTCCAAAAAAAC 
NANOG_R1_F_Stricker CTTGCTTCCTGGCACGAGATGTTGGTTAGGTTGGTTTTAAATT 
242 
NANOG_R1_R_Stricker CAGGAAACAGCTATGACCCCAACAACAAATACTTCTAAATTCACCAC 
AutMID1 (example) CGTATCGCCTCCCTCGCGCCATCAGACGAGTGCGTCTTGCTTCCTGGCACGAG Amplicon 
size +35 ButMID1 (example) CTATGCGCCTTGCCAGCCCGCTCAGACGAGTGCGTCAGGAAACAGCTATGAC 
      
UBE3A cDNA cloning     
UBE3A_cDNA_fwd CAGCAGTTGAATCCATATTTGAG 
280 
UBE3A_cDNA_rev CCTCAGTTTCAAAAGAAGATGG 
      
UBE3A allele distinction      
UBE3A _mat_MGB AATTTGAAGAACAAGGAGT   
UBE3A _pat_MGB TTTGAAGGAGAACAAGGA   
      
Methylated oligos     
MON1 AAGCACGCCTGCGCGGCCGCAG   
MON2 CTGGCGCGCATGCTCAGGCGGGG   
MON3 GGCGCAGAGTGGAGCGGCCGCCGGA   
MON4 AGCGGTCAGTGACGCGATGGAGCGG   
CON1 GCCATTGTGCGTGACGACAGCA   
CON2 GCGTCGGGTACTGACGCGGCGAC   
CON3 GCTCCGTGACGCGGGGCGGAGGGGC   
CON4 AAAGCAGCAGCCCTCGAGCGCCCAT   
      
Methylated fragment     
T7_Promoter AATACGACTCACTATAGGG 
1413 
M13_rev CAGGAAACAGCTATGAC 
      
gRNAs for CRISPR/Cas9     
gRNA1 CCCCCAGGTCATTCCGGTGA   
gRNA2 GGCAAACAAGCACGCCTGCG   
gRNA3 TGTCTCTTGAGAGAAGCCAC   
gRNA4 GCTCCTCAGACAGATGCGTC   
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T7 assay     
SNRPN_short1_Seq_F2 aggtagacatgtccattgat 
520 
SNRPN_CpG77_R1 gagcggacaggataccatcg 
      
Epi-Pluri-Score analysis     
ANKRD46_for BIOTIN-AGGGGAGGGGTTAGATAGGGGTAG 
173 
ANKRD46_rev CCACAATTTTAATACTTTCCCTAATTCAAAAC 
ANRD46_seq CACAATTTTAATACTTTCCC   
C14ORF115_for BIOTIN-GATTTTTTGGGGGGAGTGGTTTAAGT 
182 
C14ORF115_rev CCACCTTCCAACCTAAAACATTTAAATCACC 
C14ORF115_seq CCAAAACCAATTTCATATC   
POU5F1_for GATTTTTGGTATTGTGTTTTTAGGGGTTAGTTA 
416 
POU5F1_rev BIOTIN-TAAAACCCAATCAATCCAAAATCTAATCCC 
POU5F1_seq TAGTTTTTTAAATTTATTGAATG   
Table 10 
 
8.3. Next-Generation Bisulphite Sequencing 
 
 
Table 11. Chromosomal regions according to UCSC browser, build hg19. 
 
ICR Locus / gene   CpG sites  Chromosomal region  
 
SNRPN  Prader-Willi / Angelman locus  21 chr15:25200011 -25200250  
ICR1  IGF2 / H19  14 chr11:2021080-2021248  
ICR2  KCNQ1OT1  7 chr11: 2721560- 2721680  
NESPAS  GNAS  17 chr20:57429210- 57429446  
CpG85  RB1  11 chr13:48,893,505-48,893,690  
IG-DMR  DLK1 / MEG3  15 chr14: 101277219-101277485  
    POU5F1  POU5F1  10 chr6:31,138,276-31,138,507  
NANOG  NANOG  6 chr12:7,941,603-7,941,810  
Table 11 
 
Table 12. Methylation and read numbers at analysed loci in assayed cell lines 
corresponding with Figure 20 and Figure 21. 
 
  
SNRPN ICR1 ICR2 NESPAS CpG85 IG-DMR POU5F1 NANOG 
CpG sites 
 
21 14 7 17 11 15 10 6 
          hESCs H1 
         Methylation % 30.4 54.0 48.2 42.2 94.9 93.6 9.0 15.2 
Reads 
 
1549 1826 2371 1285 269 1245 756 971 
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hESCs H9 
         Methylation % 37.1 37.1 47.5 36.0 95.1 95.3 20.6 25.9 
Reads 
 
643 753 658 2659 9678 2740 3369 1070 
          Control fibroblasts 
       Methylation % 39.0 41.7 50.3 40.3 59.1 62.7 49.3 34.9 
Reads 
 
885 2879 3580 2347 232 7298 858 628 
Control 42 
         Methylation % 36.0 39.4 53.7 1.6 92.0 91.9 1.6 5.7 
Reads 
 
374 1292 1328 918 2827 1298 753 1489 
Control 645 
         Methylation % 41.7 46.8 53.9 6.0 91.3 92.0 1.0 2.3 
Reads 
 
699 1343 2463 1453 2485 1289 698 4390 
          Patient fibroblasts 
       Methylation % 42.8 44.7 56.5 46.5 94.0 3.2 80.5 45.1 
Reads 
 
776 1837 1212 1855 3222 1311 748 374 
Patient B1 
         Methylation % 38.4 0.9 57.7 3.1 95.8 61.9 8.9 14.0 
Reads 
 
616 3201 2843 1910 154 1635 524 967 
Patient D 
         Methylation % 39.8 44.8 56.0 43.7 95.4 60.1 8.0 16.4 
Reads 
 
691 2299 1777 2526 459 1544 1059 900 
Patient H 
         Methylation % 37.6 39.7 54.3 63.6 96.1 65.8 12.4 27.8 
Reads 
 
2336 1875 5296 1075 576 2308 1160 571 
Patient P 
         Methylation % 36.4 43.4 2.0 4.1 94.8 53.9 21.8 42.1 
Reads 
 
1161 2566 1198 1764 405 3304 1241 2824 
          hESCs H9 
         Methylation % 38.1 91.7 49.9 41.3 95.9 96.5 18.5 43.5 
Reads 
 
2886 390 581 8425 8438 458 2916 1538 
 
AGI-0 
         Methylation % 0.9 75.4 49.3 45.4 91.6 93.8 12.0 30.1 
Reads 
 
1151 1387 2072 1316 608 1632 680 1350 
MCH2-10 
         Methylation % 28.8 68.9 55.7 3.3 95.2 89.0 16.9 33.5 
Reads 
 
1214 1021 1576 1155 694 1558 610 1134 
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Control fibroblasts 2 
       Methylation % 
    
55.6 58.6 
  Reads 
     
2591 1025 
  Control fibroblasts 3 
       Methylation % 
    
79.3 64.9 
  Reads 
     
2593 1020 
  
          Patient blood 
        Methylation % 
    
63.1 61.6 
  Reads 
     
475 1290 
  Table 12 
 
Table 13. Methylation and read numbers at analysed loci after methylation induction 
with a modified CRISPR/Cas9 system corresponding with Figure 28. 
 
 
No gRNA gRNA1 + gRNA3 gRNA2 + gRNA4 
D0 
   Methylation 
% 1.5 22.8 3.1 
Reads 278 863 665 
D7 
   Methylation 
% 1.0 15.7 5.6 
Reads 894 1641 772 
D14 
   Methylation 
% 0.7 30.0 11.8 
Reads 1804 750 765 
Table 13 
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8.4 Plasmid Maps 
 
 
8.4.1 TOPO Vector with Inserted 280 bp Fragment from Patient-Specific cDNA 
 
 
 
  
pCR2.1 vector + exon 9 of UBE3A del 
4,208 bp 
M13 
T7 
Fwd 
Rev 
Amp res 
Kan res 
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8.4.2 Cas9-DNMT3A-DNMT3L Construct 
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8.4.3 Plasmid containing gRNA1 
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